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SUMMARY / 
Diabetes mellitus is characterized by derangements in 
carbohydrate, protein and fat metabolism caused by the complete or 
relative insufficiency of insulin secretion and/or insulin action. There are 
two main forms of diabetes, Type 1 (Insulin dependent diabetes mellitus) 
and Type 2 (Non-insulin dependent diabetes mellitus). Type 1 diabetes is 
due to autoinmiune-mediated deterioration of pancreatic P-cells, resulting 
in absolute insulin deficiency. Type 2 diabetes is far more common and 
characterized by insulin resistance and/or abnormal insulin secretion, 
either of which may ^ predominate. People with Type 2 diabetes are not 
dependent on exogj^ nous insuliftrbut may require it for the control of 
blood glucose levels, if this is not achieved with diet alone or oral 
hypoglycaemic agents. Insulin resistance is a state of reduced insulin 
sensitivity, an inability of insulin to lower plasma glucose levels through 
suppression of hepatic glucose production in liver and stimulation of 
glucose uptake in skeletal muscles and adipose tissue. The coexistence of 
insulin resistance and hyperinsulinemia appears to contribute directly or 
indirectly to many other disorders, such as dyslipidemia, hypertension, 
atherosclerosis and a procoagulant state, linking together with insulin 
resistance, which has now assumed the status of syndrome, namely 
Syndrome X. 
Numerous plants have been reported to possess hypoglycaemic 
activity and mechanisms for the antidiabetic action of such plants have 
been described. There are plants, which exhibit properties similar to the 
well known sulfonylurea drugs like glybenclamide, effecting 
hypoglycaemia in normal animals by stimulating insulin release from 
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pancreatic p-cells, besides reducing hepatic clearance of insulin hormone 
while others act like the biguanides specifically, metformin which, 
although antihyperglycaemic, does not effect hypoglycaemia in normal 
state. Metformin-like activities of plants, augments insulin action by 
increasing the number of glucose transporters, inhibit gluconeogenesis, 
reduces absorption from the intestine but increases glucose metabolism in 
the liver. Because of many side effects and doubt about the efficacy and 
safety of the present day oral hypoglycaemic agents which have promoted 
a search for safer and more effective drugs for the treatment of diabetes in 
particular type 2 diabetes mellitus. This has led to explore alternative 
medicines including natural therapies. A multitude of herbs, spices and 
other plant materials are being used in the management of diabetes 
mellitus especially in third world countries and many more are being 
explored for the antidiabetic activity. Streptozotocin was top priority 
diabetogenic agent for inducing diabetes mellitus into rats because of its 
less mortality. 
Antihyperglycaemic effect of nearly 18 plants was studied in STZ-
induced diabetic rats and 3 marine extracts both in sucrose loaded rat 
model and STZ-induced diabetic rats. Sucrose loaded rat model was 
primarily used to identify the lead molecule from plant/marine extracts. 
Streptozotocin (STZ)-induced diabetic rat model was later used to 
confirm the antihyperglycaemic activity of plant/marine extracts under 
diabetic conditions. Significant antihyperglycaemic activity was noted in 
the ethanolic extracts of the tuberous root of Gloriosa superha, Berberis 
aristata, Tephrosia purpurea, stem bark of Taxus baccata Wallichiana 
spp, leaves of Verbascum thapsus, Lycopodium clavatum, Boerhaavia 
diffusa, Eclipta alba. Acacia nilotica, Strobilanthes perottitiana, stem 
wood of Cedrus deodara, fruits of Myristica fragrans, stem bark of 
Betula utilis, hard wood of Acacia catechu and leaves of Tectona grandis. 
The average antihyperglycaemic activity profile were 22.0 (p<0.01), 23.0 
(p<0.05), 16.0 (p<0.05), 13.6 (p<0.05), 10.0 (p<0.05), 35.8 (p<0.001), 
12.0 (p<0.05), 16.9 (p<0.05), 10.3 (p<0.05), 19.6 (p<0.01), 19.5 (p<0.01), 
11.0 (p<0.05), 12.4 (p<0.05) and 10.6 (p<0.05) respectively. The marine 
extracts which were found to have antihyperglycaemic effect in sucrose 
loaded rat model were of Ceriops tagal, Sinularia erecta and Sinularia 
firma. The average antihyperglycaemic activity were noted in this model 
le. \2AVo, 12.7% and 13.0% respectively; whereas, the similar extracts 
showed 25.8%, 16.1% and 18.8% antihyperglycaemic effect in STZ-
induced diabetic rats. This is being the first report for any 
antihyperglycaemic property in the said plant/marine extracts. 
Search for lead based antidiabetic molecules/natural substances 
was one of the objectives of our studies. Three major in-vitro antidiabetic 
targets were standardised i.e. a -glucosidase, aldose reductase and protein 
tyrosine phosphatase-IB. a-Glucosidase, a major target for antidiabetic 
drug discovery, is located on the brush border membrane of small 
intestine. If any agent found to inhibit this enzyme, there is possibility 
that agent may delay glucose absorption across small intestine and 
consequently prevent the postprandial hyperglycaemia. The next target 
which directly deals with secondary diabetic complications like cataract, 
neuropathy, nephropathy etc. is Aldose reductase. The enhanced 
expression and activity of this enzyme was found in diabetic situation. It 
converts more and more glucose to sorbitol, which give rise to 
multifaceted problems that later on give rise to macro and microvascular 
complication of diabetes mellitus. Any inhibitor of aldose reductase 
would be developed as drug for the treatment of diabetic complications 
for which no drug is available yet in the market. Protein tyrosine 
phosphatase-IB, an enzyme of high importance, play important role in 
carrying out insulin signaling cascade together with protein tyrosine 
kinase. In normal circumstances there is a synchronization in between 
these two enzymes i.e. protein tyrosine kinase and protein tyrosine 
phosphatase. In the case of insulin resistance the activity of protein 
tyrosine phosphatase-IB was found to be increased because of the high 
expression of PTP gene. Therefore, for the treatment of insulin resistance 
and non-insulin dependent diabetes mellitus one has to inhibit the activity 
of protein tyrosine phosphatase-IB. An inhibitor of protein tyrosine 
phosphatase can be used effectively to reverse insulin resistance and 
consequently insulin sensitivity for liver and muscles can be increased. 
Some library compounds i.e. L-000-17-10, L-000-17-11, L-000-17-16 
and L-000-17-17 were found to inhibit both a-glucosidase and aldose 
reductase to the tune of 90 to 100% at 250 yM. Compound L-001-8-26, 
L-001-8-27, L-001-8-28, L-001-8-36, L-001-8-37, L-001-8-62 and L-
001-8-63 were found to inhibit protein tyrosine phosphatase-IB to the 
tune of 93 to 100% at 100 JJM. Their percent inhibitions were also 
compared with their standard inhibitors like Acarbose which inhibits a-
glucosidase upto 68.4% at 250 |iM, Quercitrin, a known inhibitor of 
aldose reductase was found to inhibit this enzyme by 69.6% at 250 |iM in 
the present study and the next known mammalian inhibitor i.e. 
peroxovanadate could inhibit protein tyrosine phosphatase-IB to the tune 
of 80.5% at 100 |JM concentration. 
The two standardized antidiabetic preparations i.e. CDR-134 and 
CT-1 proved their antihyperglycaemic property in STZ-induced diabetic 
rats. CDR-134 and CTl showed 25.4% (p<0.01) and 21.4% (p<0.01) 
lowering of blood glucose in diabetic rats. Both preparations showed dose 
dependency in STZ-induced diabetic rats and their ED50 values were 
calculated to be around 243 and 94.6 mg/kg, respectively. It seemed that 
CDR-134 and CT-1 exert their glucose lowering effect by inhibiting a-
glucosidase present in the brush border membrane of small intestine, with 
IC50 of 42 and 40 )ig/ml respectively. The nature of inhibition was found 
to be non-competitive in each case. 
Two rat models have been standardised by manipulating the diet 
and injecting diabetogenic agent Streptozotocin (STZ), respectively for 
studying the pathophysiology of insulin resistance, hyperinsulinemia and 
type 2 diabetes mellitus. Fructose-enriched diet fed rat and neonatal-STZ 
rat model were used as animal models for non-insulin dependent diabetes 
mellitus (type 2 diabetic condition i.e. impaired glucose tolerance and 
insulin resistance). These animal models of type 2 diabetes were used for 
the evaluation of antihyperglycaemic and insulin resistant reversal 
activity of standardized preparations i.e. CDR-134 and CT-1.These 
animal models were used to evaluate the short and long term effects of 
CDR-134 and CT-1 on primary and secondary biochemical changes 
during diabetes and insulin resistance. Biomolecules and regulatory 
enzymes of carbohydrate metabolism were chosen for the study. These 
include blood glucose, oral glucose tolerance test (OGTT), serum insulin, 
pyruvate kinase, phosphofructokinase, glycogen phosphorylase, glucose-
6-phosphatase, phosphoenolpyruvate carboxykinase, lactate 
dehydrogenase and protein tyrosine phosphatase. These animals showed 
slightly elevated fasting blood glucose, impaired glucose tolerance and 
the state of insulin resistance and hyperinsulinemia. These preparations 
(CDR-134 and CT-1) have shown promising results in these models as 
indicated by correction in impaired fasting blood glucose profile, 
impaired glucose tolerance and normalization of the elevated serum 
insulin level, as well as activating the rate limiting/regulatory enzymes of 
carbohydrate metabolism responsible for insulin resistance and type 2 
diabetes. 
After 10 weeks feeding of Fructose enriched diet to Sprague 
Dawley, significant amount of deterioration occur in oral glucose 
tolerance curve. In the case of neonatal rats oral glucose tolerance curve 
was significantly altered after 8 weeks post STZ injection. On week 13*, 
15*, 18*, 20* and 22"^ impairedness in oral glucose tolerance became 
more prominent Serum insulin level was also found to be significantly 
higher m finctose fed and neonatal-STZ rats. During five weeks treatment 
with CDR-134 in neonatal rats and fi^ctose fed rats, oral glucose 
tolerance found to become normal. CDR-134 helped in normalizing the 
oral glucose tolerance in these two rat models for non-insulin dependent 
diabetes mellitus. Three weeks feeding of CT-1 to these models also 
improved impaired glucose tolerance by correcting impaired glucose 
tolerance (IGT). 
These preparations were found to alter the activities of regulatory 
enzymes of carbohydrate metabolism in these two animal models for type 
2 diabetes and insulin resistance. CDR-134 and CT-1 were found to 
decrease the activities of glucose-6-phosphatase and 
Phosphoenolpyruvate carboxykinase and consequently reducing hepatic 
glucose production by the process of gluconeogenesis in tissues like liver 
and muscles. These agents also assisted in glucose uptake and its 
utilization by increasing the activities of pyruvate kinase, 
phosphofinctokinase and lactate dehydrogenase. Pyruvate kinase plays an 
important role in the utilization of glucose and thereby helping glucose 
uptake. Its activity was found to be decreased in the liver and muscle of 
both animal models, however, treating with CDR-134/CT-1 helped in 
bringing the activity back to normal levels. The activity of other key 
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enzyme of glucose metabolism i.e. phosphofructokinase was found to be 
diminished in the liver and muscles of fructose fed and STZ- neonatal 
rats. Both CDR-134 and CT-1 helped in the enhancement of PFK 
activity. However, both have no effect on kidney PFK. These 
preparations helped in the restoration of lactate dehydrogenase activity of 
liver only. The beneficial effect of these antihyperglycaemic and insulin 
resistant reversal agents might be due to the elevation in insulin 
sensitivity to glucose as observed by sufficient reduction in the activity of 
protein tyrosine phosphatase, one of the key enzymes of insulin signaling 
cascade involved in insulin resistance, reduction in its activity would 
definitely help in insulin action. These preparations have the potency to 
normalize the impaired glucose tolerance and altered enzyme activities 
involved in glucose catabolism and anabolism; possibly they are doing so 
by declining the activities of glucose-6-phosphatase and PEPCK and 
therefore helping in the decrease of hepatic glucose production, one of 
main reason of hyperglycaemia. It is evident that these agents improve 
insulin resistance by decreasing hyperinsulinemia and by declining the 
activity of PTPase (protein tyrosine phosphatase), glucose intolerance and 
normalizes many of the altered biochemical parameters of liver, kidney 
and muscles associated with non-insulin dependent diabetes mellitus and 
insulin resistance. 
Insulin resistance was measured using HOMA index (homeostasis 
model assessment). It is a mathematical model utilizing ratio of fasting 
glucose (mM): fasting insulin ((j,U/ml) that has been used to indicate the 
degree to which they combine to give hyperglycaemia with low, normal 
or raised basal plasma insulin concentrations. As mentioned both 
standardized preparations i.e. CDR-134 and CT-1 were found to correct 
hyperinsulinemia by decreasing fasting serum insulin in fructose fed and 
neonatal-STZ rat models, respectively. CDR-134 and CT-1 prevented the 
rise in serum insulin levels following glucose load during insulin kinetic 
studies in STZ-induced diabetic rats. Insulin resistance was found to be 
established as calculated by HOMA index formula using fasting glucose 
and fasting serum insulin. Fructose fed and neonatal-STZ rats exhibited 
insulin resistance index 5.0-6.0 which returned back to normal levels after 
the treatment with either CDR-134 orCT-1. It is again proved that CDR-
134 and CT-1 possess the property of reversing insulin resistance and 
enhancing insulin action by increasing insulin sensitivity towards 
glucose. This is being the first report about the existence of insulin 
resistant reversal property in natural products like CDR-134 and CT-1. 
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SCENE SETTING AND OUTCOME 
Diabetes mellitus has now assumed epidemic proportions in many countries of 
the world. With the present population of 19.4 million diabetics and thereby leading 
to approximately 60 million by the year 2025, India would rank first in sharing the 
global burden of diabetes. Genetic predisposition to central (visceral) adiposity, 
insulin resistance and diabetes are thought to be important determinants. Impaired 
fasting glucose (IFG) and impaired glucose tolerance (IGT) have emerged as the most 
important targets for primary prevention with lifestyle modification and 
pharmacological agents like metformin and insulin sensitizers. Insulin resistance and 
hyperinsulinemia occupy the central stage of the metabolic syndrome. 
Armamentarium available today for the treatment of diabetes is replete with large 
number of potent and focused drugs. Insulin sensitizers (thiazolidinediones), new 
generation insulin secretagogue (glimepiride), acarbose and designer insulin (lispro 
and aspart) have enormously helped in achieving better metabolic control. However, 
their impact on long term outcome of diabetes related end point remains to be proven 
and moreover they are costly and beyond the reach of our people. Our country hold 
one of the biggest heritage in plant diversity, even in the ancient times, plant based 
drugs were promising for the treatment of major diseases. Because of the adverse side 
effect imposed by the available drugs, the dialectologists have started looking into 
plant based medicines. Investigation of the present study identified some terrestrial 
plants and marine flora and fauna possessing antidiabetic property in STZ-induced 
diabetic rats, synthetic compounds hitting the novel targets (a-glucosidase, aldose 
reductase and protein tyrosine phosphatase) for the synthesis of antidiabetic 
compounds both for glucose lowering as well as insulin resistance, preclinical 
development of one standardized marine extract CDR-134 and one standardized 
herbal extract CT-1, their effect on regulatory enzymes of carbohydrate metabolism 
and insulin resistance. Overall the investigation made in the present study provide an 
overview of multiple aspects of the pathophysiology of diabetes and insulin 
resistance; multi-model therapeutic effect of medicinal plants/phytochemicals as 
antihyperglycaemic and insulin resistant reversal agents. 
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INTRODUCTION 
Diabetes mellitus with its devastating consequences has assumed epidemic 
proportion in many countries of the worid. There are an estimated 143 million people 
worldwide with diabetes, which is almost five times more than estimation of ten year 
ago. This number will probably double by 2025 (King et al, 1998). Although diabetes 
is more prevalent in developed countries, it is likely that the developing world will 
bear the brunt of the epidemic in the future. In the US, almost 16 million people are 
thought to be afflicted and third of whom are undiagnosed. The disease is 
considerably more common among the elderly and strikes African-Mexican and 
Native Americans. In India, it is estimated that presently 19.4 million individuals are 
affected by diabetes, which is likely to go up to 57.2 million by the year 2025 (King et 
al, 1998) 
Diabetes is defined as a state in which homeostasis of carbohydrate and lipid 
metabolism is improperly regulated by insulin. This resuhs primarily in elevated 
fasting and post-prandial blood glucose levels. If this imbalanced homeostasis does 
not return to normalcy and continues for a protracted period of time, it leads to 
hyperglycaemia that in due course turns into diabetes mellitus. There are two main 
categories of this disease i.e. Type 1 (Insulin dependent diabetes mellitus) and Type 2 
(Non-insulin dependent diabetes mellitus). Type 1 diabetes represents a heterogenous 
and polygenic disorder, with a number of non-HLA loci contributing to disease 
susceptibility (Lemmark and Ott, 1998). Though this form of diabetes accounts for 5 
to 10% of all cases yet there is no identified agent substantially capable of preventing 
this type of disease (Atkinson, and Eisenbarth, 2001). American Diabetes Association 
and WHO (ADA, 2001; WHO, 1999) have proposed that Type 1 diabetes can be 
divided into autoimmime/immune mediated) diabetes (Type lA) and idiopathic 
diabetes with p-cell obstruction (Type IB). The type-1 diabetes is caused by the loss 
of insulin secreting p-cells due to selective autoimmune destruction of the pancreatic 
beta cells. In this type exogenous insulin is required to prevent diabetic ketoacidosis. 
• [ 1 ] 
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Type 2 diabetes is far more common and results from a combination of defects 
in insulin secretion and insulin action, either of which may predominate. People with 
type-2 diabetes are not dependent on exogenous insulin, but may require it for the 
control of blood glucose levels if this is not achieved with diet alone or with oral 
hypoglycaemic agents. This type of diabetes accounts for 90 to 95% of all diabetic 
patients (DeFronzo, 1997). Treatment of type-2 diabetes is complicated by several 
factors inherent to the disease process, typically insulin resistance, hyperinsulinemia, 
impaired insulin secretion, reduced insulin-mediated glucose uptake and its utilization 
(DeFronzo, 1997; Polonsky et al, 1996; Groop et al, 1989). All forms of diabetes are 
characterized by chronic hyperglycaemia and the development of diabetes-specific 
microvascular pathology in the retina, renal glomerulus and peripheral nerve. As a 
consequence of its microvascular pathology, diabetes is a leading cause of blindness, 
and stage renal disease and a variety of debilitating neuropathies. 
Type-2 diabetes is the most prevalent form of diabetes. The pathogenesis of 
hyperglycaemia is rooted in a malformation of the interrelationship between insulin 
secretion and insulin action (Kahn and Porte, 1996). The islet p-cells of the pancreas 
act as glucose sensors to maintain a balance between hepatic glucose production and 
the rate of insulin-dependent utilization of glucose by muscle and adipose tissues. 
Plasma glucose changes resulting from changes in glucose production and glucose 
utilization are sensed by the islet p-cells, resulting in the adjustments of insulin 
secretions to achieve a new steady state that restores normal blood glucose levels. 
When islet p-cell function is impaired, msulin secretion is inadequate leading 
to overproduction of glucose by the liver and underutilization of glucose in peripheral 
tissue (Bergman, 1989). The resulting hyperglycaemia increases insulin secretion by 
the P-cells. Thus hyperglycaemia may result from a deficiency in either insulin 
production and secretion or insulin action. The pathophysiological abnormalities of 
type-2 diabetes range from a metabolic state of predominant insulin resistant with 
relative p-cell dysfunction to a state of severe p-cell dysfunction accompanied by 
some insulm resistance, hisiilin resistance is essentially a condition of reduced insulin 
sensitivity. Insulin sensitivity is commonly described as the ability of insulin to lower 
[ 2 ] 
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plasma glucose levels, which it does by suppressing hepatic glucose production and 
stimulating glucose in skeletal muscle and adipose tissue. 
Both inherited and acquired influences contribute to the development of 
insulin resistance. The inherited defects responsible for the more common forms of 
insulin resistance, which are typically been in individual with type-2 diabetes, are 
largely unidentified. Although mutation in insulin receptors, glucose transport and 
signalling proteins have been identified, these are relatively rare. The acquired causes 
of insulin resistance include inactivity, overeating, aging, hyperglycaemia increased 
levels of fi-ee fatty and (FFAs) etc. Studies of the relation between the insulin 
secretary capacity of |3-cells and insulin sensitivity in non-diabetic persons support the 
view that insulin secretion can compensate for insulin resistance, or that enhanced 
insulin sensitivity can mark an insulin secretary defect (Bergman, 1989). 
The coexistence of insulin resistance and hyperinsulinemia appears to 
contribute directly or indirectly to many other disorders, such as dyslipidemia, 
hypertension, atherosclerosis and a pro-coagulant state. All of these disorders are risk 
factors for coronary heart disease. The firequent occurrence in the same individual of 
several or all of the disorders linked with insulin resistance has now assumed the 
status of a syndrome in its own rights. It is variously referred to as the insulin 
resistance syndrome, metabolic syndrome, syndrome-X, or Reaven's syndrome 
(Reaven, 1988; DeFronzo and Ferraimini 1991). 
Diabetes is becoming something of a pandemic and despite the recent surge 
in new drugs to treat and prevent the condition; its prevalence continues to soar (Yost, 
2001). Although several drugs targeted (Table 1) for carbohydrate hydrolyzing 
enzymes (pseudosachharides), release of insulin fi-om pancreatic p-cells (sulphonyl 
ureas), glucose utilization (biguariides), insulin sensitizers, PPAR-y agonists 
(glitazones) are in clinical practice, the growing diabetes market observes a number of 
changes. The glitazones are meant to target the problems of insulin resistance and 
enhance insulin action at cellular level; however some of these drugs are linked to 
liver toxicity (troglitazone), including a number of deaths from hepatic failure (Tiwari 
[ 3 ] 
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and Rao, 2002; Gale, 2001; Stem, 1999) and raising the symptoms and risk factors of 
heart disease leading to heart failure (roziglitazone) (Gale, 1999). 
Table 1: Actions of antidiabetic drugs 
Agents 
Sulphonylureas and repaglimide 
Metformin 
Acarbose 
Thiazolidine diones 
Insulin 
Actions 
Increase insulin secretion 
Counter insulin resistance 
Slow carbohydrate digestion 
Selectively increase insulin sensitivity 
Decrease hepatic glucose production and 
increase peripheral glucose utilization. 
On the other hand, traditional medicinal plants with various active principles 
and properties have been used since ancient times by physicians and laymen to treat a 
great number of humans diseases such as diabetes, coronary heart disease and cancer 
(Middleton et ai, 2000; Havsteen, 1984). The beneficial multiple activities like 
manipulating carbohydrate metabolism by various mechanism, preventing and 
restoring integrity and function of P-cell, insulin releasing activity, improving glucose 
uptake and utilization and the antioxidant properties present in medicinal plants offer 
exciting opportunities to develop them into moral therapeutics. The multifactorial 
pathogenicity of diabetes demands multimodal therapeutic approach. Thus inture 
therapeutic strategies require the combination of various types of multiple agents from 
natural sources that can act as antihyperglycaemic as well as insulin resistant reversal 
agents for the treatment of diabetes and insulin resistance. 
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REVIEW OF LITERATURE 
Diabetes mellitus, long considered a disease of minor significance to world 
health, is now taking its place as one of the main threats to human health in the 21 '^ 
century (Zimmet, 2000). The past two decades have seen an explosive increase in the 
number of people diagnosed with diabetes worldwide (King et al, 1998). Pronoimced 
changes in the human enviroimiental and in himian behaviour and lifestyles have 
accompanied globalisation and these have resulted in escalating rates of both obesity 
and diabetes. Hence the recent adoption of the term diabesity (Shafrir, 1997), first 
suggested by Shafrir several decades ago (Astrup and Finer, 2000). 
Diabetes mellitus is characterized by derangements in carbohydrate, protein 
and fat metabolism caused by the complete or relative insufficiency of insulin 
secretion and/or insulin action (O'Brian and Granner, 1996). This results in elevated 
fasting and postprandial glucose level that leads to complications if left untreated 
(Saltiel, 2001). There are two main forms of diabetes (WHO, 1999) type-1 and type-2; 
type 1 diabetes is primarily due to autoimmune-mediated deterioration of pancreatic 
P-cell, resulting in absolute insulin deficiency. People with type 1 diabetes must take 
exogenous insulin for survival to prevent the development of ketoacidosis. Its 
frequency is low relative to type 2 diabetes, which accounts for over 90% cases 
globally. Type 2 diabetes is characterized by insulin resistance and/or abnormal 
insulin secretion, either of which may predominate. People with type 2 diabetes are 
not dependent on exogenous insulin, but may require it for control of blood glucose 
levels, if this is not achieved with diet alone or with oral hypoglycaemic agents. 
The global figure of people with diabetes is set to rise fi-om the current 
estimate of 150 million to 220 million in 2010, and 300 million in 2025 (King et al, 
1998). Most cases will be of type 2 diabetes, which is strongly associated with a 
sedentary lifestyle and obesity (Zimmet, 1999). This trend of increasing prevalence of 
diabetes and obesity has already imposed a huge burden on health-care system and 
this will continue to increase in fiiture (Zimmet, 2000; ADA, 1998). Epidemiological 
transition including improved socio-economic status, rural to urban migration, 
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adoption to sedentary habit and stress of modem lifestyle is largely responsible for 
this catachymic shift in the burden of diabetes. Against this backdrop of 
epidemiological transition other environmental factors like maternal and foetal 
malnutrition, early childhood of ovemutrition and unhygenic semiurban and urban 
milieu have lately been incriminated in either initiating or urmiasking the problem of 
insulin resistance and diabetes. Genetic predisposition to central (visceral) adiposity, 
insulin resistance and diabetes are thought to be important determinants. 
Although type 2 diabetes is numerically more prevalent in the general 
population, type 1 diabetes is the most common chronic disease of children. But with 
the increasing prevalence of type 2 diabetes in children and adolescents, the order 
may be reversed within one or two decades (Fagot-Campagna et al, 2000; Fagot-
Campagna and Narayan, 2001). 
Aetiology of type 1 diabetes 
Type 1 diabetes is a discrete and its pathogenesis involves environmental 
triggers that may activate autoimmune mechanisms in genetically susceptible 
individuals, leading to progressive loss of pancreatic P-cells (Harrison et al, 1999). 
Predisposition is mediated by a nvmiber of genes that interact in a complex manner 
with each other and environment. The environmental factors that precipitate type 1 
diabetes in genetically susceptible individuals, have remained speculative, although 
viruses - including in utero exposure, which is remote from clinical onset - have been 
suggested, as have dairy products and early weaning onto cow's milk, and increased 
dietary nitrate and nitrite (Harrison et al, 1999; Tuomilehto et al, 1997). 
Table 2; Possible aetiological factors in Type 1 Diabetes 
Non-genetic Genetic 
Viral infection (e.g. coxsackie, cytomegalovirus Human leukocyte antigen 
(HLA) associated 
Early infant diet (early assertion of breast feeding/ early 
introduction of cow's milk 
Non-HLA associated. 
Perinatal infections 
Toxins (e.g. dietary nitrosamines, bafilomycin, coneanamycin A) 
Vaccine administration 
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Type 2 diabetes develops in individuals mostly over the age of 40 years 
(Bowen-Jones and Gill, 1997) and is a multifactorial disease with genetic and 
environmental components; it is characterized by a progressive deterioration in the 
regulation of blood glucose concentrations usually associated mth obesity, decreased 
physical activity and increased caloric of intake. Recently, the incidence of type 2 
diabetes has increased in both younger individuals as well as in the older age group; 
the increase of affected individuals under the age of 20 is attributed to similar factors 
(Fagot-Campagna et al, 2000). Type 2 diabetes is characterized by a disruption of the 
secretion of insulin from islet p-cells and decreased insulin sensitivity of peripheral 
tissues (increased insulin resistance) (Fagot-Campagna et al, 2000). These two 
pathophysiological features are present to varying degrees in different patients. 
Increased circulating insulin concentrations are a marker for the decreased sensitivity 
occurring in obesity whereas p-cell dysfunction results in lack of appropriate insulin 
secretion in relation to the ambient glucose concentration. At diagnosis, many patients 
can be treated with dietary advice. If this is ineffective, insulin secretion can be 
augmented by sulphonylureas drugs, which stimulate p-cell secretion. When this fails 
during the progression of the disease, insulin replacement therapy in the form of 
injection is required. 
The highest prevalence of type 2 diabetes is found in indigenous population 
that have become "westernized". These include the Pima Indians of Arizona (Knowler 
et al, 1990) where the prevalence is greater than 50% in age groups over 35 years and 
the Australians aboriginal people (Daniel et al, 1999); and Nauruans of the Pacific 
islands (Dowse et al, 1990). 
Insulin Resistance and Type 2 Diabetes 
Insulin resistance has emerged as a far-reaching endocrine phenomenon. The 
term insulin resistance signifies an impaired biological response to insulin, and insulin 
resistance is known to underlie the deterioration of glucose homeostasis that leads to 
the typical forms of type 2 diabetes particularly wdth obesity. The development of 
insulin resistance is met initially with a compensatory increase in insulin secretion. 
The coexistence of insulin resistance and hyperinsulinemia appears to contribute 
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directly or indirectly to many other disorders such as dysHpidemia, hypertension, 
atherosclerosis, and a procoagulant state. All of these disorders are risk factors for 
coronary heart disease. 
INSULIN RESISTANCE 
Insulin Sensitivity and Insulin Resistance 
The acute metabolic action of insulin and their essential importance for 
survival are well recognized (Cahill, 1971). Insulin directs the selection of metabolic 
fuels for energy production, and in doing so it is the only hormone committed to the 
prevention of hyperglycaemia (Cheatham and Kahn, 1995). Several metabolic 
processes are exquisitely sensitive to insulin; hence modest alterations of insulin 
sensitivity can incur widespread metabolic disturbances. Insulin resistance describes 
an impaired biological response to insulin (ADA, 1998), but there is sufficient 
variability in normal sensitivity to insulin that there is no specific boundary at which 
sensitivity ends and resistance begins. The need for a flexible interpretation of insulin 
resistance is emphasized by evidence that insulin resistance affects different tissues 
and different actions of insulin to different extents. There is no absolute definition of 
hyperinsulinemia, since an insulin concentration that is raised for an individual is 
usually still within the wide range of normality. While hyperinsulinemia may 
compensate for resistance to some actions of insulin, it can resuh in over expression 
of actions that retain normal or nominally impaired reactivity to insulin. Also, high 
concentrations of insulin might act via receptors for insulin like growth factors-1. This 
accentuation of some of the actions of insulin with simultaneous resistance to other 
actions gives rise to a diversity of clinical presentations and sequelae of insulin 
resistance (Reaven, 1988; DeFronzo and Ferrannini, 1991). 
Insulin Resistance in Type-2 Diabetes 
Whole body insulin-stimulated glucose utilization, measured by the 
euglycemic-hyperinsulinemic clamp technique, is reduced in obesity and type 2 
diabetes (DeFronzo, 1988). The major site of impaired insulin-stimulated glucose 
utilization is skeletal muscle, which shows reduction in glucose uptake, glycogenesis, 
glucose oxidation (DeFronzo, 1988; Kelly, 1988; Shulman et al, 1990). hisulin-
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stimulated glucose uptake is impaired and suppression of lipolysis is decreased in 
adipocytes from type 2 diabetic patients (Olefsky, 1981; Groop et al, 1989) although 
responsiveness to insulin may vary considerably between different adipocyte depots. 
Elevated circulatory FFA (Free Fatty Acids) will disrupt the glucose-fatty acids 
(Randle cycle), aggravating insulin resistance in muscle and liver. Insulin-induced 
suppression of hepatic glycogenolysis and gluconeogenesis is impaired in type 2 
diabetes, but usually this is not sufficient marked to make a significant impact on 
hyperglycaemia until the hyperglycaemia is severe (Jeng et al, 1994). The ability of 
insulin-resistant individuals to ward off type 2 diabetes will depend largely upon the 
adaptive capacity of the pancreatic p-cells to maintain increasing insulin 
concentration (Polonsky et al, 1996). Those who cannot sustain sufficient 
hyperinsulinemia suffer deterioration in glucose homeostasis i.e. impaired glucose 
tolerance (IGT). An increasing mismatch between escalating insulin resistances and 
inadequate compensatory hyperinsulinemia causes a progression of IGT into frank 
type 2 diabetes. By the time type 2 diabetes has developed, insulin resistance appears 
to be almost fully established. However, hyperglycaemia continues to worsen due to 
increasingly compromised p-cell fimction. As hyperglycaemia becomes severe, p-cell 
failure is usually clearly evident, with a delayed and diminished insulin response to a 
glucose challenge (Polonsky et al, 1996). 
The Insulin Resistance Syndrome 
The concept of a syndrome linked to insulin resistance and hyperinsulinemia 
emerged from a realization that obesity and type 2 diabetes associated with a high 
prevalence of multiple metabolic abnormalities and on these disturbances that are risk 
factors for coronary heart disease. These include dyslipidemia, increased triglycerides 
and small dense LDL-C and decreasing HDL-C, hypertension, atherosclerosis and a 
procoagulant state (Reaven, 1995). Insulin resistance may be compensated by 
hyperinsulinemia, limiting the disturbance of glucose homeostasis to IGT, while other 
features of the syndrome may range from subclinical to advanced. Several features of 
this syndrome are different to separate from the normal ageing process or the 
consequences of diabetes itself. Many of these events are promoted by insulin 
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resistance and inseparable from raised insulin concentrations, and it is the coexistence 
of the two conditions that may provide a significant pathogenic insult to this vascular 
system. However, it should be remembered that most components of syndrome X also 
can occur quite independently, without the presence of insulin resistance or 
hyperinsulinemia. 
Obesity 
Obesity is a cause of insulin resistance. Android obesity, which is 
characterized by a gross excess of adipose tissue within and around the abdomen, is 
the main type of obesity associated with type 2 diabetes and increased vascular risk 
(Kopelman and Albon, 1997). This adipose depot shows a high rate of turnover, 
possibly due to increased catecholamine-mediated p-adrenoceptor activity, with high 
activities of hormone-sensitive lipase as well as lipoprotein lipase. Adipose tissue 
turnover increases plasma free fatty acids (FFAs) and certain cytokines (e.g. TNF-a 
and IL-6). Increased nutrient intake and decreased nutrient utilization due to low 
levels of physical activity will foster the vicious spiral of hyperinsulinemia and insulin 
resistance. 
Hyperinsulinemia and Insulin Resistance 
It is presimied that subtle increases in hyperglycemia stimulate extra insulin 
secretion, e.g. in obesity. Hyperinsulinemia, in turn, downregulates insulin receptors 
by increasing receptor internalization and degradation. Insulin probably also exerts 
other negative effects on insulin signalling at the post-receptor level (Kahn, 1997). 
Dyslipidemia 
The dyslipidemia of obesity and type 2 diabetes usually features increased 
VLDL-TG. The production of VLDL-TG is increased by insulin, and this effect 
appears to persist when other actions of insulin are reduced by insulin resistance. 
Small dense LDL-C, which is more atherogenic subclass of LDL-C, often is increased 
in association with insulin resistance and hyperinsulinemia together with a reduction 
in HDL-C (Reaven, 1995). 
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Hypertension 
Raised blood pressure is commonly accompanied by reduced sensitivity to 
insulin and higher insulin concentration. Also hypotension is highly prevalent in 
obesity and type 2 diabetes (DeFronzo and Ferrannini, 1991). Since hyperinsulinemia 
has been implicated as a cause of increased renal sodium reabsorption, increased Na"^ -
Vt exchange in arterial smooth muscle, and increased sympathetic vascular tone, this 
offers a mechanism to account for the link with hypertension. 
Atherosclerosis 
The dyslipidemia and hypertension of syndrome X are established risk factors 
for atherosclerosis (DeFronzo and Ferrannini, 1991). It has also been suggested that 
hyperinsulinemia might enhance atherogenesis via other mechanism such as increased 
incorporation of cholesterol and FFA within the vascular wall and increased 
proliferation of vascular smooth muscle. 
Pro-coagulant State 
Type 2 diabetes is an atherothrombotic disease, unstable plaque and clots in 
the coronary arteries are a major cause of this high incidence of myocardial infarction. 
Among the procoagulant features of type 2 diabetes is an increased concentration of 
plasminogen activator inhibitor-1 (PAI-1), reducing the early lysis of clots (Jokl and 
Colwell, 1997). This has been attributed tentatively to insulin resistance and 
hyperinsulinemia (Reaven, 1995). 
Hyperuricaemia 
Several features of syndrome X appear to show more than a causal association 
vdth raised serum uric acid concentrations. Since insulin resistance has been reported 
to reduce urinary clearance of uric acid; hyperuricaemia might also shelter beneath the 
umbrella of syndrome X (Reaven, 1995). 
Cellular Basis of Insulin Resistance 
The binding of insulin to its receptor in the plasma membrane instigates an 
array of intracellular signalling pathways (Cheatham and Kahn, 1995; Kahn, 1994). 
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These give rise to the diverse biological actions of insulin on enzymes, transporters 
and transcription factors. 
Insulin Actions 
Insulin binds to the a-subunit of the insulin receptor, causing a conformational 
change in the p-subunits. This exposes the ATP binding domain and activates tyrosine 
kinase A (TKA) and autophosphorylation at tyrosine residues of the p-subunit. This in 
turn, mediates phosphorylation of tyrosine on a range of protein substrates, notably 
insulin receptor substrates (IRS) 1 and 2, she, and various uncharacterised proteins 
(White, 1997). The phosphotyrosine residue of these proteins bind to SH2 domains or 
other signalling kinases, which open the multiple pathways of insulin action. Different 
IRS proteins appear to channel signal transduction preferentially into different 
pathways. However, there is sufficient overlap that elimination of one IRS protein 
severely impairs but does not completely obliterate any pathway. The P1-3K 
(Phosphoinositol-3-kinase) pathway, which signals through Protein Kinase B (PKB/ 
Akt) is particularly important for this acute metabolic effect of insulin. It stimulates 
the translocation of GLUT4 glucose transporters into the plasma membrane, and, 
therefore, is crucial for insulin-stimulated glucose transport. The PI-3-K pathway also 
participates in the acute regulation of glycolysis, lipogenesis and protein synthesis 
(Cheatham and Kahn, 1995). Interaction of IRS proteins with GRB2 and she routes 
signal transduction into the ras-MAP pathway, which appears to be the main conduit 
to the nucleus. 
Inherited and Acquired Disturbances 
At the cellular level, the aetiology and pathogenesis of insulin resistance are 
almost certainly multifactorial in the typical forms of type 2 diabetes. The genetic and 
environmentally induced disabilities create signalling bottlenecks of sufficient 
severity to substantially impair one or more major transduction pathways. A single 
gene mutation to explain insulin resistance in the vast majority of type 2 diabetes 
patients has not been identified, although abnormal levels of expression of several 
genes may be suspected (Kahn, 1994). An inherited predisposition to low insulin 
sensitivity is supported in high concordance of insulin resistance and type 2 diabetes 
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in twins. The role of environmental factors is supported by the progressive nature of 
insulin resistance during the long prodromal accession to type 2 diabetes. 
Site of Insulin Resistance 
Insulin resistance has been studied mainly in muscle, liver and adipose tissues, 
where insulin exerts its main acute metabolic actions. The insulin receptor is 
structurally normal in type 2 diabetes, and the wealth of 'spare' receptors ensures that 
a reduced population of insulin receptors in type 2 diabetes does not make a major 
combination to insulin resistance in most patients. However, this variety of impaired 
actions of insulin in states of insulin resistance suggest that important rate-limiting 
constrictions are located early in the signal transduction pathway, before the different 
pathways are fully separated. Indeed decreased phosphorylation and TKA of the 
insulin receptor, p-subunit, decreased phosphorylation of lRS-1 and decreased 
activities of PI-3K have been observed in type 2 diabetes (Kahn, 1997; Kahn, 1994). 
Site directed mutagenesis of the p-subunit, which decreases the number of tyrosine 
residue phosphorylated, carries an approximately proportional decrease of insulin 
action (Cheatham and Kahn, 1995). This emphasizes the detrimental consequences of 
subtle conformational adjustment to the p-subunit. Since different sites of p-subunit 
phosphorylation appear to affect the activation of different IRS proteins preferentially 
(White, 1997), it is theoretically possible for changes in the pattern of p-subunit 
phosphorylation to alter the balance of signal transduction into different post receptor 
pathways. 
Gene knockout studies in mice have established that the insulin receptor is 
essential for survival, whereas IRS-1 knockout causes insulin resistance and reduced 
growth, but not frank diabetes. Interestingly, lRS-2 knockout causes insulin resistance 
and reduced p-cell mass, resulting in severe (often fatal) diabetes. These observations 
concur with the possibility that reduced signalling through different IRS proteins 
could account for the heterogeneity of insulin resistance. The knockout experiment 
also reminds that insulin resistance plus p-cell failure is consistent with type 2 
diabetes. In addition to disturbances of insulin signalling, insulin resistance may 
involve defects in the biological effectors of insulin action in some individuals. Gene 
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polymorphisms associated with glycogen synthase and protein phosphatase 1 have 
been noted, and observations at the level of glucose transporter cycling, hexokinases, 
and other key mediators of insulin action remain under suspicion. Adverse effects of 
chronically raised glucose and lipid concentrations (glucotoxicity and lipotoxicity) in 
diabetes include the aggravation of insulin resistance (Yki-Jarvinen, 1992; Boden, 
1997). 
Type 2 Diabetes (Non-insulin dependent diabetes mellitus) 
Type 2 diabetes mellitus accounts for 90-95% of all diabetes. This 
heterogenous disorder afflicts an estimated 6% of the adult population in western 
society; its worldwide frequency is expected to continue to grow by 6% per annum, 
potentially reaching a total of 200-300 million cases in 2010 (Kopelman and Hitman, 
1998). The main force driving this increasing incidence is a staggering increase in 
obesity, the single most important contributor to the pathogenesis of diabetes. 
Type 2 diabetes is a multifactorial disease that shows heterogeneity in many 
respect (Groop, 1997). The imderstanding of the disease and related disorders such as 
IGT (impaired glucose tolerance), IFG (impaired fasting glucose) is undergoing a 
radical change, particularly as data suggest that the risk of complication commences 
many years before the onset of clinical diabetes (Zimmet and Alberti, 1997). 
Previously, it was regarded as a relatively distinct disease entity, but in reality, type 2 
diabetes (and its associated hyperglycaemia or dysglycaemia) is often a manifestation 
of a much broader underlying disorder (Zimmet, 1999; Reaven, 1988). This includes 
the metabolic syndrome (sometimes called syndrome X) - a cluster of CVD risk factor 
that in addition to glucose intolerance (that is IGT or diabetes), includes 
hyperinsulinemia, dyslipidemia, hypertension, visceral obesity, hypercoagulability 
and microalbuminuria. 
There is a continuing debate as to the primary aetiological factor for the 
syndrome. Genetic factors, visceral obesity, insulin resistance and endothelial 
dysfunction may all contribute either solely or jointly (Reaven, 1988; Zimmet, 1999). 
Irrespective of the aetiologic debates, a recent report from the WHO has highlighted 
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both the need and the importance of a consistent definition of the metabolic syndrome 
and has suggested parameters (Table 3). 
Diabetic mellitus is a heterogenous group of disorders characterized by high 
blood glucose level (ADA, 2001). The pancreatic P-cell and its secretory product 
insulin are central in the pathophysiology of diabetes. In type 2 or non-insulin 
dependent diabetes mellitus, muscle and fat cells are resistant to the actions of insulin 
and compensatory mechanisms that are activated with p-cell to secrete more insulin 
are not sufficient to maintain blood glucose levels within a normal physiologic range 
(Cavaghan et al, 2000; Kahn, 2001). 
Type 2 diabetes is made up of different forms each of which is characterized 
by a variable degree of insulin resistance and p-cell dysfunction and which together 
lead to hyperglycaemia (ADA, 2001). At each end of this spectrum are single gene 
disorders that affect the obesity of the pancreatic p-cell to secrete insulin (Fajans et 
al, 2001; Owen and Hattersley, 2001) or the ability of muscle, fat and linear cells to 
respond to insulin action (Taylor and Arioglu, 1999; Barroso et al, 1999). 
Table 3: Aetiological Determinants and Risk factors of type 2 diabetes 
Genetic factors: 
Genetic markers, family history, thrifty gene(s) 
Demographic characteristics: 
Sex, age, ethnicity 
Behavioural and life style-related risk factors: 
Obesity (including distribution of obesity and duration) 
Physical inactivity 
Diet 
Stress 
Westernization, urbanization, modernization 
Metabolic determinants and intermediate risk categories of type 2 diabetes: 
Impaired glucose tolerance 
Insulin resistance 
Pregnancy-related determinants (partly, gestational diabetes, diabetes in 
offspring of women v^th diabetes during pregnancy, in the uterine mal or one 
nutrition) 
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The Concealed Burden of Impaired Glucose Tolerance 
Type 2 diabetes is increasingly common indeed epidemic, primarily because 
of increases in the prevalence of a sedentary life style and obesity (Zimmet, 1995) 
The possibility of prevailing type 2 diabetes by interventions that affects the lifestyle 
of subjects at high risk for the disease is now the subject of a number of studies; these 
have focused on people with impaired glucose tolerance (IGT) (Tuomilehto et ai, 
2001). IGT is defined as hyperglycaemia (with glucose values intermediate between 
normal and diabetes) following a glucose load (WHO, 1999). It represents a key stage 
m the natural history of type 2 diabetes as these people are at much higher future risk 
than the general population for developing diabetes (Harris and Zimmet, 1997). 
Subjects with IGT also have a heightened risk of macrovascular disease 
(Harris and Zimmet, 1997). Because of this, and the association with other known 
CVD risk factors including hypertension, dyslipidemia and central obesity (Zimmet 
and Alberti, 1997), the diagnosis of IGT, particularly in apparently healthy and 
ambulatory individual, has important prognostic implications (Perry and Baron, 
1999). Impaired fasting glucose (IFG) was introduced recently as another category of 
abnormal glucose metabolism (ADA, 1998). It is defined on the basis of fasting 
glucose concentration and like IGT, it is associated with risk of CVD and ftiture 
diabetes (Table 4). 
Table 4: Values for diagnosis of diabetes and other types of hyperglycaemia. 
Diabetes mellitus fasting 
2-h post-glucose load 
Impaired glucose tolerance fasting 
2 h post-glucose load 
Impaired fasting glucose fasting 
2 h post-glucose load 
Glucose Concentration (mM) 
Plasma 
venous 
>7.0 
>ll . l 
<7.0 
7.8-11.0 
6.1-6.9 
<7.8 
Capillary 
>7.0 
>12.2 
<7.0 
8.9-12.1 
6.1-6.9 
<8.9 
Whole 
blood 
venous 
>6.1 
> 10.0 
<6.1 
6.7-9.9 
5.6-6.0 
<6.7 
Capillary 
>6.1 
>II.l 
<6.1 
7.8-11.0 
5.6-6.0 
<7.8 
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Diabetes in Children and Youth 
Type 2 diabetes in children, teenagers and adolescents is a serious new aspect 
of the epidemic and an emerging public health problem of significant proportions 
(Fagot-Campagna and Narayan, 2001; Rosenbloom et al, 2001). Although type 1 
diabetes remains the main form of the disease in children worldwide, it seems 
possible that type 2 diabetes will be predominant from within ten years in many ethnic 
groups and potentially in Europid (of European descents) groups and reported from 
several developed countries like US, UK, Australia, Hong Kong and Japan. 
The rising prevalence of obesity and type 2 diabetes in children is 
symptomatic of the effect of globalisation and industrialization affecting all societies 
with sedentary life style and obesity, the predominant factors involved. As a result of 
this new and alarming scenario (Zimmet, 2000), a joint consensus statement has been 
issued recently by the American Diabetes Association and American Academy of 
Pediatrics (ADA, 2000). 
Genetic Differences in insulin secretion 
Maturity-onset diabetes of the young (MODY) is a clinically heterogenous 
group of disorders characterized by non-ketonic diabetes mellitus, an autosomal 
dominant mode of inheritance, onset usually before 25 years of age and frequently in 
childhood or adolescence, and a primary defect in pancreatic p-cell function (Fajans et 
al, 2001; Owen and Hattersley, 2001). MODY can resuU from mutations in any one 
of at least six different genes that include the glycolytic enzyme glucokinase and five 
transcriptive factors: hepatocyte nuclear factor (HNF)-4a, HNF-la, insulin parameter 
factor 1 (IPF-1), HNF-lp neurogenic differentiation 1/p cell E-box transactivator 2 
(Neuro Dl BETA 2). 
All are expressed in the pancreatic p-cell and mutations lead to p-cell 
dysfunction and diabetes mellitus in heterozygous state. Glucokinase is expressed at 
highest levels in pancreatic p-cell and liver (Newgard and Matschinsky, 2001), 
Heterozygous mutation leading to partial deficiency of glucokinase are associated 
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with MODY and homozygous mutation resuhing in complete deficiency of this 
enzyme lead to pennanent neonatal diabetes mellitus (NJ0stad, 2001). 
The transcription factors HNF-la, HNF-ip and HNF-4a are involved in the 
tissue specific regulation of gene expression in the liver, pancreatic p-cells and other 
tissues (Cereghini, 1996; Ryffel, 2001). In the pancreatic p-cell, they regulate the 
expression of msulm as well as proteins involved in glucose transport, glycolysis and 
mitochondrial metabolism, all of which are important in the regulation of insulin 
secretion (Ryffel, 2001). Mutations in these genes produce defects in insulin secretory 
responses to a variety of factors, particularly glucose, which are present before the 
onset of hyperglycaemia (Fajans et al, 2001; Owen and Hattersley, 2001). Insulin 
promotor factor-1 (IPF-1) is a homeodomain containing transcription factor involved 
in pancreas development (Jonsson et. al, 1994; Edlund, 1998), transcriptional 
regulation of a number of p-cell genes including insulin, glucokinase, islet amyloid 
polypeptide and glucose transporter 2 (GLUT2) (Edlund, 1998), and mediation of 
glucose-stimulated insulin gene transcription (Marshak et al, 1996). 
p-cell Dysfunction in type 2 diabetes 
In type 2 diabetes, more moderate abnormalities of secretion are present that 
cause glucose intolerance only if insulin resistance is also present. The genetic basis 
of P-cell dysfunction in this form of diabetes is more complex, involving both 
multiple interacting genes and environmental factors which determines whether 
diabetes will develop and at what age despite a genetic predisposition, diabetes may 
never manifest, and hyperglycaemia, when it occurs, usually do later in life (50+ 
years) (NTH, 1995), although there has been a disturbing increase in the prevalence of 
type 2 diabetes in children in recent years (Ludwig and Ebbeling, 2001). The 
compensatory hypersecretion of insulin in insulin resistant states is due to an 
expansion of p-cell mass (Pick et al, 1998), alteration in the expression of key 
enzymes of p-cell glucose metabolism, and is believed to be a consequence of 
increased levels of this glycolytic enzyme hexokinase (Milbum et al, 1995). In 
normal pancreatic p-cells glucokinase mediates the conversion of glucose to glucose 
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6-phosphate and to determine the threshold at which glucose stimulate insulin 
secretion (Newgard and Matschinsky, 2001). Insulin resistance is associated with 
increased p-cell hexokinase activity leading to secretion of insulin at lower glucose 
concentration. It has been suggested that increased free fatty acids in serum could 
precipitate p-cell failure (Cavaghan et al., 2000). Short-term exposure of pancreatic 
islets to free fatty acids increases insulin secretion, but long-term exposure inhibits 
glucose-induced insulin secretion and biosynthesis, and may lead to p-cell deaths by 
apoptosis. These effects may be mediated by increased expression of proteins, which 
uncouple glucose metabolism from oxidative phosphorylation a key link between p-
cell glucose metabolism and insulin secretion (Zhang et al., 2001). 
Genes and type 2 Diabetes 
The identification and characterization of the genes involved in type 2 diabetes 
will add an essential level to our understanding of the pathways regulating p-cell 
fimction, including those for p-cell compensation. A common amino acid 
polymorphism (Pro 12 Ala) in peroxisome proliferator-activated receptor-y (PPAR y) 
has been associated v^th type 2 diabetes (Altschuler et al., 2000). People homozygous 
for the Prol2 allele are more insulin resistant than those having one Alal2 allele and 
have a 1.25-total increased risk of developing diabetes. There is also evidence for 
interaction between this polymorphism and fatty acid, thereby linking this locus with 
diet (Luan et al, 2001) Diabetic islets show reduced insulin gene transcription; this 
might be due, at least impact, to reduced insulin action in that tissue and indicate that 
activation of insulin gene transcription is an important effect of insulin-mediated 
signalling (Leibiger et al., 2001). 
Genetic variation in the gene encoding Calpain-10, a ubiquitously expressed 
cysteine protease, has also been associated with type 2 diabetes, increasing risk as 
much as three fold (Horikawa et al., 2000) through affects on both the normal 
function of the P-cell and insulin action in muscle and fat. 
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Mitochondrial Mutations and Diabetes 
Point mutation or deletions in mtDNA have been associated with a large 
spectrum of diseases, with symptoms such as muscle weakness, cardiomyopathy, 
optic nerve atrophy, retinal dystrophy, impaired hearing and hyperglycaemia (diabetes 
mellitus). Point mutations in mitochondrial and RNA genes are the primary cause of 
these pathophysiological manifestations. A specific maternally inherited form of 
diabetes mellitus was first linked to mutation in the mtDNA in 1992 (Ballinger et al, 
1992). Often associated wAh. neurosensory deafness; it is also called maternally 
inherited mitochondrial diabetes and deafness (MIDD). Altogether, mitochondrial 
diabetes accounts for approximately 1% of all cases of diabetes (Maassen et al, 
2001). The molecular diagnosis of mitochondrial diabetes is complicated by an 
invariably low degree of heteroplasmy in the peripheral white blood cells usually used 
for genetic analysis. The mitochondrial diabetes phenotype illustrates the importance 
of normal respiratory-chain function in the p-cell for glucose homeostasis. 
In contrast to the above mentioned rare monogenic, mitochondrial diabetes, 
type 2 diabetes is common and polygenic in nature (Froguel and Velho, 2001) 
Patients usually displays both resistance to insulin at its target tissues (mainly skeletal 
muscle) as well as defective insulin secretion (Polonsky et al, 1996). Although the 
contribution of variations in mtDNA to the development of type 2 diabetes is 
unknown, a 50% decrease in mtDNA copy number in skeletal muscle of type 2 
diabetes was observed. Reduced mtDNA content was also reported in peripheral 
blood cells in such patients even before the onset of the disease (Lee et al, 1998). 
UCP2 is an inner mitochondrial membrane protein that tends to diminish the 
proton gradient generated by the respiratory chain. Its over expression in p-cells 
attenuates ATP generation and insulin secretion in response to glucose (Chan et al, 
2001). It is of interest that deletion of the UCP-2 gene in mice enhances islet ATP 
generation and insulin secretion during glucose stimulation (Zhang et al, 2001). Type 
2 diabetics usually have both hyperglycaemia and hyperlipidaemia. This is thought to 
induce the phenomenon of 'glucolipotoxicity' in the p-cell, leading to lipid 
accumulation, impaired glucose metabolism and alterations in mitochondria (linger et 
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al, 1999). Chronic exposure of p-cells to fatty acids induces changes in the 
expression of numerous genes, among them, is UCP-2 gene, which correlates with 
reduced glucose-evoked insulin secretion (Lameloise et al, 2001). 
Drug Targets for Type 2 Diabetes and Insulin Resistance 
The current therapeutic approaches were largely developed in the absence of 
the fine molecular targets or understanding of pathogenesis of the diseases. In last 
few years a large number of molecular drug targets involving various biochemical 
pathways have been worked out. These are based on the basis of predicted roles in 
modulating one or more key aspects of the pathogenesis of the diabetes and metabolic 
syndrome. These are: (1) reducing excessive glucose production by liver (2) targeting 
P cells (3) targeting insulin signalling pathways (4) targeting lipid metabolism 
Reducing Excessive Hepatic Glucose Production 
Liver by way of gluconeogenesis and glycogenolysis plays a very important 
role in regulating endogenous glucose production by synthesis or break down of 
glycogen. Increased rates of hepatic glucose production are largely responsible for 
development of overt hyperglycaemia. Glucagon contributes to hyperglycaemia 
through induction of gluconeogenesis and glycogenolytic pathways (linger, 1971; 
Shah et al, 2000) its receptor; a seven transmembrane domain G-protein receptor 
could be a target for development of small-molecules antagonists (Connell, 1999). 
Besides, several enzymes that regulate rate-controlling steps in gluconeogenesis or 
glycogenolytic pathways can also be used as molecular target for therapeutic 
intervention. One such enzyme is inhibition of hepatic glycogen phosphorylase 
(Treadway et al, 2001), an enzyme that catalyses release of glucose from glycogen. 
Others are fructose-1, 6- biphosphatase and glucose-6-bi phosphatase (Zhang and 
MoUer, 2000). Whereas inhibition of fructose 1-6 biphosphatase would selectively 
block gluconeogenesis by disrupting the conversion of fructose-1,6-biphosphate to 
fructose-6-phosphate, inhibition of glucose-6-phosphatase would attenuate final step 
in hepatic glucose production common to gluconeogenic and glycogenolytic 
pathways. 
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Treating p-cells 
Two distinct gut derived peptide hormones glucagon-like-peptide-1 (GLP-1) 
and gastric inhibitory peptide (GIP) act through their respective G protein coupled 
receptors on (3 cells to potentiate glucose stimulated insulin secretion (Drucker, 2001). 
Administration of any of these two hormones to humans can potentiate insulin 
secretion. Since both hormones are subject to rapid amino terminal degradation by 
dipeptidylpeptidase-IV (DP-IV), use of .modified GLP-1 peptide agonists resistant to 
this enzyme has been recommended. It is observed that DP-IV null mice have 
increased circulating active GLP-1 along with enhanced insulin secretion, and an 
otherwise healthy phenotype (Marguet et al, 2000). Thus, development of GLP-1 
analogues and DP-IV inhibitors is likely to yield important new therapeutic 
approaches that might circumvent the liabilities of hypoglycaemia, weight gain and 
secondary failures associated with sulphonylurea use. 
Targeting the insulin signalling pathways 
Insulin resistance can be due to multiple defects in signal transduction such as 
impaired activation of insulin receptor-tyrosine kinase and reduced activation of 
insulin stimulated phosphatidylinositol-3-OH kinase (PI-3-K). A number of molecular 
targets are now being investigated as ways of enhancing insulin mediated signal 
transduction. Elevated expression of PTP 1B has been reported in insulin resistant 
patients (Drake and Posner, 1998). Over expression of this enzyme prevents insulin 
receptor kinase activation. A PTP IB knock out mouse was more insulin sensitive 
than control littermates (Table 5). Thus inhibition of PTP IB represents a good target 
for drug discovery (Goldstein et al, 1998). 
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Table 5: Potential drug targets in the insulin signaling pathway 
Target 
PTP-IB 
Protein 
Tyrosine 
Phosphatase 
SHIP-2 
GSK-3 
1KB Kinase 
PKCe 
Insulin, small 
molecules/activators/potentiators 
Efficacy of vanadium 
compounds; PTP-IB* (null) mice 
(insulin sensitive and obesity 
resistant); efficacy of PTP-IB 
antisense oligonucleotide 
SHIP-2*'- mice (Insulin 
sensitive) 
Efficacy of GSK-3 inhibitors in 
rodent model 
Efficacy of high-dose 
salicylate/inhibits 1KB kinase) 
1KB kinase*'- mice (insulin 
sensitive) 
Activated in muscle in 
association with fatty acid 
induced insulin resistance. 
Apparent direct activation of 
rhc receptor 
Mediates dephosporylation of 
insulin receptor (and its 
tyrosyl-phosphorylated 
substrate) 
Dephosphorylation of 
phosphoionositides (e.g. 
products of PI3K). 
Phosphorylation of glycogen 
synthase leading to inhibition 
of glycogen synthesis 
potential, negative regulation 
of other insulin signaling 
events. 
Serine threonine 
phosphorylation of insulin 
signaling intermediate (e.g. 
IRS proteins) 
Negative regulation of insulin 
signaling; potential threonine 
phosphorylation of IRS 
proteins. 
Other putative negative regulators of insulin signalling have recently been 
implicated as independent drug targets. Glycogen synthase kinase-3 (GSK-3) has a 
clear role in opposing the effect of insulin by inhibiting the activation of glycogen 
synthase and the subsequent accumulation of glycogen in muscle (Weston and Devis, 
2001). Recent results with selected inhibitors of GSK- 3 activity in vivo could indeed 
augment insulin action (Henriksen et al, 2001). SH2 domain containing inositol 5-
phophatase type 2 (SHIP 2) may function to dephosphorylate key phospholipids e.g. 
phosphatidyl inositol phosphate generated by insulin mediated PI (3) K activation. 
Recently hetero2ygous null mice have been shown to mark enhanced sensitivity to 
[ 23 ] 
Review of Literature 
insulin, implicating this enzyme as diabetic target (Clement et al, 2001). Protein 
kinase C9 could be an additional drug target as increased muscle PKC9 activity has 
been observed in the context of fatty acid induced insulin resistance (Shulman, 2000). 
Targeting Lipid Metabolism 
Since obesity plays an important role in development of insulin resistance, 
attenuating the appetite and/or enhancing energy expenditure will be of great use in 
treating type 2 diabetes. Melanocortin-4 receptor (MCR-4) offers the prospects of 
ameliorating obesity and type 2 diabetes. Thus, either an increase in the expression of 
a natural MCR-4 antagonist or knock out of the receptor itself produces a strong 
phenotype with multiple features of metabolic syndrome (Klebig et al, 1995; Huszar 
et al, 1997). Appetite reduction through central inhibition of fatty acid synthase also 
offers a new target (Loftus et al, 2000). cAMP activated protein kinase, acetyl CoA 
carboxylase, adipocyte related complement protein 30, PPAR-y and PPAR-a 
represent some of the mechanisms that could be exploited to reverse or prevent 
obesity related lypotoxicity.(Winder and Hardie, 1999; Abu-Elheiga et al, 2001; 
Willsone/a/.,2000). 
PPARs are ligand activated transcription factors, which are members of 
nuclear receptor family offering a promising therapeutic target for metabolic 
syndrome. PPAR-y is a predominant molecular target for insulin sensitising 
thiazolidinedione (TZD) drugs (Willson et al, 2000; Moller and Greene, 2001). 
PPAR-y effect the gene transcription in adipose tissues leading to induction of 
adipocyte genes, such as those for lipoprotein lipase and fatty acid transporter-1, 
which results in improvement in insulin action along with lowering of triglycerides 
and FFA levels (Moller and Greene, 2001). A closely related nuclear receptor, PPAR-
a is the molecular target for fibrate class of lipid modulating drugs. (Willson et al, 
2000). PPAR-a agonists have an independent insulin sensitising effect arising from 
reduction in muscle lipid content (Ye et al, 2001). 
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Treatment of Insulin Resistance and Type 2 diabetes 
Given that insulin resistance is an early and pervading feature of typical forms 
of type 2 diabetes and other components of syndrome, it may be surprising that 
insulin resistance is not widely recognized as a clinical entity deserving its own 
therapeutic attention. Treating uisulin resistance is not a simple matter of either giving 
more insulin to push the signalling pathways harder, or reducing insulin 
concentrations to reduce the consequences of hyperinsulinemia. Either approach 
carries penalties. Giving more insulin can increase those actions of insulin that are 
impaired by the bottlenecks of signal transduction. However, everting the desired on a 
severely compromised pathway of insulin {e.g. impaired glucose transport) can result 
in gross accentuation of other less desirable actions of insulin {e.g. lipogenesis, 
leading to hypertriglyceridemia and obesity, or sodium retention, promoting 
hypertension), hideed, excess insulin exacerbated insulin resistance at the receptor 
and post-receptor levels. Thus, the detrimental effects of hyperinsulinemia can be 
increased by insulin therapy and thus is added risk that excess insulin will precipitate 
episodes of hypoglycaemia, reducing insulin concentrations is a particular problem in 
type 2 diabetes. 
Antidiabetic Drugs 
For type 2 diabetes it is clearly a priority to provide effective control of the 
hyperglycaemia to reduce macro and micro vascular complication (Skyler, 1997; 
UKPDS, 1998). The standard approach begins with dietary advice and exercise and 
healthy living advice, particularly designed to facilitate weight loss in the obese. 
These measures are ineffective in more than four-fifth of newly diagnosed type 2 
diabetes patients, and the progressive nature of type 2 diabetes dictates that most 
patients required drug therapy. Oral agents, notably sulphonylureas, metformin and 
acarbose, are instituted as monotherapy and a new class-TZDs (Thiazolidinediones) 
has become available recently (Table 6). If adequate glycaemic control is not 
achieved with oral monotherapy. Then two different classes of oral drugs are used in 
combination (Bailey, 1996). hisulin therapy sometimes is supplemented with an oral 
agent to further improve glycaemic control and/or lower insulin dosage. 
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Table 6: Current therapeutic agents for type-2 diabetes 
Drug class 
Insulin 
Sulphonyl ureas (e.g. 
glibenclamide) plus 
nateglimide and 
repaglimide 
Metformin (biguanides) 
Acarbose 
Pioglitazone, rosiglitazone 
(Thiazolidinediones) 
Molecular target 
Insulin receptor 
SU receptor/K^ ATP 
channel 
Unknown 
a-glucosidase 
PPAR-Y 
Sites of action 
Liver, muscle, fat 
Pancreatic P-cell 
Liver (muscle) 
Intestine 
Fat, muscle, liver 
Adverse events 
Hypoglycaemia, 
weight gain 
Hypoglycaemia 
weight gain 
Gastrointestinal 
disturbance lactic 
acidosis 
Gastrointestinal 
disturbances 
Weight gain, edema, 
anaemia 
Acarbose competitively inhibits a-glucosidases in the brush border of the 
small intestine (Lebovitz, 1997). This slows carbohydrates digestion and lowers post-
prandial hyperglycaemia. Although insulin resistance is not addressed directly. The 
blood glucose lowering effect vdth reduced glucotoxicity without increasing/and 
possibly decreasing) insulin concentrations; thereby reducing at least one part of 
insulin resistance. Sulphonylureas and a new short-acting insulin releaser 
(repaglinide) act directly on the islet p-cells to close ATP-sensitive K^  channels, 
which stimulates insulin secretion (Groop, 1992; Bailey, 1998). The efficacy of these 
agents depends on the presence of enough (i-cells with sufficient functional reserve. 
However, the endogenous insulin response to glucose is usually diminished in 
advanced states of type 2 diabetes. Thus, a small drug-induced increases in insulin 
secretion, especially post-prandially, are clinically valuable to assist glycaemic 
control. Insulin therapy usually will provide effective glycaemic control when oral 
agents are inadequate (Galloway, 1990). However, insulin administration does not 
reinstate an entirely normal pattern of glycaemic control, and although glucotoxicity 
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is decreases, the vicious spiral of insulin resistance and hyperinsulinaemia is not 
broken. 
Metformin is the only established antidiabetics drug that deals with insulin 
resistance. Its glucose-lowering effect is mainly a consequence of reduced hepatic 
glucose output (gluconeogenesis and glycogenolysis) and increased insulin stimulated 
glucose uptake and glycogenesis in skeletal muscle (Bailey and Turner, 1996). 
Metformin improves insulin action in tissues that are acutely sensitive to insulin by 
increasing insulin-stimulated-insulin receptor phosphorylation and tyrosine-kinase A 
(Stith et al, 1996). Another action of metformin is to reduce fatty acid oxidation in an 
apparently insulin-independent marmer, which serves to redress the imbalance in the 
glucose-fatty acid cycle. Thus, metformin improve insulin sensitivity in lined and 
skeletal muscle without raising insulin concentrations. In fact, insulin concentrations 
tend to fall during chronic therapy (UPKDS, 1998). Metformin also improves insulin 
action in adipose tissue but obesity is offset by increased glucose turn over and lower 
insulin concentration. Metformin offers a range of benefits that combat insulin 
resistance and various aspect of syndrome X consistent with the treatment regimens 
for type 2 diabetes that are initiated with metformin show a particularly favourable 
long-term reduction in morbidity and mortality from micro and macrovascular 
complications (UKPDS, 1998). 
Thiazolidinediones (TZDs) 
PPARs (Peroxisome proliferator activated receptors) are ligand activated 
transcription factors (members of nuclear receptor family), which offer a promising 
therapeutic approach to the metabolic syndrome. The known beneficial effects of 
PPAR ligands are largely consistant with mechanism that can ameliorate lipotoxicity. 
PPAR-y is the predominant molecular target for insulin sensitising thiazolidinedione 
(TZDs) drugs (Wilson et al, 2000). New compounds with markedly enhanced 
potency and selectivity for the receptor have recently been discovered (Moller and 
Greene, 2001). This new class of oral antidiabetic agents targets the nuclear PPAR-y, 
which increases transcription of certain insulin sensitive genes. Thus, TZDs provide a 
new approach to the treatment of insulin resistance (UKPDS, 1998). Although, their 
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long-term clinical efficacy is still under investigation, their blood glucose-lowering 
activity appears to be increased in the presence of at least normal circulating levels of 
insulin. Hence, efficacy is greater in combination with insulin therapy or an insulin 
releaser. Consistent with the different circular mechanisms of TZDs and metformin, 
preliminary clinical studies have suggested that the two classes of agents can be used 
in combination to achieve additive blood glucose-lowering activity. 
The TZDs represented by troglitazone, roziglitazone and pioglitazone, have 
recently been introduced in the market as insulin sensitizers for the treatment of type 2 
diabetes. These agent improve sensitivity to insulin by binding to the nuclear receptor 
like peroxisome proliferator activated receptor-y (PPAR-y), which acts in conjuction 
with the retinoid X receptor (RXR) by de-repression to increase transcription of 
certain insiilin sensitive gene (Spiegelman, 1998), like in adipose tissue where PPARy 
is highly expressed, lipoprotein lipase (LPL), fatty acid transporter protein (FATP), 
adipocyte fatty acid binding protein (aP2), fatty acyl CoA synthase, transports uniform 
GLUT4. There is preliminary preclinical evidence that TZDs might reduce renal 
complications and prolong the granulation of functionally impaired P-cells 
(Buckingham et al, 1998), although the mechanism is undetermined. Troglitazone 
was efifective for type 2 diabetes, it has been withdrawn from the market as a result of 
idiosyncratic hepatotoxicity; however, this has not been observed with rosiglitazone 
or pioglitazone (Saleh, 1999). TZDs are especially effective in combination with 
insulin to reduce the high insulin dosage and improving glycaemic control in type 2 
diabetes and they are also used effectively in combination with other class of 
antidiabetic agents (Patel et al, 1999). 
Animal Models to study Diabetes and Insulin Resistance 
Spontaneous diabetes is a common occurrence in many animal species. In 
addition, animals can be rendered diabetic by a wide variety of experimental 
procedure. Diabetic animal may be regarded as model of the disease in man. 
However, such animals display a wide diversity of pathophysiology, and, in fact, no 
animal syndrome corresponds precisely to any type of diabetes in human subject. The 
most common diabetic syndromes in animals occur in the context of obesity, 
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hyperinsulinemia and insulin resistance (Mordes and Mordes, 1983). Diabetes may be 
produced experimentally by means of surgery, viral infection, the administration of 
various hormones and chemical agents and genetic manipulation of selective 
interbreeding. Both the spontaneous and experimental animal models have been used 
effectively to study the etiologies, complications, treatments and prevention of 
diabetes (Mordes and Mordes, 1983). There are many advantages to the study of 
diabetes in animals. In human populations, for example, genetics are difficult to study 
and impossible to control. In contrast, rodent colonies allow many generations to be 
studied accurately in a relatively short period of time. 
Use of Chemical Agents for producing Diabetes in animals 
Chemically induced diabetes mellitus is the most commonly used animal 
model of diabetes. These agents provide relatively permanent diabetes that is suitable 
for long-term studies. Alloxan, a cyclic urea analogue, was the first agent in this 
category to produce permanent diabetes in laboratory animals. STZ (Streptozotocin) 
has replaced alloxan as a principal agent used to produce experimental diabetes. This 
is due to greater selectivity of p-cells for STZ. The lower mortality rate seen in STZ 
diabetic animals and the longer half-life of STZ in the body (15 min) (McNeil, 1999). 
Alloxan Induced Diabetes 
The mechanism by which alloxan (2,4,5,6-tetraoxohexa-hydropyrimidine) 
produces diabetes in susceptible species is not clear. It has been shown that alloxan 
has several effects on the P-cells of pancreas and it is likely that combination of these 
effects results in the destruction of p-cells by alloxan. Two factors appear to make the 
islet especially sensitive to the effect of alloxan; one is that it is rapidly taken up into 
islet cells (Gepts, 1963) and the second is the sensitivity of islet to peroxides (Dunn et 
al, 1943). Another mechanism proposed for the diabetogenic effect of alloxan is its 
ability to react with protein sulfhydryl (SH) group. This involves reaction of alloxan 
with SH group on glucokinase, a signal recognition enzyme in the pancreatic p-cells 
that couples changes in blood glucose concentration of insulin secretion (Rakieten et 
al, 1963; Junod et al, 1969; Lenzen et al, 1988). By this mechanism, inhibition of 
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glucokinase and other SH containing membrane proteins on the p-cells would 
eventually result in cell necrosis (Lazarow, 1946; Lazarow et ai, 1948). Alloxan has 
been used in a wide variety of species for the induction of experimental model of 
diabetes mellitus including rodents, such as rat, mice, dogs, cats and nonhuman 
primates. The dose required for the induction of diabetes varies between species and 
route of administration. In rats, the dose of alloxan ranges from 50-300 mg/kg 
depending on the route of administration (Duff and Murray, 1968). The lower dose 
range is typically administered by intravenous injection while the higher one is used 
primarily by subcutaneous. 
STZ Induced Diabetes 
Streptozotocin (STZ) is a broad-spectrum antibiotic that is produced from 
Streptomyces achromogenes (Rakieten et al., 1963). The chemical structure of STZ 
comprises a glucose molecule with a highly reactive nitrosourea side chain that is 
thought to initiate its cytotoxic action. The glucose moiety directs this agent to the 
pancreatic p-cells where it binds to a membrane receptor to generate structural 
damage (Johansson and Tjalve, 1978). At the intracellular level, three major 
phenomena currently held responsible for p-cell deaths are process of methylation, 
free radical generation and nitric oxide (NO) production. 
Methylation- The deleterious effect of STZ results from the generation of highly 
reactive carbonium ion (CHs"^ , formed from decomposition of the nitrosomoiety. The 
CHa"^  ions cause DNA breaks by alkylating DNA bases at various positions (Uchigata 
et al, 1982), resulting in activation of the nuclear enzyme poly (ADO-ribose) 
synthetase as a part of the cell repair mechanism. 
Free Radicals- Free radical involvement in STZ effect has also been investigated. 
Hydrogen peroxide has been shown to be produced in pancreatic islets upon STZ 
exposure m vivo and in vitro (Gandy et al, 1982; Papaccio et al, 1986). 
Nitric Oxide- Involvement of NO has also been proposed as a possible mechanism for 
mediating the diabetogenic effect of STZ (Kown et al, 1994). The precise metabolic 
process leading to NO generation from STZ is unclear (Turk et al, 1993), but may 
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involve the metabolism or spontaneous decay of STZ. STZ concentrates in p-cells due 
to its high affinity for the p-cell membrane, unique SH groups that render the p-cell 
membrane especially sensitive to oxidative interaction, a low capacity of p-cell to 
scavenge free radical. 
Pancreatectomy 
The induction of diabetes mellitus can be achieved through the surgical 
removal of all or part of the pancreas. In the partial pancreatectomy more than 90% of 
the organ must be removed to produce some from of diabetes (Duff and Murray, 
1968). Depending upon the amount of intact pancreatic cells, diabetes may range in 
duration from a few days to several months (Kaufmaim and Rodriguez, 1984). The 
use of pancreatectomy in combination with chemical agents such as alloxan or STZ 
(Tschoepe et al, 1989; Reiser et al, 1987) produces a stable form of diabetes mellitus 
in animals such as cats and dogs that does not occur when each procedure is applied 
independently. 
Dexamethasone-Induced Diabetes Mellitus 
Dexamethasone is a long acting glucocorticoid that stimulates 
gluconeogenesis and insulin secretion and inhibits glucose uptake by the fat cells. 
Dexamethasone has been used to produce models of non-insulin dependent diabetes 
mellitus (NIDDM) and also when used at higher doses or in combination with other 
methods, to produce a model of insulin-dependent-diabetes. Treatment of rats with 
dexamethasone produces a NIDDM thought to be due to insulin resistance (Ogawa et 
al, 1992). Dexamethasone administration decreased glucose-stimulated insulin 
secretion and significantly reduced GLUT-2 levels in the p-cells (Takahashi et al., 
1990). 
Spontaneous Insulin-dependent Diabetes Mellitus (IDDM) in Non-obese Diabetic 
(NOD) Mice 
Spontaneous development of autoimmune T-cell mediated IDDM in NOD 
mice of both sexes is the salient strain characteristic. The pathogenic role of 
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autoreactive T-cells in NOD mice has been well established (Bendelac et al, 1987). 
The prediabetic period is characterized by a heavy leukocyte infiltration of the 
pancreas (msulitis). Insulitis initiates as early as 3 to 13 week postpartum in females, 
and slightly later in males. The intra islet leukocytes, primarily CD4'^  and CD8^ T-
cells, with variable number of B-lymphocytes and macrophages/dendritic cells, elicit 
destruction of only the p-cells in the pancreatic islets. Onset of hyperglycaemia and 
glycosviria is earlier in females than in males. This variability in IDDM frequencies 
has been shown to be the consequence of envirormiental factors, both in microbial and 
dietary environments (Bowman et al., 1994). 
The BB Rat: A Unique Model of Human Type-1 Diabetes 
The BB rat is a unique rodent model that spontaneously develops insulin-
dependent (IDDM) diabetes. The clinical presentation of diabetes in the BB rats is 
similar to that of its human counterpart (Nakahooda et al., 1977). Marked 
hyperglycaemia, glycosuria, and weight loss occur within a day of onset and are 
associated with decreased plasma insulin. Unlike most NOD mouse colonies, both 
sexes of BB rats are equally affected. The pancreas of afflicted animal has less than 
0.1% of normal insulin content, and light microscopic examination of the pancreas at 
the end stage of disease shows small islets containing virtually no p-cells (Nakhooda 
et al, 1977). The progression from normal to severely decompensated glucose 
homeostasis occurs very rapidly, over intervals of hours to a few days (Nakhooda et 
al., 1978). 
Neonatal STZ Model of Type 2 diabetes 
Animal studies have been usefiil in exploring the molecular mechanisms 
underlying the development of type 2 diabetes. Neonatal rats treated with STZ (80-
120 mg/kg) at birth (nO) or within the first 5 days following birth (nl-5) experience 
severe pancreatic p-cell destruction, accompanied by a decrease in pancreatic insulin 
stores and a rise in plasma glucose levels (Blondel et al., 1989; Weir et al., 1981). 
However, in contrast to adult rats treated with STZ, the p-cell of the treated neonates 
partially regenerates (Wang et al., 1996). Following an initial spike in plasma glucose, 
the STZ-treated neonatal rat become normoglycaemic by 3 weeks of age. In the next 
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few weeks, the p-cell number increases, the extent depending upon both the age at 
which the animal is treated with STZ and the species of the treated rat (Blondel et al, 
1989; Weir et al, 1981; Wang et al, 1996; Bonner-Weir et al, 1981; Iwase et al, 
1994). The aging process also affects the diabetic state of the STZ-treated rat. 
Although 10 weeks old n2 STZ Wistar rats exhibit normal non-fasting glucose and 
insulin levels, they are markedly glucose intolerant. However, these animals become 
progressively more glucose intolerant with age. By 6 months of age, a glucose 
challenge provokes a condition of severe hyperglycaemia and hyperinsulinemia. 
(Schaffere/a/.,1993). 
Pancreatic Insulin secretion in Neonatal STZ Model- The regulation of insulin 
secretion is extremely complex, involving numerous secretagogues and modulators. 
The most important controller of insulin secretion ii glucose. The mechanism 
imderlying glucose signalling involves its metabolism to generate ATP, which in turn 
promotes the closure of ATP-dependent K*-channel, resulting in the depolarisation of 
the p-cells. A voltage dependent Ca" -^influx into the cell ensues, with the rise in Ca"^  
triggering insulin secretion (Aschroft et al, 1994). The ATP dependent mechanism is 
not imique to glucose because other metabolites, such as glyceraldehyde and marmose 
also function as insulin secretagogues. Insulin secretion triggered by these metabolic 
secretagogues is generally defective in the neonatal type 2 diabetes model (Giroix et 
al, 1983; Grill etal, 1991; Porthaera/., 1988). 
Insulin Resistance in Neonatal STZ Model- It was noticed that the whole body 
glucose utilization was normal in the 10 weeks old n2 STZ Wistar female rat, but was 
significantly reduced in the severely diabetic n5 STZ female Wistar rat. A likely 
scenario is that an early step m the signal transduction pathway of insulin becomes 
defective, causing increased insulin sensitivity of several events, including 
glycogenesis, lipogenesis, glucose production, amino acid transport and glucose 
oxidation (Kergoat et a/., 1991; Melin et al, 1991). Severe insulin resistance is also a 
characteristic of some insulin sensitive tissue of n2 STZ male Sprague-Dawley rats. 
Some investigators have found that adipocytes prepared from 6 wks old n2 STZ male 
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Sprague-Dawley rats exhibit a dramatic reduction in insulin-mediated acceleration of 
both glucose oxidation and lipogenesis (Trent et al, 1984). 
Defective Carbohydrate and Lipid Metabolism in Neonatal STZ Rat- Maintenance 
of glucose homeostasis in the nondiabetic and diabetic rat largely depends upon the 
metabolism of glucose by liver and muscle. Usually, an increased rate of hepatic 
gluconeogenesis is considered one of the dominant mechanisms underlying the 
development of hyperglycaemia in type 2 diabetes (Consoli et ai, 1989). The defect 
in peripheral glucose uptake and metabolism has been the focus of several studies 
using perfused hearts isolated from the n2 STZ male Wistar rat. It has been 
documented that basal rates of glucose utilization are significantly reduced in diabetic 
hearts; a defect attributed to a combination of reduced glucose transport and impaired 
flux through the rate-limiting en2ymes of glycolysis, phosphofructokinase (Schaffer et 
al, 1986). In contrast to glucose metabolism, fatty acid metabolism of the n2 STZ 
heart is normal. Neither the rate of endogenous fatty acid oxidation nor the levels of 
long chain fatty acyl esters are altered by the type 2 diabetes condition (Schaffer et 
al, 1991). This is not surprising m the light of evidence that the neonatal STZ model, 
in contrast to the adult STZ model, exhibits no significant alteration in plasma free 
fatty acid and triglyceride levels. 
Fructose-induced Type-2 diabetes and insulin Resistance 
Critical insights into the etiology of insulin resistance have been gained by the 
use of animal models where insulin action has been modulated by strictly controlled 
diet, an intervention not possible in human studies. Early work clearly demonsfrated 
that diets high in simple sugars (in particular fiuctose) led to insulin resistance 
(Storlien et al, 2000). Chronic administration of fiuctose to normal rats led to both 
hyperinsulinemia and in vivo insulin resistance. The insulin resistance resulting from 
chronic feeding is due to the diminished ability of insulin to suppress hepatic glucose 
production, and not to a decrease in insulin-stimulated glucose uptake by muscles. 
Wistar rats are fed a diet consisting of about 66% fiuctose, 22% protein and 12% fat, 
while control group are kept on a standard diet consisting of 59% starch, 20% protein 
and 12% fat, both the diet composition are also supplied with vitamins, minerals and 
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fibre approximately. Their body weight and blood glucose are checked on alternate 
days for 15 wks (Yagi et al, 1995). 
Insulin resistance, hyperinsulinemia and hypertriglyceridemia have been 
demonstrated in Sprague-Dawley rats fed with fructose-enriched diet (Reaven et al, 
1991). Although the exact molecular mechanism involved is unknown, it is believed 
that chronic feeding of fructose affects the early steps of insulin action in muscle and 
liver. This conclusion was drawn by comparing the phosphorylation status of the 
insulin receptor (IR) and insulin receptor substrate-1 (IRS-1), as well as the 
association of the IRS-1 with phosphotidylinositol 3-kinase (PI 3-kinase), and 
phosphotyrosine phosphatase (SHP2) in the liver and muscle. There were no 
differences in IR and the IRS-1 protein level in the liver and muscles of rats in control 
and fructose fed group. However, tyrosine-phosphorylation of the insulin receptor 
after insulin stimulation was reduced significantly in the liver of fructose fed rats. 
These data suggest that changes in the early steps of insulin signal transduction may 
have an important role m the insulin resistance observed in these rats (Bezerra et al, 
2000). Since endogenous hyperinsulinemia and hypertriglyceridemia have been 
identified as factors that increase the risk of coronary artery disease (CAD), it is likely 
that they contribute to the increased prevalence of CAD in hypertensive patient 
(Bezerra era/., 2000). 
db/db mice: Animal Model for Type 2 Diabetes Mellitus 
Prior to the development of transgenic and knockout technologies, most rodent 
studies on the insulin resistance of type-2 diabetes were performed with monogenic 
models of obesity, especially the ob/ob and db/db mice. Investigations by Friedman 
and Halaas (1998) uncovered the genetic pathways responsible for obesity in these 
strains, defect in the adipocytes derived hormone leptin (ob/ob) or its receptor (db/db). 
In addition to studies on the regulation of food intake and energy expenditure by this 
hormone, investigators have focused on the mechanism by which this system might 
impact on insulin sensitivity. Leptin acts as a synaptic modulator on acruate neurons, 
and it has profoimd effects on hypothalamic neuropeptide (NPY) neuron functions. 
NPY, actmg via specific NPY feeding receptors (Gerald et al, 1996), is a powerful 
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central appetite stimulant (orexigenic peptide), selective (Herberg and Coleman, 
1977) for carbohydrate and fat. Repeated central NPY injections ultimately lead to 
obesity, whereas exogenous leptin blocks all feeding responses to NPY. When 
administered into cerebral ventricles or specific hypothalamic nuclei, NPY robustly 
and rapidly increases feeding and suppresses energy expenditure, and thereby 
promote obesity. The mode of development of obesity in ob/ob mice is due to 
complete lack of feedback from leptin. Both hypothalamic NPY content and secretion 
are consequently elevated, and this result in hyperphagia and decreased energy 
utilization, obesity, and hyperinsulinemia (Rohner-Jeanrenaud et al, 1996). In db/db 
mice, lack of leptin receptor results in similar NPY abnormalities to the ob/ob mice. 
The db/db mouse is a well-characterized model of type-2 diabetes. The 
background for the db/db mouse is the C57BL/Ks strain (Coleman, 1978). The major 
deficiency of the C57BL/KsBom-db mouse (db/db) is lack of a functional leptin 
receptor. This leads to defect in leptin signaling and a complete lack of feedback from 
leptin. Both hypothalamic NPY content and secretion are consequently elevated, and 
this result in hyperphagia and decreased energy expenditure, obesity, insulin 
resistance, hyperinsulinemia, hyperglycaemia and dyslipidemia. The db/db mouse 
develops NIDDM from around week 10. The disease is stable until week 20 
(Coleman, 1978), where destruction of pancreatic p-cells can be recognized clinically 
as decreasing levels of plasma insulin and very severe hyperglycaemia. The db/db 
mouse has a maximal life span of 9-12 months. The male mice are more diabetic than 
females, and will normally die earlier than females. The advantage of using male mice 
for experimental procedure is that the fluctuations in plasma parameters are less than 
in females where estrogen cycle affects the clinical diabetes. 
Zucker Fatty Rat 
The fatty {fa; lap/") mutation in rat arose spontaneously in an outbred stock in 
the Zucker laboratory (Zucker et al, 1961). Obese Zucker rats are characterized by 
hyperphagia, hyperlipidemia, and mild glucose intolerance (lonescu et al., 1985). 
Obesity is accompanied by profound hyperinsulinemia detectable as early as 21 days 
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of age (Zucker and Antoniades, 1972). Pancreatic islets are enlarged and yield an 
exaggerated response to a glucose stimulus (Shiano et al, 1973). 
Zucker Diabetic Fatty (ZDF) Rat 
These rats arose from interbreeding of substrain of fa/fa that showed 
hyperglycaemia (Peterson et al., 1990). In this strain all males develop obesity, insulin 
resistance and overt type 2 diabetes between 7 and 10 weeks of age with 
hyperglycaemia. Females are obese, insulin resistant but do not become diabetic. 
These rats exhibit many characteristics of human diabetes like hyperglycaemia levels 
of pancreas and its response for glucose (Tokuyama et al., 1995). There is reduced 
pancreatic p-cell number and decreased GLUT-4 levels in heart of obese y o ^ Zucker 
rats and m adipose tissue, heart and skeletal muscle of ZDF rats (Slieker et al., 1992). 
Antidiabetic Plants 
Since ancient times plants have always been an exemplary source of drugs and 
many of the currently available drugs have been derived directly or indirectly from 
them. India has about 4500 plant species and among them, several thousands have 
been claimed to possess medicinal properties. Research conducted in last few decades 
on plant mentioned in ancient literature are used traditionally for diabetes have shown 
anti-diabetic properties. The ethnobotanical information reports about 800 plants that 
may possess antidiabetic potential (Alarcon-Aguilara et al., 1998). Several such herbs 
have shown antidiabetic activity when assessed using presently available technique 
(Saifi et al., 1971; Mukharjee et al, 1972; Ajit kar et al., 1999; Jafri et al., 2000). A 
wide array of plant derived active principles representing numerous chemical 
compounds has demonstrated activity consistant with their possible use in the 
treatment of NIDDM (Bailey and Day, 1989; Ivorra et al., 1988; Maries and 
Famsworth, 1995). Among these are alkaloids, glycosides, galactomannan gun, 
polysaccharides, peptidoglycans, hypoglycans, guanidine, steroids, carbohydrates, 
glycopeptides, terpenoids, amino acids and inorganic ions. Even the discovery of 
vwdely used hypoglycemic drug, metformin came from the traditional approach of 
using Galega officinalis. Thus, plants are a potential source of antidiabetic drugs (and 
others too) but this fact has not gained enough momentum in the scientific 
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community. The reasons may be many including lack of belief among the 
practitioners of conventional medicine over alternative medicine, alternative forms of 
medicine are not very well defined, possibility of quacks practicing such medicine 
providing alluring and magical cures and natural drugs may vary tremendously in 
content, quality and safety. 
Although, oral hypoglycaemic agents/insulin are the mainstay of treatment of 
diabetes and are effective in controlling hyperglycaemia, they have prominent side 
effects and fail to significantly alter the course of diabetic complications (Rang and 
Dale, 1991). As the knowledge of heterogeneity of these disorders increases, there is a 
need to look for more elKcacious agents with lesser side effects. Though development 
of modem medicine resulted in the advent of modem pharmacotherapeutics including 
insulin, biguanides, sulfonylureas and thiazolidinediones; there is still a need to look 
for new drug as no drug (except strict glycaemic control with insulin) has been shown 
to modify the course of diabetic complications. In relation to plants also, barring a few 
studies (Grover et al, 2000; Srivastava et al, 1988; Karunanayake et al, 1990), most 
of the studies have not assessed the impact of these plants on the course of diabetic 
complications. Most widely studied plants may be summarized as follows: 
Acacia arabica or nilotica: Babul (Hindi), Indian Gum Arabic tree (English) 
It occurs in the wild throughout India and is also cultivated. Feeding of 94% 
seed diet to normal rats showed significant hypoglycaemic effect as compared to 
control but the same diet failed to show any hypoglycaemic effect in alloxanized rats 
(175 mg/kg sc) indicating that plant acts through release of insulin (Singh et al., 
1975). Powdered seeds of Acacia arabica administered in different doses exerted a 
significant effect in normal rabbits with no acute toxicity and behavioral changes 
(Wadoode/a/., 1989). 
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Aegle marmelose: Bad or Sirphal (Hindi), Holy Fruit tree (English) 
It is a medium sized, armed deciduous tree found wildly, especially in dry 
forests and is also cultivated throughout India. Oral administration of aqueous extract 
of Aegle marmelos root bark showed hypoglycaemic effect in normal fasted rats 
(Karunanayake et al, 1984). Aqueous extract of the leaves significantly controlled 
blood glucose, urea, body weight, liver glycogen and serum cholesterol of alloxan-
induced diabetic rats as compared to control (Ponnachan et al, 1993). The extract was 
equi-effective in comparison to insulin in restoring blood glucose and body weight to 
normal levels (Seema et al, 1996). Aqueous leaf extract administered orally for 28 
days also normalized STZ-induced histopathological alterations in the pancreatic and 
kidney tissues of rats (Das et al, 1996). 
Allium cepa: Pyaz (Hindi) and Onion (English) 
It is cultivated throughout India and is an important dietary constituent. Ethyl 
ether extract showed most potent hypoglycaemic action in normal fasted rabbits 
(Augusti, 1973). Petroleum ether insoluble fraction of the dried onion powder 
exhibited significant antihyperglycaemic activity in diabetic rabbits (Mathew and 
Augusti, 1975). Petroleimi ether and chloroform extract showed significant lowering 
in blood glucose during OGTT (Gupta et al, 1977). Anti-oxidant and hypolipidemic 
activity is reported (Babu and Srinivasan, 1997). Administration of a sulfur containing 
amino acids isolated from Allium cepa Liim. to alloxan-induced diabetic rats 
significantly controlled blood glucose and lipids in serum and tissues and normalized 
activities of liver hexokinase, glucose-6-phosphatase and HMGCoA reductase 
(Kumarie/fl/.,1995). 
Allium sativum: Lahasun (Hindi) and Garlic (English) 
Oral administration of ethanol, petroleum, ether, ethyl ether extract of Allium 
sativum causes significant reduction in blood sugar in alloxan diabetic rats (Mathew 
and Augusti, 1973; Jain and Vyas, 1975). Aqueous homogenate of garlic orally given 
to sucrose fed rabbits significantly increased hepatic glycogen, decreased fasting 
blood glucose, serum triglycerides as compared to control (Zacharias et al, 1980). In 
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subcutaneous glucose tolerance test in rabbits, garlic decreased hyperglycaemic peak 
(Roman-Ramos et al, 1995). It also prevented diabetic cardiovascular complications 
in STZ-induced diabetic rats (Patumraj et al, 2000). Administration of SACS, a sulfur 
containing amino acid is the precursor of allicin and garlic oil (Sheela and Augusti, 
1992). It helps in the reduction of the serum lipids, blood glucose and the activities of 
serum enzymes like alkaline phosphatase, acid phosphatase and lactate dehydrogenase 
and liver glucose-6-phosphatase; increased liver and intestinal HMGCoA reductase 
activity and liver hexokinase activity (Sheela and Augusti, 1992). SACS also 
controlled lipid peroxidation better than glibenclamide and insulin. Furthermore, 
SACS significantly stimulated in vitro insulin secretion from P-cells isolated from 
normal rats (Augusti and Sheila, 1996). Hypolipidemic effect has also been reported 
(Augusti and Mathew, 1973). 
Aloe vera or Aloe barbadensis: Ghee Kunwar and Kumar panthu (Hindi) 
Extracts of aloe gum effectively normalizes glucose tolerance in both normal 
and diabetic rats (Al-Awadi and Gumaa, 1987). The dried sap of this plant has shown 
significant hypoglycaemic effect both clinically and experimentally (Gharmam et al., 
1986). It has shown significant hypoglycaemic potential in alloxan-induced diabetic 
rats (Ajabnoor, 1990). Both Aloe vera and Aloe gebberellin inhibit inflammation and 
improved wound healing in STZ diabetic mice (Davis and Maro, 1989; Chithra et al., 
1998). 
Eucalyptus globulus: Safeda (Hindi) 
Aqueous extract of eucalyptus increased peripheral glucose utilization in the 
mouse abdominal muscle and stepwise enhancement insulin secretion from the clonal 
pancreatic beta cell line (Gray and Flatt, 1998). 
Ficus bengalensis: Indian banyan tree or Bur (Hindi) 
A glucoside isolated from the bark of F. bengalensis showed more potent 
hypoglycaemic action as compared to crude ethanolic extract and the activity was half 
of tolbutamide (Augusti, 1975). Some glycosides isolated from F. bengalensis possess 
significant hypoglycaemic, hypolipidemic and serum insulin raising effects in 
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moderately diabetic rats (Cherian and Augusti, 1993). Antioxidant properties of this 
plant have also been reported (Daniel et al, 1998). 
Gymnema syivestre: Gudmar or Merasingi (Hindi) and Periploca of the woods 
(English) 
Antihyperglycaemic effect of dried leaf powder of Gymnema syivestre was 
seen in alloxan induced diabetic rabbits along with decrease in the activity of 
gluconeogenic enzymes and reversal of pathological changes in the liver 
(Shamnugasundaram et al, 1983). Oral administration of varying doses of aqueous 
extract to normal and STZ diabetic rats showed significant dose dependent 
hypoglycaemic activity (Chattopadhyay, 1999). 
Ipomoea batatas'. Sakkarkand or Mitha Alu (Hindi) 
Oral feeding of this plant reduces hyperinsulinemia in Zucker fatty rats. In 
addition, inhibition of blood glucose level after glucose loading was observed after 7 
weeks treatment along with regranulation of pancreatic P cells and reduction insulin 
resistance (Kusano and Abe, 2000). Hypolipidemic activity has also been described 
(Kusano and Abe, 2000). 
Momordica charantia: Karela (Hindi) and Bitter Gourd (English) 
Extract of fruit pulp, seed, leaves and whole plant of Momordica charantia has 
shown hypoglycaemic effect in various animal models (Sharma et al., 1960; Gupta 
and Seth, 1962; Jose et al., 1976; Ali et al., 1993). Chronic oral administration of 
extract to normal mice for 13 days improved OGTT while no significant effect was 
seen on plasma insulm levels (Bailey and Day, 1985). The fruit juice of this plant 
significantly increased the number of P cell in diabetic rats (Ahmad et al., 1998). 
Musa sapientumi Kela (Hindi) and Banana (English) 
Chloroform extract of M. sapientum flowers significantly reduced blood 
glucose and glycosylated hemoglobm and increased total hemoglobin in alloxanized 
rats (Pari and Maheshwari, 1999). Hypolipidemic activity has also been described 
(Horigomee/a/., 1992). 
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Pterocarpus marsupium: Vijayasar or Bijasal (Hindi) and Indian Malabar 
(English) 
Numerous studies conducted by various group have shown hypoglycaemic 
activity of the wood extract in different animal models (Gupta, 1963; Trivedi, 1963; 
Shah, 1967; Saifi et al, 1971). Oral administration of the bark decoction showed a 
hypoglycaemic action in alloxanized diabetic rats (Pandey and Sharma, 1976). 
Flavanoid fraction of P. marsupium has been shown to cause pancreatic beta cell 
regranulation and may explain the antidiabetic mechanism of the plant (Chakravarthy 
et al, 1980). Epicatechin isolated from the ethanol extract of this plant has been 
shown to enhance insulin release and conversion of proinsulin to insulin in vitro 
(Sheehan et al, 1983). Phenolic constituents such as marsupin and pterostlben 
significantly lowered blood glucose level in STZ diabetic rats and the effect was 
comparable to metformin (Manickam et al, 1997). 
Swertia chirayita: Chirata (Hindi) 
Ethanol extract of S. chirayita helped in lowering blood glucose level 
significantly in various animal models (Sekar et al, 1987). Hexane fraction of this 
plant when fed to normal rats significantly reduced blood glucose and increased 
plasma IRI simultaneously without influencing hepatic glycogen content 
(Chandrasekar et al, 1990). Swerchirin, isolated from hexane fraction, showed 
antihyperglycaemic effect in STZ diabetic rats (Saxena et al, 1991). It also stimulated 
insulin release from isolated islets (Saxena et al, 1993). 
Syzigium cumini (Eugenia jambolana): Jamun (Hindi) and Black Berry (English) 
It is widely distributed throughout India and Indian folk medicine mentions its 
use for the freatment of diabetes mellitus (Chopra et al, 1958; Nandkami, 1992). 
Preliminary studies on S. cumuni seeds have shown hypoglycaemic effect (Mahapatra 
et al, 1985). Aqueous extract of S. cumuni seeds showed hypoglycaemic and 
antioxidant activity (Prince et al, 1998). Treatment with lyophilised powder of E. 
jambolana also partially restored altered hepatic and skeletal muscle glycogen content 
and hepatic glucokinase, hexokinase, glucose-6-phosphate and phosphofructokinase 
levels (Grover et al, 2000). 
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Trigonellafoenum graecum: Methi (Hindi) and Fenugreek (English) 
The hypoglycaemic effect of fenugreek seeds has been demonstrated in 
experimentally induced diabetic rats, dogs, mice and healthy volunteers (both IDDM 
and NIDDM) (Robes et ai, 1984; Riyad et ai, 1988; Alarcon-Aguilara et al., 1998). 
Extract of this plant produced dose dependent fall in blood glucose both in normal as 
well as diabetic rats (Khosia et al., 1995). Aqueous leaf extract to normal and 
alloxanized diabetic rats showed significant hypoglycaemic and antihyperglycaemic 
effect (Abdel-Berry et al., 1997). Seed powder normalized alteration in hepatic and 
renal glucose-6-phosphatase and fructose 1, 6-bisphosphatase activity (Gupta et al., 
1999). 
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SCOPE AND PLAN OF PRESENT WORK 
According to the recent estimates, the human population worldwide appears 
to be in the midst of an epidemic of diabetes in particular type 2 diabetes mellitus and 
insulin resistance. Despite the great strides that have been made in the understanding 
and management of type 2 diabetes, insulin resistance and diabetes related 
complications are increasing unabated. Various models of experimental diabetes are 
though present for investigators to explore numerous physiological and biochemical 
defects observed during the progression of disease. Moreover, there will always be 
physiological, pathological and morphological differences among different animal 
models of diabetes. The purpose of this study was to standardize/develop suitable 
animal models for type 2 diabetes and insulin resistance which can mimic the disease 
present in the human being. However, an unavoidable reality is this that none of 
models are perfectly equivalent to the human disease state. Parallel to this, recent 
developments in understanding the pathophysiology of disease process have opened 
up several new avenues to identify and develop novel therapies to combat the diabetic 
plague and insulin resistance by developing plant based insulin resistant reversal 
agents. Concurrently, identification of phytochemicals from natural sources provide 
an exciting opportunity for the development of new types of management therapeutics 
for diabetes and insulin resistance. This has accelerated the global efforts to harness 
and harvest those terrestrial flora and marine flora and fauna that bear substantial 
amount of potential compounds showing multiple beneficial effects in combating 
insulin resistance, type 2 diabetes and diabetes related complications like cataract, 
neuropathy, nephropathy etc. Therefore, as the problem of diabetes and insulin 
resistance are spreading unabated, there is an urgent need of identifying indigenous 
natural resources in order to procure them and study in depth, their potential on 
different antidiabetic in vitro targets and in vivo animal models for type 2 diabetes and 
insulin resistance in order to develop them as antidiabetic drugs. 
The present study is an attempt to identify few target based antidiabetic 
compounds (like a-glucosidase, aldose reductase and protein tyrosine phosphatase 1 
B inhibitors) standardize/develop animal models for type 2 diabetes and insulin 
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resistance by manipulation in the diet or chemical treatment fructose-enriched diet fed 
rats and preclinical development of identified herbal and marine extracts 
Chapters I details the antihyperglycaemic effects in some terrestrial flora and 
marine flora and faima in STZ-induced diabetic rats. This chapter also deals the 
results of few target based designed (a-glucosidase, aldose reductase and protein 
tyrosine phosphatase inhibition) synthetic compounds both for diabetes and insulin 
resistance. Identification of few lead compounds is one of the main achievements of 
this section. 
Chapter II deals with antidiabetic effects of one standardized marine 
preparation CDR-134 and one herbal extract CT-1, their effect on regulatory enzymes 
of carbohydrate metabolism (pyruvate kinase, phosphofructokinase, lactate 
dehydrogenase, glycogen phosphorylase, glucose-6-phosphatase and protein tyrosine 
phosphatase). Lowering the activities of glucose-6-phosphatase and protein tyrosine 
phosphatase by the above said preparations under in vivo conditions are the novel 
findings. 
Chapter IE deals with the studies about the measurement of insulin resistance 
index using HOMA in the animal models for non-insulin dependent diabetes mellitus 
and insulm resistance. This chapter provides new chemical entities for the 
development of insulin resistant reversal agents from herbal source. 
Overall the studies of present dissertation will help in selecting the antidiabetic 
plants and marine substances for further study, clinical development of CTl and 
CDR-134 for diabetes as well as insulin resistance and the optimization of leads for 
best synthetic antidiabetic compounds hitting the novel target Protein tyrosine 
phosphatase-IB. 
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MATERIALS AND METHODS 
ANIMALS 
Male/Female inbred/outbred Charles Foster/Sprague DawleyAVistar strain of 
albino rats (8-10 weeks of age: body weight 160±20 gm) were procured from the 
animal colony of Central Drug Research Institute, Lucknow, India. Rats were always 
placed in groups of three to five in polypropylene cages. The following norms were 
always followed for animal room environment: Temperature 23±2°C; Humidity 50-
60%; Light 300 Lux at floor level with regular 12h light cycle; Noise level 50 decibel; 
ventilation 10-15 air changes per hour. The animals had free access to pellet diet 
(Lipton, India) and tap water unless stated otherwise. 
CHEMICALS 
Folin ciocalataeu's phenol reagent, fructose, sodium pyruvate, oxaloacetate, 
tris HCl, potassium chloride, magnesium chloride, adenosine triphosphate, adenosine 
diphosphate, glucose-6-phosphate were procured from Sisco Research Laboratory 
(SRL), Bombay. Streptozotocin, bovine serum albumin, adenosine monophosphate, 
NADH, NADPH, glycogen, PEP, LDH, MDH, glucose-1-phosphate, fructose-6-
phosphate, sodium fluoride, EDTA, aldolase, triosephosphate isomerase were 
purchased from Sigma Chemical Company, St. Louis, USA. Casein, starch, sucrose, 
glucose were purchased from Himedia, Bombay. Ethanol, methanol, chloroform, 
sodium acetate, sulphuric acid, hydrochloric acid, acetic acid, lithium sulphate, 
potassium dihydrogen phosphate, dipotassium hydrogen phosphate, citric acid, 
sodium citrate were purchased from E-Merck, Germany. The Radioimmunoassay kits 
for serum insulin measurements were purchased from Bhabha Atomic Research 
Centre (BARC), Bombay, India. All other chemicals and solvents used were of 
highest piority grade. 
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Metformin 
CH3 
N 
NH 
H,C 
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Rosiglitazone Glidazide 
HOH2C 
Acarbose 
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Acarbose 
o-4,6-dideoxy-4-[ls-(la,4a,5p,6a)]-4,5,6-trihydroxy-3-(hydroxymethyl)-2-
cyclopyranosyl-( 1 -4)-D-glucose; 
4",6"-dideoxy-4"-[(ls)-(l,4,6/5)-4,5,6-trihydroxy-3-hydroxymethyl-2-
cyclohexenylamino] -maltotriose; 
Bay g 5421; Glucobay; Prandase; Precose 
C25H43NO18MW 645.60 
C 46.51%; H 6.71%; N 2.17%; O 44.61% 
Pseudotetrasaccharide containing an unsaturated cyclitol moity. An a-glucosidase 
inhibitor that reduces sugar absorption in the gastrointestinal tract. 
Amorphus powder [a]o^^ +165° (c=0.4 in water) 
Glibenclamide 
5-ChIoro-N-[2-[4-[[[(cyclohexylamino) carbonyl] amino] sulfonyl] phenyl] ethyl]-2-
methoxybenzamide; 
l-[[p-[2-(5-chloro-0-anisamido)ethyl]-phenyl] sulfonyl]-3-cyclohexylurea; 
N- [4-ip-(2-methoxy-5-chlorobenzamido) ethyl) benzosulfonyl]-N'-cycIohexyIurea; 
N^-[4-[p-(2-methoxy-5-chlorobenzoylaniino)ethyl]ben2enesulfonyl]-N^-
cyclohexylurea; 
Glybenclamide; glyburide; HB-419; U-26452; Adiab; Azuglucon; Bactiverit; Dia-
basan; Diabeta; Daonil; Duraglucon; Euglucon; Gilemal; Gliben- Puren N; Gli-diabet; 
Glimidstada; Glucoremed; Gluco-Tablinen; Glycolande; Lederglib; Libanil; 
Lisaglucon; Malix; Maninil; Micronase; Praeciglucon. 
C23H2gClN305S MW 494.01 
C 55.92%; H 5.71%; CI 7.18%; N 8.51%; 016.19%; S 6.49% 
Second generation sulfonylurea with hypoglycaemic activity. 
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Gliclazide 
N-[[(Hexahydrocyclopenta [c] pyrrol-2 (14) -yl) amino] carbonyl] -4-
methylbenzenesulfonamide; 
l-(hexahy(lrocyclopenta[c] pyrrol-2 (14)-yl)-3-(p-tolylsulfonyl) urea; 
N-(4-methylbenzenesulfonyl)-N'-(3-azabicyclo [3.3.0]-oct-3-yl)urea 
l-(3-azabicyclo[3.3.0] oct-3-yl)-3-(p-tolyIsuIfonyl)-urea 
S-1702; Diamicron; Glimicron; Nordialex; 
C15H21N3O3S MW 323.42 
C 55.714%; H 6.55%; N 12.99%; 0 14.84%; S 9.91% 
Crystal from anhydrous ethanol mp I80-182°C, LD50 orally in mice >3 gm/kg 
(Duhault). 
Metformin 
N,N-Dimethylimidodicarbonimidic diamide 
1,1 -dimethylbiguanide 
N,N- dimethylbiguanide 
N', dimethylguanylguanidine (DMGG) 
LA-6023 
C4HUN5 MW 129.16 
C 37.2%; H 8.58%; N 54.22% 
Oral hypoglycaemic agent 
Hydrochloride 
Diabetosan; Diabex; Glucophage; Metiguanide; 
C4H11NS.HCI MW 165.63 
Prisms from water, mp 232° (Werner, Bell). Crystal from propanol, mp 218-220° 
(uncover) (Shapuro). 
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Soluble in water, 95% alcohol. Practically insoluble in ether, chloroform. 
LD50 in rats (mg/kg): 1000 orally, 300 s.c. (Rx Bulletin). 
Roziglitazone 
5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl] methyl]-2,4-thia2olidinedione 
5-[[4-[2-[N-methyl-N-(2-pyridinyl) amino] ethoxy] benzyl]-2, 4, - thiazolidinedione 
BRL- 49653 
CsHipNaOaS MW 357.43 
C 60.49%; H 5.36%; N 11.76%; 0 13.43%; S 8.97% 
Insulin sensitizer; binds to peroxisome proliferator activated receptor (PPAR-y). 
Standardized Preparations: 
CT-1 
1. Background: This plant was randomly collected for general biological 
screening programme. Whole plant ivmed out to be a promising 
antihyperglycaemic agent. 
2. Distribution: It is available in temperate regions of Himalayas from Kashmir 
to Bhutan and in Nepal also. 
3. Availability: This plant is available throughout the year. 
4. Storage: Dried whole plant is powered in disintegratar. Powder is charged in 
hot extraction unit and submerged in deionised water. Allow to stand for 10 
minutes and then drained off. Material soaked again with similar quantity of 
deionised water and temperature is raised to 98-100° C and maintained for 2h. 
Heating discontinued and allowed to stand for 10 min. 
4. Processing: Whole plant extract is strained through muslin and collected 
separately. The concentrated extract is spread in trays and dried in a vacuum-
shelves drier (temp>60'' C) for about 6-7 hrs. The dried residue is collected 
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and powered in a pulveriser to give a blackish brown power of uniform 
particle size. 
CDR-134 
1. Background: The mangrove was randomly collected for general biological 
screening programme. Interestingly epicarp of fruit turned out to be a 
promising antihyperglycaemic agent. 
2. Distribution: hi tidal forests along the east and west coastal areas up to 
Maharastra and Andaman islands. 
3. Availability: The fruits are available throughout the year. 
4. Collection devices: Motorboats and Dongies are required for bulk collection 
of this material. 
5. Storage: Various parts of fruit are collected, chopped into small pieces for 
shade drying. After proper drying the material is stored in cold room for 
further work. 
6. Physical Characteristics: Mangrove trees upto 10 m tall with bijugate leaves, 
leaflets obovate, entire rounded at apex, tapering at base, fruits large, globose, 
splitting tardily into 4 valves, seeds 10-15 in number, pyramidal shaped with a 
corky testa. 
7. Quality control specifications: 
Physical status : Dark brown solid material 
Ash content : not more than 35.0% 
Acid insoluble ash : not more than 3.0% 
Ethyl acetate extractive : not less than 2.5% 
Butanol extractive : not less than 10.0% 
HPLC-fmgerprinting : HPLC chromatogram at A,=230 nm 
(Butanol extractive) (gradient) with one identified 
marker (Gedunin) 
(Rt.-lOmin) 
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Evaluation of Plant extracts/fractions for Antihyperglycaemic activity 
Sucrose loaded rat model: Single dose protocol 
Male albino rats of Charles Foster strain of average body weight I60±20 g 
were selected for study. The blood glucose of each animal was checked after 16 hours 
starvation using glucostrips (Boehringer Mannheim). Animals showing blood glucose 
between 60 to 80 mg/dl (3.33 to 4.44 mM) were divided into groups of five to six 
animals in each. Rats of experimental group were administered suspension of the 
desired test extract orally (made in 1.0% gum acacia) at 250mg/kg-body weight. 
Animals of control group were given an equal amount of 1.0% gum acacia. A glucose 
load (2.0 gm/kg) was given to each animal orally exactly after 30 min post 
administration of the test sample/vehicle. Blood glucose profile of each rat was again 
determined at 30, 60, 90 and 120 min post administration by glucostrips. Food but not 
water was withheld firom the cages during the course of experimentation. Quantitative 
glucose tolerance of each animal was calculated by Area under curve method. 
Comparing the AUC of experimental and control groups determined the percentage 
antihyperglycaemic activity. Statistical comparison was made by Dunnett's test. 
Streptozotocin-induced diabetic rats: Single dose protocol 
Male albino rats of Sprague Dawley strain of body weight 160±20g were 
selected for this study. Streptozotocin (Sigma, USA) was dissolved in 100 mM citrate 
buffer pH 4.5 and calculated amoimt of the fi-esh solution was injected to overnight 
fasted rats (60 mg/kg) intraperitoneally. Blood was checked 48 h later by glucometer 
(Boehringer Mannheim) and animals showing blood glucose value between 250 to 
450 mg/dl (13.9 to 25 mM) were included in the experiments and termed diabetic. 
The diabetic animals were divided into groups consisting of three to six animals in 
each group. Rats of experimental groups were administered suspension of the desired 
test extract orally (made in 1.0% gum acacia) at 250 mg/kg-body weight. Animals of 
control group were given an equal amount of 1.0% gum acacia. Blood glucose level 
was again checked at 1, 2, 3, 4, 5, 6, 7 and 24 hours, respectively post administration 
of glim acacia/test extract. Food but not water was withheld from the cages during the 
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experimentation. The average % fall in blood glucose values from 1 to 7 hours by test 
extracts were calculated according to the area under curve (AUC) method. Comparing 
the AUC of experimental and control groups determined the percent 
antihyperglycaemic activity. Statistical analysis was done by Dunnett's test. 
In-vitro determinants for the evaluation of antidiabetic activity 
Preparation of a-Glucosidasefrom Rat Intestinal Mucosa 
This was done according to a slight modification of the procedure reported by 
Cogoli et al. (1972). hitestine of male albino rats (CF strain, average body weight 
200±20 g) were excised opened and the mucosa was collected and pooled. A 10% 
homogenate was prepared m 150mM KCl using Potter Elvejhem glass homogenizer 
fitted with Teflon pestle. The homogenate was centrifuged at l,000xg for 15 min and 
the supernatant was decanted and stored at 4°C. The supernatant was dialyzed at 4°C 
against 50 mM Tris-HCl buffer pH 7.0 with two to three changes of buffer. The 
dialyzed supernatant was saturated with ammonium sulphate to a final concentration 
of 30%. The sample was kept at 4°C overnight and then centrifuged to collect the 
precipitate and the supernatant separately. The 30% ammonium sulphate saturated 
supernatant was further saturated to 60% with ammonium sulphate. Again the 
precipitate and supernatant were separated by centrifugation. Finally the 60% 
ammoniimi sulphate saturated supernatant was flirther saturated to 100% with further 
addition of ammonium sulphate. The precipitate and supernatant was once again 
separated and all the samples were analysed for a-glucosidase activity using p-
nitrophenyl-a-D-glucopyranoside (PNPG) as substrate. The enzyme activity was 
found maximum in 60-100% ammonium sulphate precipitate (Table-1) and this 
fraction was stored at 4°C and used as a source of enzyme for studying the effect of 
test compounds. 
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Table-1: Purification steps of a-GIucosidase from Rat Intestinal mucosa 
Crude extract 
1000 xg supernatant 
0-30% ammonium sulphate 
precipitate 
30-60% ammonium 
sulphate precipitate 
60-100% ammonium 
sulphate precipitate 
100% saturated ammonium 
sulphate supernatant 
Total Protein 
mg/ml 
1.50±0.03 
0.74±0.09 
0.18±0.02 
0.31±0.03 
0.60±0.06 
0.12±0.02 
Total Activity 
(nmol/min) 
433.4±0.30 
358.02±8.07 
99.48±0.78 
224.24±2.83 
822.55±3.23 
Nil 
Specific activity 
(nmol/min/mg 
protein) 
288.94±10.1 
483.81±89.7 
552.69±38.9 
723.36±94.2 
1370.9I±53.8 
Nil 
Fold 
Purification 
1.0 
1.68 
1.91 
2.50 
4.74 
Determination of a -Glucosidase Inhibitory Activity 
100 ^1 of purified a-glucosidase (0.1 mg/ml) and 25^1 of glutathione (1.0 
mg/ml) were added and the total volume was made up to 1 ml by adding 0.67 mM 
phosphate buffer (pH 6.8). The reaction mixtiu-e was incubated at room temperature 
for 10 min with the desired test compound (10 mM) dissolved in 100% DMSO. 
Reaction was started by the addition of 50 y.1 p-nitrophenyl-a-D-glucopyranoside (3 
mg/ml) and increase in absorbance was recorded at 400 nm for a period of 5 min at 
the interval of 30 sec (Lebovitz, 1997; Chiba, 1997). 
Aldose Reductase 
Preparation of Aldose reductase from rat erythrocytes 
10 ml blood was withdravm from overnight fasted male SD (Sprague Dawley) 
rats in heparinized vials and was incubated with 50 mM D-glucose at 37°C for 6 hours 
in a Dubnofif metabolic shaker with gentle shaking. Subsequently the blood was 
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centrifuged at ISOOxg for 10 min at 4°C and the erythrocyte were separated and 
washed three times with Phosphate Buffered Saline (PBS) [0.145 M NaCl/O.l M 
Potassium Phosphate pH 7.4, 9:1 v/v]. Washed erythrocytes were hemolyzed in 4 
volumes of Buffer A (10 mM Potassium Phosphate pH 6.0/5 mM 2-mercaptoethanol). 
The hemolysate was centrifuged at lO.OOOxg for 1 hour in cold and dialyzed 
overnight against 100 volimies of the same buffer A. Dialyzed hemolysate was again 
centrifuged at lO.OOOxg for one hour at 4°C and then supernatant was used as source 
of enzyme (Srivastava et al, 1986). 
Assay mixture for the determination of aldose reductase activity in a 1.0 ml 
final volume contained 0.1 mM NADPH, 50 mM Potassium Phosphate buffer pH 6.0, 
10 mM DL-glyceraldehyde, 5 mM 2-mercaptoethanol, 0.4 M LiS04 and an 
appropriate amount of the enzyme. The effect of library compounds was studied by 
incubating 250 |xg of library compounds in the reaction system and determining the 
residual enzyme activity. The reaction was started by the addition of 0.1 mM NADPH 
(Srivastava et al, 1986; Saab et al, 1999). The decrease in absorbance at 340 nm was 
measured at 37°C for 4 min. One unit of enzyme activity was d^\r)f^^ ^x^\ of 
NADPH utilized/min at 37°C. ^^^ ' '^^ — 
Protein Tyrosine Phosphatase (PTPase) 
Preparation of Protein Tyrosine Phosphatase 
Animal was sacrificed by cervical dislocation; tissues life^j^gftii^^ and 
muscle were excised, washed in cold saline and tissues were homogenised in buffer 
containing HEPES 25 mM pH 7.0, EDTA 1 mM, DTT 1 mM, PMSF 0.0025% (w/v) 
and Aprotinin 1 U/ml using a Potter Elvejhem homogeniser. The homogenates were 
centrifiiged at 600xg for 10 min. Pellet was discarded and supernatant was again 
centrifuged at lO.OOOxg for 20 min to seperate mitochondria. The post mitochondrial 
supernatant was then centrifuged at 100,000xg for 45 min. The final supernatant was 
designated as the cytosolic fraction and the pellet was designated as the particulate 
fraction. The particulate fraction was solubilized before assay by stirring at 4°C for 45 
min. in 25 mM HEPES pH 7.0,2.5% PMSF and 1% Triton X-100. 
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PTPase assay was performed according to Goldstein et al. (2000); assay 
mixture was made in a final volume of 1.0 ml containing 10 mM pNPP in 50 mM 
HEPES buffer pH 7.0, with 1 mM DTT and 2 mM EDTA. The reaction was stopped 
by the addition of 500 ^1 of 0.1 N NaOH and the absorbance was determined at 410 
nm. A molar extinction coefficient of 1.78x10'' M"'cm'' was utilized to calculate the 
concentration of the p-nitrophenolate ions produced in the reaction mixture. One unit 
of enzyme activity was defined as the amount of enzyme required to form 1 ^mol p-
nitrophenolate ion per min during the initial reaction period. 
Measurement of insulin resistance 
The steady state basal plasma glucose and insulin concentrations are 
determined by their interactions in a feed back loop. A computer-solved method has 
been used to predict the homeostatic concentrations, which arise from varying degrees 
of P-cell deficiency and insulin resistance. Comparison of fasting values of glucose 
and insulin with model's predictions allows a quantitative assessment of the 
contributions of insulin resistance and p-cell deficiency to the fasting hyperglycaemia 
(Mathews et al, 1985). A method was devised for the measurement of insulin 
resistance, known as Homeostasis Model Assessment (HOMA), which was based on 
the relationship between fasting blood glucose and fasting insulin level. This measure 
had been used in various population trials including UKPDS. According to this 
model, insulin resistance was measured by the formula: 
Insulm resistance (HOMA)= Insulin/ 22.5 e-'"s""=°^ « 
=Io X hiGo / 22.5 
P-cell dysfunction = (20 x IQ) / (Go- 3.5) 
Where Go was fasting glucose concentration (mM) and lo was fasting insulin 
concentration (^U/ml) 
[56 
Materials and Methods 
Development of animal models for evaluation particularly type II 
diabetes mellitus and insulin resistance 
Neonatal STZ rat model 
One-day old pups of Wistar strain rats were taken along with mother. 
Streptozotocin was given subcutaneously to these pups at 120 mg/kg dose level 
(Portha et al, 1974; Weir et al, 1982). Weaning was done on 4'*' week; males and 
females were separated on 5^ week. OGTT was performed on 6*, 8*^ , 11*, 13*, 15*, 
18*, 20* and 22"** weeks post STZ-injection; OGTT was found to be maximally 
impaired and insulin level was high as compared to normal control on 22" week, 
therefore this week was selected to start the treatment of CDR-134/ CT-1 once daily 
for 5 weeks and 3 weeks respectively. 
Fructose-enriched diet fed rats 
Control group of male Sprague Dawley rats were fed either with standard diet 
(59% Starch, 29% Casein and 4% Fat) and experimental group of fhictose-enriched 
diet (66% Fructose, 22% Casein and 12% Fat) (Yagi et al, 1995). This feeding was 
continued for 10 weeks and during feeding Glucose Tolerance Test was performed on 
2, 4, 6, 8 and 10 week. On 11* week animals of Fructose fed group showed a 
maximimi level of glucose intolerance as depicted in the graph (p<0.05). However, 
glucose tolerance curve of standard diet group was found to be normal. Further 
animals were selected from the fructose fed group (n=12) and divided into groups 
each containing six animals, were termed as Fructose-enriched Control and Fructose-
enriched -H CDR-134/ CT-1. One more group was made of Standard diet fed rats, 
termed as a Normal Control. 
Protocol for the evaluation of the effect of CDR-134 and CT-1 in animal models 
for type 2 diabetes and insulin resistance 
CDR-134, a marine based antidiabetic agent, was fed to fructose fed rats and 
neonatal rats for five weeks once daily. Body weight was recorded on alternate days. 
An oral glucose tolerance test was performed weekly and on the last week of feeding 
after OGTT, blood was collected from retro orbital plexus; each animals were 
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sacrificed using cervical dislocation and tissues like liver, kidney and muscle were 
kept at -SOT for biochemical studies. 
CT-1, a plant based antidiabetic agent, was given orally to fructose fed rats 
and neonatal rats to see the efficacy of this agent in animal model for type 2 diabetes 
and insulin resistance. This test drug was fed for three weeks once daily. Oral glucose 
tolerance test (OGTT) was performed weekly and body weight was recorded on 
alternate days. Finally on the last day of treatment with CT-1, blood was collected and 
each animal were sacrificed using cervical dislocation method and tissues like liver, 
kidney and muscle were stored at 80°C for further studies. 
Preparation of Homogenate 
The ovemight-starved animals were sacrificed by cervical dislocation. The 
liver, kidney and muscle were quickly excised, washed thoroughly with chilled 
normal saline and kept at -80°C. Tissues were taken out and thawed at the time of 
enzymatic studies. A 10% homogenate was prepared of liver, kidney and muscle in 
150 mM KCl with the help of Potter Elevejham homogenizer with Teflon pestle. This 
homogenate was termed as crude homogenates. These crude homogenates were 
centrifixged at 3000xrpm for 20 min in cold, cell and debris free supernatant was used 
for determining the activity of Glycogen phosphorylase, Glucose-6-phosphatase, 
Pyruvate kinase, Phosphofiiictokinase, Phosphoenolpyruvate Carboxykinase, Lactate 
dehydrogenase and Protein tyrosine phosphatase. 
Blood Glucose 
The glucose content of the blood was determined enzymatically using glucose 
oxidase and peroxidase according to the method of Bergmeyer and Benut (1963). To 
0.2 ml aliquot of deproteinized blood was added 1.25 ml buffer enzyme mixture 
containing phosphate buffer (120 mM, pH 7.0), peroxidase (40 ng/ml), glucose 
oxidase (250 ^g/ml) and the chromogen, 0-dianisidine-di-HCl (10 |ig/ml). The light 
orange colour of the complex was read after 20 min at 436 nm in Shimadzu UV-190 
double beam spectrophotometer. Glucometers were also used using glucostrips 
(Boehringer Mannheim). 
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Serum Insulin 
Serum insulin was estimated using the radioimmunoassay kit (RIAK-1) 
provided by BARC, Mumbai, by the following method. EDTA-phosphate buffer 0.3 
ml (0.01 M EDTA, 0.04 M phosphate, pH 7.4), containing 0.5% BSA (w/v) was 
mixed with 0.1 ml of standard insulin or unknown samples and 0.1ml of antibody 
(antiinsulin guineapig serum diluted 1:1,000,00 times) and kept overnight at 4°C, 0.1 
ml of 1125-insulin (about 1x10*^  cpm) was then added to the sample mixture and was 
again kept for 5 min at 4°C. Subsequently, 0.1 ml of the second antibody (anti-
guineapig-globulin raised in rabbit) was added. Antibody bound reactivity was 
separated from that of unbound one by precipitation in 12% polyethylene glycol 6000 
and counted in Minnigamma counter (Wallac, LKB) according to Wilson and Miles 
(1977). 
Pyruvate kinase (ATP: Pyruvate phosphotransferase, EC 2.7.1.40) 
It was assayed according to Bucher and Pfleiderer (1955). Their procedure 
was modified by using tris-HCl buffer in place of triethanolamine. The reaction 
mixture contained tris-HCl buffer 200 mM, pH 7.4; KCl 100 mM; MgCb 10 mM; 
ADP 5 mM; PEP 5 mM; LDH 4 units; NADH2 0.24 mM and enzyme protein. Optical 
density was measured at 340 nm at 30 sec interval for 3 min. 
PEP Carboxykinase (GTP: Oxaloacetate carboxylase (phosphorylating), EC 
4.1.1.32) 
It was assayed according to Ward et al, (1969). The reaction mixture 
contained tris-HCl buffer 200 mM, pH 7.4; MnCb 10 mM; NaHCOj 20 mM; GDP 1 
mM; MDH 9 units; PEP 5 mM; NADH2 0.24 mM and enzyme protein. Optical 
density was measured at 340 nm at 30 sec interval for 3 min. 
Glucose-6-phosphatase (D-glucose-6-phosphate phosphorylase; EC 3.1.3.9) 
Glucose-6-phosphatase activity was determined according to the method of 
Hubscher and West (1965). The assay system contained 0.3 M citrate buffer pH 6.0; 
EDTA 28 mM; NaF 14 mM, 400 ^1 of glucose-6-phosphate 200 mM in a total 
volume of 1.0 ml. The reaction was started with an appropriate amount of enzyme. 
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The mixture was incubated at 37°C for 30 min after which the reaction was sloped by 
addition of 1.0 ml of 10% TCA. Protein free supernatant was taken after 
centrifiigation at lOOOxg for 15 min for the estimation of Pi according to the method 
of Taussky and Shorr (1953). 
Glycogen phosphorylase (a-1.4, glucan: orthophosphate glucosyl transferase, EC 
2.4.1.1) 
It was assayed according to Rail et al. (1957). Assay mixture (0.4 ml) 
contained 0.2 ml mixture A [containing glycogen (57 mg); G-l-P (188 mg); NaF (42 
mg) and 5-AMP (4 mM) in 10.0 ml distilled water] and 0.1 ml B, enzyme protein (80-
100 |ig). It was incubated at 37°C for 30 min; the reaction was stopped by 0.1 ml TCA 
(5% w/v) and 0.4 ml sodiimi acetate (100 mM) was added to prevent spontaneous 
hydrolysis of G-l-P present in the incubation mixture. Protein free supematant was 
taken after centrifiigation at lOOOxg for 15 min for the estimation of Pi according to 
the method of Taussky and Shorr (1953). 
Phosphofnictokinase (ATP: F-6-P-l-phosphotransferase, EC 2,7.1.11) 
It was assayed by the method of Racker (1947). The reaction mixture 
contained tris-HCI buffer (pH 8.6) 200 mM, MgCb 10 mM, F-6-P 10 mM, ATP 10 
mM, NADH2 0.24 mM, aldolase 0.6 units, TPl 17 units, GDH 2 units, and enzyme 
protein (250-350 mg). Optical density was measured at 340 nm at 30 sec interval for 3 
min. 
Lactate dehydrogenase (L-Iactate: NAD oxide reductase, EC 1.1.1.27) 
Lactate dehydrogenase activity was determined according to Romberg (1955). 
The assay mixture contained 200 mM tris HCl buffer pH 7.4, 100 mM KCl, 5 mM 
sodium pyruvate and enzyme protein. The reaction was started by the addition of 0.24 
mM NADH and change in absorbance was recorded at 340 run for 3 min at 30 sec 
interval. 
Protein tyrosine phosphatase 
Modifying Goldstein et al. method (2000), assay was performed in a final 
volume of 1.0 ml at 37°C for 30 min in reaction buffer containing 10 mM pNPP in 50 
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mM HEPES buffer pH 7.0 with 1 mM DTT and 2 mM EDTA. The reaction was 
stopped by the addition of 500 |j.l of 0.1 N NaOH and the absorbance was determined 
at 410 nm. A molar extinction coefficient of l.TSxlO'* M''cm"' was utilized to 
calculate the concentration of the p-nitrophenolate ion produced in the reaction 
mixture. 
Expression of enzyme units 
One unit of the enzyme is the amount required to convert the transformation of 
one mmol of substrate or the formation of one mmol of product per min under 
specified experimental conditions. The extinction for oxidation or reduction of 
pyridine nucleotides was measured at 340 nm using silica cuvettes of 1 cm path length 
and extinction coefficient of 6.22x10^ cm /^mole (Horecker and Komberg, 1948) was 
used to calculate reduced NAD/NADP. 
Activity of PK, PFK, PEPCK, LDH and AR were expressed as nmol of NAD 
formed/min/mg of protein. 
Blood Glucose values are expressed as mM. 
Serum insulin values are expressed as |aU/ml 
Glucose-6-phosphatase and glycogen phosphorylase activities were expressed 
as nmol Pi released/min/mg protein. 
Protein tyrosine phosphatase activity was expressed as nmol of p-nitrophenol 
formed/min/mg protem 
Statistical analysis 
Each biochemical parameter was expressed in terms of Mean±SD. Groups 
were compared by analysis of variance v^th student 't' test. Significance difference 
were set at * - p<0.05; ** - p<0.01 or *** - p<0.001. 
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CHAPTER I 
Traditional medicines most often applies to plants that are being employed as 
adjuvants in the management of diabetes mellitus in many of the Asian countries 
including India. Scientific research exploring the benefit of several hundreds of 
various medicinal plants credited with antidiabetic properties has been reported. A 
wide array of plant derived active principles representing numerous chemical 
compounds has demonstrated activity with their possible use in the treatment of Type 
2 diabetes (Baily and Day, 1989; Ivorra et al, 1988; Maries and Famsworth, 1995). 
Even the discovery of widely used hypoglycemic drug metformin came from the 
traditional approach of using Galega officinalis. Though development of modem 
medicine resiilted in the advent of modem pharmacotherapeutics including insulin, 
biguanides, sulfonylureas and thiazolidinediones (Bailey, 1999) there is still a need to 
look for new drugs as none of the dmg (except strict glycaemic control with insulin) 
has been shown to modify the course of diabetic complications. Many plant species 
are known in folk medicine of different cultures to be used for their hypoglycaemic 
properties and therefore used for the treatment of diabetes mellitus. The beneficial 
multiple activities like manipulating carbohydrate metabolism by various 
mechanisms, preventing and restoring the function of p-cell insulin releasing activity, 
improving glucose uptake and utilization and the antioxidant properties present in 
medicinal plants offer exciting opportunities to develop them into novel therapeutics. 
Evaluation of antidiabetic property in terrestrial plants as well as marine flora and 
fauna and search for new antidiabetic lead molecules have also become one of the 
major objectives of present day diabetic research. 
Oceans are known to cover around 71% of earth's surface and harbour more 
biochemical diversity than land. Yet marine bioprospecting and use of marine natural 
products as pharmacological agents have lagged behind efforts to find commercial 
products as compared to their terrestrial counterparts. Marine environment is an 
exceptional reservou: of biologically active products, some of which have been found 
to be useful as biochemical tools for exploring cellular processes at molecular level, 
one of the richest source for its floral wealth and diversity (Goel, 1996). It is a store of 
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numerous phytochemicals that can be used as potential alternative to the synthetic 
drugs. Various molecular species alongwith hypoglycaemic polysaccharides have 
been used as a traditional treatment for diabetes. Nevertheless, no medicine capable of 
elicitmg a radical cure of diabetes has yet been discovered. Marine flora and fauna 
may, therefore, provide new avenues in the search for alternative antihyperglycaemic 
drugs. 
The present study details the antihyperglycaemic activity profile of the 
ethanolic extracts of the tuberous root of Gloriosa superba, Berberis aristata, 
Tephrosia purpurea, stem bark of Taxus baccata ssp. Wallichiana, leaves of 
Verbascum thapsus, Lycopodium clavatum, Boerhaavia diffusa, Eclipta alba. Acacia 
nilotica, Strobilanthes perottitiana, stem wood ofCedrus deodara, fruits ofMyristica 
fragrans, stem bark of Betula utilis, hard wood of Acacia catechu and leaves of 
Tectona grandis. 
Effect of Plant Extracts on STZ-induced-diabetic rats 
Table 1 shows the average antihyperglycaemic effect of all the studied 15 
ethanolic extracts of various plants on streptozotocin-induced diabetic rats at a fixed 
single arbitrary dose i.e. 250 mg/kg. It is evident from the results that only five 
alcoholic extracts showed the antihyperglycaemic effect. The ethanolic extracts of 
Lycopodium clavatum, Boerhaavia diffusa, Eclipta alba. Acacia nilotica and 
Strobilanthes perottitiana, Gloriosa superba, Berberis aristata, Tephrosia purpurea, 
Taxus baccata ssp. Wallichiana, Verbascum thapsus, Cedrus deodara, Myristica 
fragrans, Betula utilis, Acacia catechu and Tectona grandis have shown blood 
glucose lowering on STZ-induced diabetic rats during 1 to 7 h period. 
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Table 1: Studied Plant extracts: Name, Parts used, Place and 
month of collection and average antihyperglycaemic activity 
s. 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
Plant Name and part used 
Lycopodium clavatum (PL) 
Boerhaavia diffusa (PL) 
Ecliptaa}ba(PL) 
Acacia nilotica (SB) 
Strobilanthes perottitiana (PX) 
Termimlia chebula (FR) 
Gloriosa superba (Tvberous 
Root) 
Berberis aristata (Root) 
Taxus baccata ssp. wallichiam 
(Stem bark) 
Tephrosia purpurea (Root) 
Verbascum thapsus (Leaves) 
Ficus racemosa (Fruits) 
Musa paradisiacal Uan. (Fndt) 
Acacia catechu (Hard Wood) 
Betula utilis (Stem Wood) 
Cedrus deodara (Stem Wood) 
Myristicafragrans (Fruits) 
Tectona grandis (Leaves) 
Month of 
Collection 
June 
May 
May 
May 
July 
October 
February 
May 
June 
September 
June 
May 
May 
May 
May 
June 
October 
August 
Locality 
Bageshwar, Uttranchal (India) 
Tuticorin, Tamilnadu (India) 
Virudhu Nagar, Tamilnadu (India) 
Virudhu Nagar and Tirunelveli, 
Tamilnadu (India) 
Palghat, Kerala (India) 
Kanyakumari, Tamil Nadu (India) 
Erode, Tamil Nadu (India) 
Almora, Uttranchal (India) 
Bageshwar, Uttranchal (India) 
Lucknow, U.P. (India) 
Almora, Uttranchal (India) 
Lucknow, U.P. (India) 
Tuticorin, Tamil Nadu (India) 
Virudhu Nagar, Tamil Nadu (India) 
Bageshwar, Uttranchal (India) 
Ranikhet, Uttranchal (India) 
Kanyakumari, Tamil Nadu (India) 
Tirunelveli, Tamil Nadu (India) 
% 
Activity 
35.8*** 
12.0* 
16.9* 
21.5** 
10.3* 
11.2* 
22.0** 
23.0* 
13.6** 
16.1* 
10.0* 
17.8** 
29.0*** 
12.4* 
11.0* 
19.6** 
19.5** 
10.6* 
* p<0.05, ** p<0.01, *** p<0.001 
Abbreviations: PL-whole plant, PX-whole plant without roots, SB-stem bark, FR-Fruits 
Fig. 1 presents the antihyperglycaemic activity profile of the ethanolic extract 
of the whole plant of Lycopodium clavatum. Lowering in blood glucose in this case 
was evident firom 1 h and that continued till 7 h. The peak lowering was obtained at 6 
h post treatment; there was no significant difference in the blood glucose profile of 
control and I. clavatum extract treated groups at 24 h. Fig. 2 shows the 
antihyperglycaemic effect of Boerhaavia diffusa extract, which showed decline in 
blood glucose fi-om 3 to 24 h post treatment, the peak lowering was found to be at 24 
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h. Figiire 3 depicts the lowering in blood glucose by whole plant ethanolic extract of 
Eclipta alba. The peak lowering was found to be from 2 to 7 h. Figure 4 shows the 
antihyperglycaemic activity profile of control and Acacia nilotica extract treated 
groups. Acacia nilotica extract started declining blood glucose level just after the 
treatment and this effect persisted till 6 h. At 24 h there was no significant difference 
between the glucose profiles of the control and A. nilotica extract treated groups. 
Strobilanthes perottitiana extract showed lowering in blood glucose from 2 to 7 h 
(Fig. 5). The peak lowering in blood glucose level in this case was found at 7 h post 
treatment. The lowering in a known ethanolic extract of fruits of Terminalia chebula 
was found to be between 1 to 6 h, peak lowering was observed at 6 h post extract 
treatment as shown in Fig. 6. 
Fig. 7 shows the antihyperglycaemic effect of ethanolic extract of the tuberous 
root of Gloriosa superba on STZ-induced diabetic rats. It is evident from the results 
that lowering in blood glucose profile of STZ-induced diabetic rats by treatment with 
this ethanolic extract was between 1 to 7 h and the peak lowering was observed at 7 h. 
The ethanolic extract of the roots of Berberis aristata showed almost similar type of 
antihyperglycaemic activity (Fig 8). Fig. 9 shows the antihyperglycaemic activity 
profile of the ethanolic extract of the stem bark of Taxus baccata ssp. wallichiana. 
Administration of ethanolic extract of stem bark of Taxus baccata ssp. wallichiana 
helped in declining the blood glucose level 1 h post treatment and this effect persisted 
till 24 h. The antihyperglycaemic effect of the ethanolic extract of the roots of 
Tephrosiapurpurea has been depicted in Fig 10. The test extract resulted in moderate 
lowering in blood glucose profile of STZ-induced diabetic rats. The lowering in blood 
glucose level persisted till 4 h and the peak lowering in blood glucose level was 
observed at 2 h. The effect of the ethanolic extract of the leaves of Verbascum thapsus 
on STZ-induced diabetic rats is shown in Fig 11. The administration of this test 
extract resulted in moderate lowering in blood glucose. The peak lowering was 
observed in this case at 2h post treatment. The ethanolic extract of the fruits of Ficus 
racemosa demonstrated an average lowering of 17.8% on STZ-induced diabetic rats 
during 1 to 7 h post treatment as shown in Fig. 12. It is evident from the Fig. 13 that 
the ethanolic extract of stem wood of Cedrus deodara exhibited antihyperglycaemic 
activity on Streptozotocin-induced diabetic rats from 1 to 7 h, and the effect was 
completely lost at 24 h. Maximum lowering in blood glucose was found to be at 7 h 
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post treatment. Fig. 14 shows the antihyperglycaemic activity of the ethanolic extract 
of the fiaiits of Myristica fragrans on STZ-induced diabetic rats. Administration of 
ethanolic extract of this part of the plant to STZ-induced diabetic rats resulted in 
moderate lowering in blood glucose. Lowering in blood glucose was found to be from 
3 to 7 h post treatment, whereas no significant difference in blood glucose levels 
between control and treated groups was noticed at 24 h. Peak lowering in blood 
glucose was observed at 7 h post treatment. The ethanolic extract of the stem wood of 
Betula utilis was also found to possess antihyperglycaemic activity on STZ-induced 
diabetic rats as shown in Fig 15. Administration of ethanolic extract of the stem bark 
of Betula utilis was found to decline blood glucose level from 1 to 3 h in diabetic rats 
as compared to diabetic control. The maximum decline in blood glucose was noted at 
3 h post treatment. Fig. 16 shows the antihyperglycaemic activity in ethanolic extract 
of the hard wood of Acacia catechu on STZ-induced diabetic rats. It is evident from 
the results (Fig. 16) that ethanolic extract of Acacia catechu helped in the decline of 
blood glucose level of diabetic rats from 5 to 7 h post treatment, whereas no 
significant effect was observed at 24h post treatment. Peak decline in blood glucose 
level was observed at 7 h. The ethanolic extract of the leaves of Tectona grandes also 
showed antihyperglycaemic activity on STZ-induced diabetic rats (Fig. 17). 
Administration of the ethanolic extract of the leaves of Tectona grandes resulted in 
moderate lowering of blood glucose level of STZ-induced diabetic rats. Peak lowering 
in blood glucose in this case was observed between 2 to 7 h post treatment. The 
ethanolic extract of an well known antidiabetic plant Musa paradisiaca when given to 
STZ-induced diabetic rats showed consistence lowering in blood glucose level from 1 
to 7h (Fig 18). Significant antihyperglycaemic activity was noted in the ethanolic 
extracts of the tuberous root of Gloriosa superba. Berberis aristata, Tephrosia 
purpurea, stem bark of Taxus baccata Wallichiana spp, leaves of Verbascum thapsus, 
Lycopodium clavatum, Boerhaavia diffusa, Eclipta alba, Acacia nilotica, 
Strobilanthes perottitiana, stem wood of Cedrus deodara, fruits of Myristica 
fragrans, stem bark of Betula utilis, hard wood of Acacia catechu and leaves of 
Tectona grandis. The average antihyperglycaemic activity profile were 22.0 (p<0.01), 
23.0 (p<0.05), 16.0 (p<0.05), 13.6 (p<0.05), 10.0 (p<0.05), 35.8 (p<0.001), 12.0 
(p<0.05), 16.9 (p<0.05), 10.3 (p<0.05), 19.6 (p<0.01), 19.5 (p<0.01), 11.0 (p<0.05), 
12.4 (p<0.05) and 10.6 (p<0.05) respectively. 
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Results and Discussion 
Effect of marine extracts on Sucrose loaded rats & STZ-induced-diabetic rats 
Ethanolic extract of leaves of marine flora Ceriops tagal prevent the rise in 
blood glucose of rats during postprandial state post sucrose administration. As shown 
in Fig 19 that extract of leaves of C. tagal help in the decline of blood glucose level 
starting from 30 to 120 min as compared to control group. The maximum lowering in 
blood glucose was observed at 120 min post sucrose load. The overall 
antihyperglycaemic activity in C. tagal leaves was found to be 12.4% in this model. 
The ethanolic extract of leaves of C. tagal was also found to be one of the promising 
antihyperglycaemic remedy on streptozotocin-induced diabetic rats. This ethanolic 
extract when fed to streptozotocin (STZ)-induced diabetic rats at 250 mg/kg dose, 
helped in the decline of blood glucose level starting from Ih and this effect persisted 
till 7 h (Fig 20). The maximum lowering in blood glucose was observed at 7 h post 
administration of C. tagal leaves extract, the overall antihyperglycaemic activity was 
found to be 25.8% (p<0.01) in this model. 
The methanolic extract of Sinularia erecta was also found to have antidiabetic 
activity as evidenced from the results shown in Fig. 21. The methanolic extract of this 
marine faima S. erecta prevented the rise in blood glucose following sucrose load as 
compared to control group, which was treated with vehicle only. The 
antihyperglycaemic potential of this marine fauna was evidenced, the way it 
prevented postprandial hyperglycaemia as compared to control group at 30 min post 
sucrose administration. The average antihyperglycaemic activity of this extract in this 
model was calculated to be around 12.7% (p<0.05). This methanolic extract also 
showed blood glucose lowering potential on STZ-induced diabetic rats. Figure 22 
presents the antihyperglycaemic activity profile of methanolic extract ofS. erecta. As 
evidenced from the Fig. 22, the methanolic extract of 5. erecta helped in lowering 
blood glucose starting from 1 to 7 h and the peak lowering was obtained at 7 h post 
treatment. The overall antihyperglycaemic activity was calculated to be around 16.1% 
(p<0.05) on STZ-induced diabetic rats. 
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Results and Discussion 
Figure 23 depicts the antihyperglycaemic activity profile of Sinularia firma in 
sucrose loaded normal rats. The methanolic extract of marine fauna S. firma was 
found to inhibit the increase in postprandial hyperglycaemia. The lowering potential 
of this extract began at 60 min and continued till 120 min. The overall 
antihyperglycaemic activity of the methanolic extract of S. firma was calculated to be 
aroimd 13.0% (p<0.05) in sucrose loaded normal rats. Figure 6 presents the 
antihyperglycaemic activity profile of the methanolic extract of marine fauna S. firma 
on STZ-induced diabetic rats. The lowering in blood glucose level of STZ-induced 
diabetic rats was evident from 1 h and continued till 7 h. The overall average 
antihyperglycaemic activity of this extract was calculated to be around 18.8% 
(p<0.05) m STZ-induced diabetic rats. 
Effect of Library Compounds on in-vitro antidiabetic targets: 
Table 2 shows the percent inhibition of a-Glucosidase, Aldose reductase and 
Protein tyrosine phosphatase exhibited synthetic compounds based on combinatorial 
chemistry. This inhibition was compared with the inhibition shown by standard 
inhibitors like Acarbose, Quercitrin and Peroxovanadate. L-000-17-10, L-000-I7-11, 
L-000-17-16 and L-000-17-17 showed percent inhibition of 91.6, 93.6, 100, 98.3 
respectively on a-glucosidase and 98.0, 92.0, 90.0, 100 respectively on aldose 
reductase. L-001-8-26, L-001-8-27, L-001-8-28, L-001-8-36, L-001-8-37, L-001-8-62 
and L-001-8-63 showed percent inhibition of 98.4, 97.8, 97.4, 97.4, 98.9, 100 and 
93.0 on protein tyrosine phosphatase respectively (Table 2). 
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Table 2: Effect of synthetic library compound on three in-vitro targets 
(a-Glucosidase, Aldose Reductase and Protein Tyrosine Phosphatase) 
s. 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
Compound Code 
L-000-17-10 
L-000-17-11 
L-000-17-16 
L-000-17-17 
L-001-8-26 
L-001-8-27 
L-001-8-28 
L-001-8-36 
L-001-8-37 
L-001-8-62 
L-001-8-63 
Acarbose 
Quercitrin 
Peroxovanadate 
% Inhibition 
a -
Glucosidase* 
91.6 
93.6 
100 
98.3 
• 
68.4 
Aldose 
Reductase* 
98.0 
92.0 
90.0 
100 
69.6 
PTPase** 
-
-
-
-
98.4 
97.8 
97.4 
97.4 
98.9 
100 
93.0 
80.5 
*250nM l^OOuM 
Discussion 
Indigenous herbs used as remedies against diabetes in the traditional Indian 
system of medicines (ISM) or in ethno-medicinal practices have not produced any 
good marketable antidiabetic drugs. This failure may be attributed to the incorrect 
pharmacognosy of the medicinal plants, following up incomplete extraction 
procedure(s), or use of insensitive and/or inadequate animal models (Chandrasekar et 
al, 1988). The oral route of administration was preferred as it is simple and 
physiological. Albino rats have been chosen for experiment because the blood sugar 
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level of rats remains fairly stable during handling, unlike other animals such as 
rabbits, (Mukherjee and Mukherjee, 1987). Streptozotocin selectively destroys 
insulin-secreting p-cells in islet of Langerhans, (Junod et al, 1969). In experiment 
with many animal species, streptozotocin produces permanent diabetes with extra 
pancreatic lesions that mimic the pathological status found in human diabetes, (Arison 
et al., 1967). Therefore streptozotocin-induced diabetes is reproducible, convenient 
and can produce diabetes of graded severity suitable for experimental diabetes (Junod 
et al, 1969). In the light of the above reports, an attempt was made to study the effect 
of some selected indigenous plants in lowering blood glucose level in STZ-induced 
diabetic rats. The ethanolic extract of plant Lycopodium clavatum was found to be 
very effective in lowering blood glucose level. This plant has already been reported to 
possess antifungal activity against Candida albicans (Zhang et al., 2002), and 
therefore this multiple activity plant can be developed as a potent antidiabetic agent. It 
is evident from the result that the ethanolic extract of Boerhaavia diffusa produced 
significant antihyperglycaemic effect at 250 mg/kg dose on streptozotocin-induced 
diabetic rats (Abo and Ashidi, 1999). Ethanolic extract of whole plant of Eclipta alba 
was observed to have significant blood glucose lowering effect on streptozotocin-
induced diabetic rats, which has earlier been reported to possess hepatoprotective 
activity, (Singh et al., 2001; Saxena et al., 1993). In the present study the ethanolic 
extract of Acacia nilotica showed decline in blood glucose levels in diabetic rats and 
the lowering was found to be consistent. Acacia nilotica has already been studied very 
much for its various pharmacological properties like antihypertensive (Gilani et al, 
1999), anti-inflammatory (Dafallah et al, 1996) and antimicrobial activity (Abdel et 
al, 1992). Strobilanthes perottitiana showed glucose lowering activity in STZ-
induced diabetic rats, which has also been reported for anticancer activity (Li et al., 
1993). The ethanolic extract of the fhiits of a well-known antidiabetic plant 
Terminalia chebula, when administered to STZ-induced diabetic rats declined the 
blood glucose level of rats. Terminalia chebula has also been reported for wound 
healing property (Suguna et al, 2002), antidiabetic activity, (Sahu and Kuttan, 2002) 
and anticancer activity (Saleem et al, 2002). 
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Administration of ethanolic extract of roots of Berberis aristata has shown 
marked blood glucose lowering activity on STZ-induced diabetic rats. This plant also 
possesses anticancer activity (Anis et al, 2001). The tuberous root extract of 
terrestrial plant Gloriosa superba produced significant (p<0.01) decrease in blood 
glucose level on STZ-induced diabetic rats throughout the 7 h time period. Gloriosa 
superba has earlier been reported to possess insecticidal property (Choochote et al, 
2001). Fruits of Ficus racemosa exhibited antihyperglycaemic activity on STZ-
induced diabetic rats (p<0.01) in the present study which is in conformity to earlier 
report (Bhaskara et al, 2002). This plant has also been shown to possess anti-
inflammatory (Mandal et al, 2000), antibacterial (Mandal et al, 2000), 
hepatoprotective (Mandal et al, 1999) and antidiarrheal (Mukherjee et al, 1998) 
activities. Stem bark of Taxus baccata ssp. wallichiana has been found to possess 
antitumor activity (Gueritte-Voegelein et al, 1994), which in present study was found 
to have significant glucose lowering potential (p<0.01) in diabetic rats. The leaf 
extract of Verbascum thapsus has shown some antihyperglycaemic potential on STZ-
induced diabetic rats in the present study. This plant has been recently reported for its 
anti-inflammatory activity (Turker et al, 2002). In the present study the root extract 
of Tephrosia purpurea was found to possess antihyperglycaemic activity. Tephrosia 
purpurea has been reported to play an important role in erythrocyte membrane 
integrity (Gokhale et al, 2000). Fruits of Ficus racemosa showed antidiabetic 
activity, which is in accordance to the earlier report (Bhaskara et al, 2002). Ficus 
racemosa has also been shown to have hepatoprotective (Mandal et al, 1999), anti-
inflammatory (Mandal et al, 2000) and antibacterial (Mandal et al, 2000) properties. 
The ethanolic extract of the stem wood of Cedrus deodara was observed 
antihyperglycaemic in nature as it showed lowering in blood glucose level of STZ-
induced diabetic rats which has earlier been reported to have free radical scavenging 
(Tiwari et al, 2001), anti-inflammatory and analgesic activities (Shinde et al, 1999). 
The ethanolic extract of fruits of Myristica fragrans also proved to possess 
antidiabetic potency as it helped in the decline of blood glucose levels of STZ-
induced diabetic rats, which earlier have been reported for hypolipidemic (Ram et al, 
1996), antihypercholesterolemic (Sharma et al, 1995) and anxiogenic activities 
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(Sonavane et al, 2002). The ethanolic extract of the leaves of Tectona grandes also 
exhibited mild antidiabetic potential in the studied animal model. Ethanolic extract of 
Tectona grandes leaves have also been reported for antiulcerogenic activity (Goel et 
al, 1987). In the present study the ethanolic extract of the stem wood of Betula utilis 
markedly helped in the decline of blood glucose of STZ-induced diabetic rats. This is 
first ever import of this plant to possess antihyperglycaemic potential on STZ-induced 
diabetic rats, which was earlier found to cause respiratory allergy (Singh and Kumar, 
2002). The ethanolic extract of hard wood of Acacia catechu was also found to 
possess antihyperglycaemic activity on STZ-induced diabetic rats for the first time. 
Acacia catechu exhibited plantlet regeneration fi-om seedling (Sahni and Gupta, 
2002). The finits of the known antidiabetic plant Musa paradisiaca showed 
antihyperglycaemic activity on STZ-induced diabetic rats in the present study, which 
confinns the earlier report (Lintas et al, 1995). Antiulcerogenic activity in this plant 
has already been reported (Goel et al, 2001). The present study clearly indicates that 
the extracts of these plants are the potent blood glucose lowering agents in 
hyperglycaemic conditions and with fiirther studies, these plants may be developed as 
blood sugar lowering agent. It is therefore, now imequivocally established that the 
antidiabetic ingredients of these plants may have marked antihyperglycaemic action 
with probable mechanisms involving insulin secretagogues (like glybenclamide) or 
having insulin like components. In conclusion, the present results have unveiled the 
antidiabetic activity in Lycopodium clavatum, Boerhaavia diffusa, Eclipta alba, 
Acacia nilotica and Strobilanthes perottitiana, Gloriosa superba, Berberis aristata, 
Tephrosia purpurea, Taxus baccata ssp. Wallichiana, Verbascum thapsus, Cedrus 
deodar a, Myristica fragrans, Betula utilis, Acacia catechu and Tectona grandis 
possess antihyperglycaemic effect on streptozotocin-induced diabetic rats. These 
plants may be added to the growing list of hypoglycaemic and antihyperglycaemic 
plants. However controlled clinical trials will be required to confirm their 
antihyperglycaemic action and general safety. 
The results of the present study clearly indicate that ethanolic extract of leaves 
of mangrove plant Ceriops tagal and methanolic extracts of marine soft corals 
Sinularia erecta and Sinularia firma are antihyperglycaemic in nature. The ethanolic 
extract of marine flora C tagal was found very effective in lowering blood glucose 
level as evidenced fi-om the fact that it inhibits the rise in postprandial hyperglycaemia 
[ 76 ] 
ITA 
Results and Discussion 
in sucrose loaded rats; it also prevents the rise in blood glucose on STZ-indueed 
diabetic rats. To our knowledge this is the first report describing'tKe' 
antihyperglycaemic potential in C. tagal ethanolic extract. There was an earlier report 
about the growth of this taxon with respect to seawater (Aziz and Khan, 2001), 
regeneration status of mangrove (Kairo et al., 2002), the lipid composition in the 
leaves of mangrove (Hogg and Gillan, 1984) and o-methyl-muco-inositol from C 
tagal found to be stress metabolite and cryoprotectant (Richter et al, 1990). It is 
evident from the result that the methanolic extract of Sinularia erecta produced 
significant lowering at 250 mg/kg body weight dose on postprandial hyperglycaemia 
in normal rats and also helps in the decline of blood glucose level on STZ-induced 
diabetic rats. Several new isoprenoids have been isolated from this soft coral 
Sinularia erecta (Rudy et al, 1998), however, to our knowledge this is the first report 
about this marine fauna Sinularia erecta for having antihyperglycaemic activity in 
this soft coral. Methanolic extract of Sinularia firma inhibits the rise in postprandial 
hyperglycaemia and also help in lowering blood glucose level on STZ-induced 
diabetic rats. With further studies, the extracts of all these three i.e. Ceriops tagal, 
Sinularia erecta as well as Sinularia firma may be useftil as blood sugar lowering 
agent. 
Studies with inhibitors of in-vitro targets produced some very interesting 
results which can open new vistas for the development antidiabetic drugs using 
combinatorial chemistry. These inhibitors of a-glucosidase, aldose reductase and 
protein tyrosine phosphatase can be developed into antidiabetic agents after 
confirming their antidiabetic potential in animal models for diabetes. These inhibitors 
belong to three major site from where hyperglycaemia can be prevented i.e. glucose 
absorption from brush border membrane can be prevented using the inhibitors of a-
glucosidase like Acarbose; complication of diabetes mellitus can be prevented by 
lowering down the activity of aldose reductase and thereby cataract, neuropathy and 
neuropathy etc. Finally the most important target i.e. Protein tyrosine phosphatase 
(PTP), a major target for the freatment of insulin resistance. Inhibitors of PTPase can 
be used to prevent the dephosphorylation of phosphoryiated tyrosine residues of 
signaling proteins involved in insulin signaling cascade. 
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CHAPTER II 
Animal models featuring physiological and pathological changes characteristic 
of each diabetes subtype are important to understand this complex disease better and 
to propose potential treatments. For example, specific etiological factors and/or 
genetic backgrounds can be selected and combined to produce a particular type of 
experimental diabetes, allowmg the researcher to explore particular biochemical or 
anatomical alterations. In this way, animal model can provide a means to study 
disturbances found in human diabetes (Mordes and Mordes, 1981). However there are 
variations in susceptibility to diabetes among different strains of mice/rats and also 
amongst males and females of the same strain. Besides there is species variation e.g. 
guinea pigs are resistant to alloxan induced diabetes mellitus. 
Fructose-enriched diet fed Rat model 
As shown m Fig. 1, after 10 weeks of feeding of fructose-enriched diet to the 
Sprague Dawley rats, significant amount of deterioration occur in the oral glucose 
tolerance curve as compared to control group fed with standard diet. This 
development in the glucose intolerance becomes progressive after each week 
deviating from the normal pattern of glucose tolerance curve. It clearly depicts the 
abnormality in oral glucose tolerance curve after 10 weeks feeding of fructose-
enriched diet. 
Neonatal-STZ Rat Model 
The other way to develop animal model for insulin resistance and type 2 
diabetes is by injecting STZ to one-day-old pups of Wistar rats. As shown in the Fig. 
2 that after 6 weeks of STZ injection there is an increase in the fasting blood glucose 
as compared to normal rats, which reaches upto 10 mM after a glucose load of 2.5 
gm/kg body weight. After 13 weeks fasting blood glucose was found to be 6mM that 
is found to be increased upto 12 mM after a glucose load. This increase in blood 
glucose becomes more progressive till 22 weeks post STZ injection. Glucose 
tolerance becomes impaired in neonatal rats on 22"^  week post streptozotocin 
injection as indicated in Fig. 2. 
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Results and Discussion 
Antidiabetic effect of CDR-134 
Effect of CDR-134 in STZ-induced diabetic rats 
Figure 3 presents antihyperglycaemic activity profile of the ethanolic extract 
of CDR-134 in STZ-induced diabetic rats. Lowering in the blood glucose was evident 
from 1 h that continued till 7 h. The peak lowering was obtained at 7 h post CDR-134 
treatment as compared to the control group. The overall antihyperglycaemic activity 
was found to be 25.4%. 
Fig 3: Antihyperglycaemic effect of CDR-134 
D123 In STZ-induced diabetic rats 
0\J.KJ 
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Fig. 3: Effect of CDR-134 in lowering blood glucose on STZ-induced diabetic 
rats. The maximum lowering was observed at 7h post drug treatment. The 
overall antihyperglycaemic activity was found to be 25.4%. 
Dose Dependency of CDR-134 in diabetic rats 
Dose dependency of CDR-134 was observed in STZ-induced diabetic rats at 
different dose starting from 62.5 to 500 mg/kg body weight. As shown in the Fig. 4 
that CDR-134 help in the controlling the blood glucose in a dose dependent manner. 
Its ED50 was calculated to be 243 mg/kg. 
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30 
Fig 4: Determination of ED50 of CDR-134 D123 preparation 
in STZ-induced diabetic rats 
3 4 5 
Time (h) 
24 
• Diabetic Control 
• CDR134-D123(62.5mg/l<g) 
-CDR134-D123{125mg/kg) 
- CDR134-D123(250mg/l<g) 
- CDR134-D123(375mg/kg) 
• CDR134-D123(500mgykg) 
Fig. 4: Dose dependency of CDR-134 in STZ-induced diabetic rats. Loweing in 
blood glucose was found to be dose dependent. EDso was found to be 243.5 mg/kg 
body weight. 
Effect of CDR-134 on a-Glucosidase (in-vUro) 
To trace the mechanism of action of CDR-134 D123, it was incubated with a-
glucosidase in vitro for 10 min. As depicted in the Fig. 5 it inhibits a-giucosidase in a 
dose dependent manner and its inhibition on a-glucosidase was found to be non-
competitive. CDR-134 inhibited rat intestinal alpha-glucosidase activity with an IC50 
of42.0^ig/ml(Fig. 6). 
182] 
Results and Discussion 
Fig 5: Effect of CDR-134 on a-Glucosidase 
• Control • CDR-134 50 ug/ml A CDR-134 100 ug/ml • CDR-134 150 ug/ml 
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Fig. 5: Line Weaver Burk Plot (Vv vs y[S]: Inhibition of a-Glucosidase (m-
vitro) by CDR-134. The nature of inhibition was found to be non-competitive 
Fig 6: Effect of CDR-134 on a-glucosidase 
inhibition 
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Fig. 6: %Inhibition of a-Glucosidase (in-vitro) at different concentration of 
CDR-134 and determination of IC50 for CDR-134 
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Effect of CDR-134 on Oral Glucose Tolerance in Fructose-fed rats and Neonatal 
rats 
During the five-weeks treatment with CDR-134 in neonatal rat model, the 
trend of glucose tolerance becomes normal after each week. It is presumed that this 
antidiabetic agent prevents the rise in the blood glucose level after a glucose load of 
2.5 gm/kg. This rise in blood glucose level ftirther decreases with interval of time. 
The effect of CDR-134 in finctose fed rats was found to be quite promising. On the 
day 0 of treatment, all the treatment and control group were found to have almost 
same pattern of glucose intolerance during oral glucose tolerance test. There were 
clear difference in fasting blood glucose, fiiictose fed group was found to have fasting 
blood glucose more than 6mM as compared to normal rats. CDR-134 helps in 
normalizing the oral glucose tolerance curve in finctose fed rats and neonatal rats as 
shown in Fig. 7 and Fig. 8 respectively. 
Effect of CDR-134 on Glucose metabolism in fructose-fed and neonatal STZ rats 
As shown in the Fig. 9 (a-b) that the pyruvate kinase activity got diminished in 
the fructose fed and neonatal rats. CDR-134 helps in the restoration of enzyme 
activity and thereby making glucose utilization more efficient in the liver and muscle. 
However the same antidiabetic agent has no effect on pyruvate kinase isolated from 
kidney. Glucose-6-phosphatase, one of the rate-limiting enzymes in gluconeogenesis, 
has been found to be modulated under the treatment of CDR-134. The activity of 
glucose-6-phosphatase was found to be increased in fructose fed and neonatal rats, 
which got reversed in liver, kidney and muscle after CDR-134 feeding. 
Phosphofructokinase, one of the regulatory enzymes of glycolysis, its activity was 
found to be decreased in liver of fixictose fed rats and neonatal rats, which got 
enhanced after CDR-134 treatment. Its activity was also found to be restored in 
muscle of neonatal rats with CDR-134 feeding. CDR-134 plays an important role in 
restoring the activity of lactate dehydrogenase (LDH) mainly in muscle. Its activity 
decreased in fructose fed and neonatal rats, which got normalized after CDR-134 
treatment. There is no significance difference in the activity of LDH isolated from 
liver and kidney. 
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Pyruvate Kinase 
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Fig. 9(a): Effect of CDR-134 on regulatory enzymes of carbohydrate metabolism following five 
weeks treatment in fructose fed and neonatal rats. Specific Activities are Mean SD. Statistical 
Significance measured by ' f test * p<0.05, " p<0.01, *** p<0.001 
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Fig. 9(b): Effect of CDR-134 on regulatory enzymes of carbohydrate metabolism following five 
weeks treatment in fructose fed and neonatal rats. Specific Activities are Mean SD. Statistical 
Significance measured by "f test * p<0.05, " p<0.01, * " p<0.001 
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Results and Discussion 
Phosphoenolpyruvate Carboxykinase (PEPCK) is another enzyme, which 
control the regulation of gluconeogenesis. Its activity was found to be activated in the 
liver of fructose-fed and kidney of neonatal rats, which was decreased by CDR-134. 
PEPCK activity got decreased in the kidney of fructose fed and muscle of neonatal 
rats. Their activity gets restored after treatment with CDR-134. 
Another enzyme, glycogen phosphorylase, a rate limiting enzyme in 
glycogenolysis, their activity was foimd to altered in fructose fed and neonatal rats. Its 
activity gets normalized in liver and kidney following treatment with CDR-134, 
however it has no effect on muscle phosphorylase. In neonatal rats glycogen 
phosphorylase activity was found to be activated in liver and kidney, which reverted 
back to normal after CDR-134 treatment. 
Protein tyrosine phosphatase, an enzyme of importance in insulin signalling 
pathway was found to be highly activated in the case of insulin resistance as reported 
earlier. Here also the activity of PTPase was observed to be increased as compared to 
normal rats in the muscle and to some extent in liver of both fructose fed and neonatal 
rats, which get lowered down with the treatment of CDR-134 proving this agent to 
possess insulin sensitizing potential. 
CDR-134 also helps in normalizing the enzymatic activities involved in 
carbohydrate metabolism. It is evident from the Figures that CDR-134 improves 
insulin resistance, glucose tolerance and normalizes many of the altered biochemical 
parameters of liver, kidney and muscles associated with type 2 diabetes and insulin 
resistance in fructose-fed rats and neonatal rats. 
Antidiabetic effect of CT-1 
Effect of CT-1 in STZ-induced diabetic rats 
CT-1, a plant based antihyperglycaemic agent, was found to be effective in 
diabetic rats made by STZ injection. The lowering in blood glucose was found to be 
effective right after one hour till the end time post-drug administration. The maximum 
declme in blood glucose was found to be at 6h. The overall % antihyperglycaemic 
activity was calculated to be 21.4% (p<0.01). 
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Antihyperglycaemic Effect of CT-1 
on STZ-induced diabetic rats 
o 
o 
o 
T3 
O 
O 
CD 
Dabetic Control 
Treated with CT-1 
3 4 5 
Time (h) 
7 24 
Fig. 10: Effect of CT-1 in lowering blood glucose on STZ-induced diabetic rats. 
The maximum lowering was observed at 7h post drug treatment. The overall 
antihyperglycaemic activity was found to be 21.3%. 
The results shown in Fig. 10 clearly demonstrate that CT-1 has 
antihyperglycaemic effect in streptozotocin-induced diabetic rats at 100 mg/kg body 
weight dose and the peak lowering effect was observed between 5 to 7 hours. 
Effect of CT-1 on a -Glucosidase iin-vUro) 
Like CDR-134, CT-1 was also found to be a potent mhibitor of a-glucosidase. 
CT-1 inhibited rat intestinal a-glucosidase activity with an IC50 of 40.0 i^g/ml (Fig. 
11). The nature of inhibition of a-glucosidase by CT-1 was also found to be non-
competitive (Fig. 12). 
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Effect of CT-1 on a-glucosidase inhibition 
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Fig. 11: "/olnhibition of a -Glucosidase (in-vitro) at different concentration of 
CT-1 and determination of IC50 for CT-1 
F 
160 
140 
120 
100 
•^ 80 
60 
40 
20 
n 
ig 12: Effect of CT-1 on a-Giucosidase 
[•Control •CT-1 50ug/ml A CT-1 lOOug/ml -CT-1 150ug/ml 
i 
-
^^^ A ^ 
^ ^ ^ ^ " ^ ^ 
^ • A ^ ^ ' ^ " ' ^ 5 -
^ ^ ^ J * ^ " ^ " ^ ^ - -
^ ^ A , , - ' ' ' ' ' ^ • • 
^ b. ^^ — - ^ ^ 
^ — i * ^ • " ~ 
-0.02-0.01 0 0.01 0.02 0.03 0,04 0.05 0.06 0.07 0.08 0.09 
1/[S] 
Fig (12): Line Weaver Burk Plot (I/v vs I/[S]: Inhibition of a -Glucosidase 
(in-vitro) by CT-1. The nature of inhibition was found to be non-competitive 
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Effect of CT-1 on Oral Glucose Tolerance in Fructose-fed rats and Neonatal rats 
It is clearly evidenced from the Fig (13) and (14) that after three weeks of 
treatment with CT-1 to finctose-fed rats and neonatal rats, the oral glucose tolerance 
becomes normal in fiiictose-fed and neonatal-STZ rats respectively after CT-1 
treatment. 
Effect of CT-1 on Glucose metabolism in fructose fed and neonatal rats: 
Pyruvate kinase plays an important role in the utilization of glucose and 
thereby helping glucose uptake. Its actiyity was observed to be decreased in the liver 
and muscle of both fioictose fed and neonatal rats, but CT-1 help in bringing their 
activity back to normal. However pyruvate kinase activity was found to be enhanced 
in the kidney of fructose fed and neonatal rats. CT-1 helps in decreasing enzyme 
activity as depicted in Fig. 15(a-b). 
Phosphofinctokinase, one of the regulatory enzymes of glycolysis, its activity 
was found to be diminished in fioictose fed and neonatal rats. CT-1 helps in the 
enhancement of their activity back to normal. It has no significant effect in the kidney. 
The activity of lactate dehydrogenase (LDH) was decreased in the liver and 
found to be increased in the kidney and muscle of fiuctose fed and neonatal rats as 
compared to normal control. However, this plant based antidiabetic agent CT-1 brings 
back the normal activity. As shown in the Fig. 15(a-b) glycogen phosphorylase 
activity was found to be increased in the kidney of neonatal and fiiictose fed rats; 
increased in the liver of finctose fed rats. Its activity was observed to be decreased in 
the muscle of fioictose fed and neonatal rats. CT-1 helps in normalizing their activity 
in all the tissues. Glucose-6-phosphatase and Phosphoenolpyruvate Carboxykinase 
(PEPCK) are the major regulatory enzymes in gluconeogenesis pathway. Their 
activity got altered in fructose fed and neonatal rats as compared to normal rats. Their 
activity gets enhanced in the liver of both animal models. Glucose-6-phosphatse 
activity was found to be increased in the kidney and muscle of fructose fed and 
neonatal rats. PEPCK activity was observed to be decreased in kidney and muscle of 
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Results and Discussion 
fixictose fed and neonatal rats especially in the tissues like liver and muscle. Its 
activity vfas found to increased in the liver and muscle but no significance difference 
was observed in kidney following feeding the rats with fructose-enriched diet and 
injecting STZ to one-day-old pups. After three weeks of CT-1 feeding, it helps in 
restoring its activity back to normal. 
This herbal preparation has the potency to normalize the altered enzyme 
activities involved in carbohydrate metabolism as shown in the Fig. 15(a-b); possibly 
it is doing so by reducing the activities of glucose-6-phosphatase and PEPCK and 
consequently helps in the reduction of hepatic glucose production, one of the main 
reasons of hyperglycaemia. 
Discussion 
There is very less report about marine plants/organisms as having 
pharmacological properties. This study has given a new direction to the drug 
discovery based on marine flora/fauna and marine organisms. It is being first time 
reported about the existence of a pharmacological property in the form of blood 
glucose lowering potential in CDR-134. There is a report about the chemical 
constituents of fruits (Saxena and Babu, 2001). In the present study the ethanolic 
extract of marine plant help in the reduction of blood glucose in STZ-induced diabetic 
rats as comparable with standard drug like glybenclamide and metformin. The 
lowering in postprandial hyperglycaemia and blood glucose in STZ-induced diabetic 
rats might be due to the action of on p-cell and help in the release of insulin. Its 
effectiveness was also evidenced from the fact that it reduces the blood glucose level 
in a dose dependent maimer. This lowering in blood glucose was supposed to be due 
the inhibitory effect of CDR-134 on a -glucosidase, an enzyme present on the brush 
border membrane of small intestine, which helps in the breakdown of carbohydrate 
and its transportation into the blood stream and therefore blocking the absorption of 
glucose from small intestine into blood stream, a major point of entry for glucose. 
In the study with CT-1 extract significantly lowered the hyperglycaemia 
associated with the diabetic rats in single dose experiment. The results in diabetic 
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animals are almost comparable to sulphonylurea, tolbutamide and biguanides 
derivative metformin. In in vitro studies CT-1 has shown considerable degree of 
inhibition in comparison to standard a-glucosidase inhibitor acarbose which indicate 
that CT-1 might be having a mechanism of action involving inhibition of a-
glucosidase, which in turn inhibits the conversion of complex polysaccharides into 
simple one resulting in the inhibition of their absorption from small intestine leading 
to a fall in blood glucose level. 
The heterogenous pathogenesis and progressive natural history of type 2 
diabetes and insulin resistance contrive a formidable therapeutic challenge (Baily, 
2000). Dual endocrine deficits of impaired insulin action and inadequate insulin 
secretion due to very high activity of protein tyrosine phosphatase in these animal 
models create an environment of chronic hyperglycaemia and general metabolic 
disarray as evidenced from the activities of regulatory enzymes. Streptozotocin has 
been shown to induce diabetes via methylation (Uchigata et al, 1982), free radical 
production (Gandy et al, 1982; Papaccio et al, 1986) and nitric oxide formation 
(Kown etal, 1994)). The results of the present study indicate that CDR-134 and CT-1 
were foimd to reduce the elevated glucose levels in animals made diabetic and insulin 
resistant by fructose feeding and in neonatal STZ-rats. These agents also act as insulin 
resistance reversal agents as indicated by normalizing the serum insulin level. 
The elevated rate of gluconeogenesis is an important contributor to the severe 
hyperglycaemia that develops in neonatal rats treated with streptozotocin (Blondel et 
al, 1989). The basal rates of glucose utilization are significantly reduced in neonatal 
heart, a defect attributed to a combination of reduced glucose transport and impaired 
flux through the rate-limiting enzymes of glycolysis, phosphofriictokinase (Schaffer et 
al, 1986). As neonatal rats ages, it not only becomes glucose intolerant but also 
insulin resistant (Schaffer et al, 1993). Early step in the signal transduction pathway 
of insulin becomes defective in neonatal rats, causing decreased insulin sensitivity of 
several events, including glycogenesis, lipogenesis, glucose production, amino acid 
transport, and glucose oxidation (Kergoat et a/., 1991; Melin et al, 1991). The utility 
of neonatal-STZ rats in evaluating the hypoglycaemic activity of new 
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antihyperglycaemic agents such as linogliride fiimarate (Marchione et al, 1989). STZ 
treated neonatal rats respond favourably to sulfonylurea therapy (Serradas et al, 
1989). 
CDR-134 and CT-1 improve hyperglycaemia by correcting glucose 
intolerance and also help in the reduction of serum insulin level. These herbal agents 
found to reduce the activity of regulatory enzymes involved in gluconeogenesis e.g. 
Glucose-6-phosphatase and Phosphoenolpyruvate Carboxykinase, which were found 
to be abruptly higher in neonatal control tissues like liver and muscle. These agents 
also assist in glucose uptake and its utilization possibly by increasing the activity of 
enzymes like Pyruvate kinase, Phosphofructokinase and Lactate dehydrogenase. 
Schaffer et al. found that chronic glipizide therapy improves insulin resistance in the 
heart of the neonatal Wistar rats. The beneficial effect of these antihyperglycaemic 
agents may be due to elevation in insulin sensitivity to glucose as observed by 
sufficient reduction in the activity of Protein tyrosine phosphatase and that may be 
helping in insulin action. 
Several studies have demonstrated that chronic fructose feeding leads to 
insulin resistance, glucose intolerance, hyperinsulinemia and hypertriglyceridemia in 
a relatively short span of time in normal rats (Zavarani et al, 1980; Hwang et al, 
1987; Reaven et al, 1991). These metabolic changes lead to essential hypertension 
(Madar et al, 1997; R6sen et al, 1997). The insulin resistance resulting from chronic 
feeding is due to the diminished ability of insulin to suppress hepatic glucose 
production, and not to a decrease in insulin-stimulated glucose uptake by muscles 
(Reaven et al, 1991). Chronic fructose-administration induces hyperglycaemia and 
hyperinsxilinemia (Reaven et al, 1989). In the present study the effect of CDR-134/ 
CT-1 on abnormal glucose metabolism and insulin resistance induced by a high 
fructose-fed rats given at a dose of 250 mg/kg. It is generally agreed that fructose 
loading induces insulin resistance and glucose intolerance. However, the effect of 
fructose treatment on plasma glucose levels reported by different researchers varied 
from no change (Hwang et al, 1987; Sambandam et al, 1997), transient elevation 
(Lee et al, 1994) to a significant elevation (Rosen et al, 1997). The present study 
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showed the transient elevation in blood glucose levels in Sprague Dawley rats 
following fructose-enriched diet feeding for 10 weeks. Serum insulin level was more 
prominent and significantly elevated in the rats after 10 weeks of feeding which get 
normalized with CDR-134 treatment. 
Chronic fructose feeding impairs insulin action in both liver and peripheral 
tissues (Thorbum et al, 1989). CDR-134 and CT-1 improve hyperglycaemia and 
decreases serum msulin level in the above said insulin resistant rats and thereby 
making insulin more sensitive by decreasing the activity of protein tyrosine 
phosphatase (PTPase) which was found to be increased after fructose feeding and in 
neonatal rats. These agents also reduce hepatic glucose production and helps in more 
and more glucose utilization by skeletal muscles. Glucose utilization was found to be 
improved in the skeletal muscle and liver as the enzyme activities like Pyruvate 
kinase, Phosphofiiactokinase and Lactate dehydrogenase were found to be enhanced 
after treatment with CDR-134 and CT-1. It may be concluded from the present study 
that CDR-134 and CT-1 perform both the improvement in glucose tolerance and the 
reduction in insulin resistance in animal models. 
The insulin resistance and hyperinsulinemia could be viewed as permissive 
representing changes that predispose an individual to high blood pressure, but not that 
necessarily cause hypertension by themselves (Reaven et al, 1991). Plasma insulin 
levels were higher in these rats but plasma glucose levels remained high, suggesting 
that the rats were insulin resistant. Increased insulin resistance and hyperinsulinemia 
were Imked to the development of hypertension (Shinozaki et al, 1997; Kocemba et 
al, 1998). Hyperinsulinemia is caused by increased insulin secretion in response to 
glucose, which result from hyperactivity of the pancreatic cells to glucose and an 
activation of sympathetic nerves (Pugazhenthi et al, 1993). Antidiabetic agents CDR-
134/CT-l prevented and attenuated the increase in both plasma insulin suggesting that 
the extract promotes insulin sensitivity. Insulin sensitivity activity has been reported 
to reduce plasma insulin levels leading by the same occasion to a reduction of plasma 
glucose and blood pressure (Dai and McNeil, 1995). It therefore, seems that these 
agents exerts its insulin resistance reversal activity by improving insulin sensitivity as 
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observed with certain antidiabetic agents like Metformin (Verma et al., 1994), 
thiazolidinedione (Su2xiki et al., 1997; Verma et al., 1998) and angiotensin-
converting enzyme inhibitors (Limura et al., 1995). 
CDR-134 and CT-1 improves hyperglycaemia and hyperinsulinemia in both 
fructose fed and neonatal STZ-rats. Therefore CDR-134 and CT-1 improve insulin 
resistance and decreases hyperglycaemia. CDR-134 and CT-1 possibly improve 
insulin resistance via their action on the muscle and liver like certain 
thiazolidinedione derivatives (Fujiwara et al, 1988). These antidiabetic agents (CDR-
134 and CT-1) like Troglitazone demonstrated to suppress glucose production in liver 
(Suter et al, 1992) as evidenced by reduction in the activities of Glucose-6-
phosphatase and Phosphoenolpyruvate Carboxykinase (PEPCK) after treatment with 
CDR-134 and CT-1. 
In conclusion, this study has shown the antihyperglycaemic effect of CDR-
134/CT-l in fructose fed rats. These results may lend further support to mount up 
evidence that the extracts may contain some compounds which, if taken in sufficient 
quantities, could conceivably be beneficial in the attenuation and prevention of insulin 
resistance, hyperinsulinemia and hypertension induced by fructose enriched diet 
feeding. Further studies are requked to establish the mechanism(s) underlying the 
antihyperglycaemic effect and insulin sensitising activity of these agents. 
[ 1 0 1 ] 
CHAPTER-III 
Insulin resistance is a characteristic feature of most patients with type 2 
diabetes mellitus and almost a universal finding in type 2 diabetic patients who are 
overweight. Insulin resistance is essentially a condition of reduced insulin sensitivity. 
Insulin resistance described as impaired biological response to insulin but there is 
sufficient variability in normal sensitivity to insulin that there is no specific boundary 
at which sensitivity ends and resistance begins. The term insulin resistance usually 
connotes resistance to the effect of insulin on glucose uptake, metabolism, or storage. 
Insulin resistance in obesity and Type 2 diabetes is manifested by decreased insulin 
stimulated glucose transport and metabolism in adipocytes and skeletal muscles and 
by impaired suppression of hepatic glucose output. These functional defects may 
result, in part, from impaired insulin signalling in all three target tissues i.e. liver, 
muscle & kidney and, in adipocytes, also fi-om down regulation from the major 
insulin responsive glucose transporters, GLUT4. In both muscle and adipocytes, 
insulin binding to its receptor, receptor phosphorylation and tyrosine kinase activity, 
and phosphorylation of IRSs are reduced. 
The fasting plasma glucose and insulin concentration in each normal subject 
or Type 2 diabetic patient are at a level characteristic for that individual for a given 
state of nutrition (Holman and Turner, 1979; Holman and Turner, 1980). The fasting 
plasma insulin concentration is largely determined by glucose concentration 
(McCarthy et al, 1977) and the basal hyperglycaemia in diabetes appears to arise 
from the feed back loop between the liver and p-cells, thereby maintaining an 
effective insulin action in the liver and at the periphery (Holman and Turner, 1979; 
Turner and Holman, 1976). The degree of basal hyperglycaemia is thus determined by 
a combination of p-cell deficiency and insulin resistance. A mathematical model of 
the glucose: insulm interactions has been used to indicate the degree to which they 
combine to give hyperglycaemia with low, normal or raised basal plasma insulin 
concentrations (Turner et al, 1979; Turner et al, 1982). This model is known as 
"homeostasis model assessment" (HOMA). 
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Metformin is the only established drug that treats insulin resistance by reversing 
it to insulin sensitive. Metformin improves insulin sensitivity in liver and skeletal 
muscle without raising insulin concentration. Thiazolidinedione (TZDs), this new 
class of oral antidiabetic agents target the nuclear PPAR-y, which increases 
transcription of certain insulin sensitive genes. But these all agents (insulin resistance 
reversal agents) bear many side effect so there is an urgent need to treat insulin 
resistance and to search for some insulin resistance reversal agent, which can reverse 
insulin resistance that too from natural source, thereby making insulin more sensitive 
in the peripheral tissues like muscle and adipocytes. The present section details the 
insulin resistance reversal property in two of the candidate antidiabetic agents. 
Effect of CDR-134 and CT-1 on serum insulin in fructose fed and neonatal rats 
It is clearly shown in the Fig l(a-b) that hyperinsulinemia can be persistently 
developed in both the animal models i.e. fructose fed rats and neonatal streptozotocin 
treated rats. In fructose fed rats serum insulin level was increased by 300% as 
compared to control group, however in neonatal rats this increase was found to be 
250%. Serum insulin level was found to be sufficiently higher after 22 weeks post 
injection of streptozotocin to one-day-old pups week. CDR-134 helps in the reduction 
of serum insulin by 73% m fructose fed and by 66% in neonatal rats. Effect of CT-1 
was also promising in preventing hyperinsulinemia as presented in Fig 2. In fructose 
fed rat serum insulin level was found to be increased by 111% and in neonatal rats by 
100%. CT-1 helps in declining the raised insulin by 45.5% in fioictose fed rats and by 
40,7% in neonatal rats. 
[ 1 0 3 ] 
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Results and Discussion 
Effect of CDR-134 and CT-1 on serum insulin proflle post glucose load on STZ-
induced diabetic rats 
Insulin sensitization studies were performed following glucose administration 
in STZ-induced diabetic rats. As shown in the Fig. 3 that CDR-134 and CT-1 both 
prevent the hyperinsulinemia following glucose load. 
Insulin Kinetics following Glucose-load 
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Fig (3): Effect of CDR-134 and CT-1 on serum insulin following glucose in 
STZ-induced diabetic rats. These antihyperglycaemic agents also prevent 
hyperinsulinemia in diabetic rat. Serum insulin are Mean±SD 
Effect of CDR-134 and CT-1 on Insulin resistance (HOMA) 
Both CDR-134 and CT-1 proved to be good insulin resistant reversal agents as 
evidenced from the Fig. 4(a-b). Insulin resistance was observed in both animal model 
following feeding of fructose-enriched diet and neonatal (one day old) rats injected 
with streptozotocin. For normal animals the median insulin resistance was reported to 
be 1.45 using HOMA index and for diabetic patients it was found to be around 2.61 
(Mathews et al., 1985). Here in this case, animals of the fructose fed and neonatal 
control group exhibited insulin resistance from 5.0 to 6.0, which comes back to the 
normal range of 1.5 with the treatment of CDR-134 and CT-1 separately. 
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Results and Discussion 
Discussion 
The basal hyperglycaemia of diabetes may be considered as a compensatory 
response with a major role in maintaining sufficient insulin secretion, from a reduced 
P-cell capacity, to control glucose efflux (Holman and Turner, 1979; Turner and 
Holman, 1976). In the present study investigations were made with HOMA model 
based on the interaction between fasting serum insulin and fasting glucose. 
Treating insulin resistance is not a simple matter of either giving more insulin 
to push the signalling pathway harder, or reducing insulin concentrations to reduce the 
consequences of hyperinsulinemia. Also there is no simple quantitative clinical test 
for insulin resistance, and there are few therapeutic options. Giving more insulin can 
increase those actions of insulin that are impaired by the bottlenecks of signal 
transduction. However, creating the desired effect on a severely compromised 
pathway of insulin action (e.g. impaired glucose transports) can result in gross 
accentuation of other less desirable actions of insulin {e.g. lipogenesis, leading to 
hypertriglyceridemia and obesity, or sodium retention, promoting hypertension). 
Indeed, excess insulin exacerbates insulin resistance at the receptor and post receptor 
levels. If adequate glycaemic control is not achieved with oral monotherapy, then two 
different classes of oral drugs are used in combination. It is evidenced from the results 
that both the drugs CDR-134 and CT-1 possess the property to reverse the insulin 
resistance and mcreases insulin sensitivity. Hyperinsulinemia was well established in 
both animal models for non-insulin dependent diabetes mellitus and insulin resistance. 
Serum insulin levels were markedly reduced after treatment with CDR-134/CT-1. 
Hyperinsulinemia was also prevented following glucose load in STZ-induced diabetic 
rats by indigenous preparations i.e. CDR-134 and CT-1. Insulin resistance was found 
to be established in both the animal models with very high value as compared with 
predicted insulin resistance value i.e. 2.89. With these studies it is being reported for 
the first time that these agent from natural background, were found to be active in 
making insulin more sensitive and one day it become reality that these agent may take 
the shape of a drug that could come to market with insulin resistant reversal potential. 
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SUMMARY 
Diabetes mellitus is characterized by derangements in carbohydrate, protein 
and fat metabolism caused by the complete or relative insufficiency of insulin 
secretion and/or insulin action. There are two main forms of diabetes, Type 1 (Insulin 
dependent diabetes mellitus) and Type 2 (Non-insulin dependent diabetes mellitus). 
Type 1 diabetes is due to autoimmune-mediated deterioration of pancreatic p-cells, 
resulting in absolute insulin deficiency. Type 2 diabetes is far more common and 
characterized by insulin resistance and/or abnormal insulin secretion, either of which 
may predominate. People with Type 2 diabetes are not dependent on exogenous 
insulin, but may require it for the control of blood glucose levels, if this is not 
achieved with diet alone or oral hypoglycaemic agents. Insulin resistance is a state of 
reduced insulin sensitivity, an inability of insulin to lower plasma glucose levels 
through suppression of hepatic glucose production in liver and stimulation of glucose 
uptake in skeletal muscles and adipose tissue. The coexistence of insulin resistance 
and hyperinsulinemia appears to contribute directly or indirectly to many other 
disorders, such as dyslipidemia, hypertension, atherosclerosis and a procoagulant 
state, linking together with insulin resistance, which has now assumed the status of 
syndrome, namely Syndrome X. 
Numerous plants have been reported to possess hypoglycaemic activity and 
mechanisms for the antidiabetic action of such plants have been described. There are 
plants, which exhibit properties similar to the well known sulfonylurea drugs like 
glybenclamide, effecting hypoglycaemia in normal animals by stimulating insulin 
release from pancreatic p-cells, besides reducing hepatic clearance of insulin hormone 
while others act like the biguanides specifically, metformin which, although 
antihyperglycaemic, does not effect hypoglycaemia in normal state. Metformin-like 
activities of plants, augments insulin action by increasing the number of glucose 
transporters, inhibit gluconeogenesis, reduces absorption from the intestine but 
increases glucose metabolism in the liver. Because of many side effects and doubt 
about the efficacy and safety of the present day oral hypoglycaemic agents which 
have promoted a search for safer and more effective drugs for the treatment of 
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diabetes in particular type 2 diabetes mellitus. This has led to explore alternative 
medicines including natural therapies. A multitude of herbs, spices and other plant 
materials are being used in the management of diabetes mellitus especially in third 
world coimtries and many more are being explored for the antidiabetic activity. 
Streptozotocin was top priority diabetogenic agent for inducing diabetes mellitus into 
rats because of its less mortality. 
Antihyperglycaemic effect of nearly 18 plants was studied in STZ-induced 
diabetic rats and 3 marine extracts both in sucrose loaded rat model and STZ-induced 
diabetic rats. Sucrose loaded rat model was primarily used to identify the lead 
molecule from plant/marine extracts. Streptozotocin (STZ)-induced diabetic rat model 
was later used to confirm the antihyperglycaemic activity of plant/marine extracts 
under diabetic conditions. Significant antihyperglycaemic activity was noted in the 
ethanolic extracts of the tuberous root of Gloriosa superba, Berberis aristata, 
Tephrosia purpurea, stem bark of Taxus baccata Wallichiana spp, leaves of 
Verbascum thapsus, Lycopodium clavatum, Boerhaavia diffusa, Eclipta alba, Acacia 
nilotica, Strobilanthes perottitiana, stem wood of Cedrus deodara, fhaits of Myristica 
fragrans, stem bark of Betula utilis, hard wood of Acacia catechu and leaves of 
Tectona grandis. The average antihyperglycaemic activity profile were 22.0 (p<0.01), 
23.0 (p<0.05), 16.0 (p<0.05), 13.6 (p<0.05), 10.0 (p<0.05), 35.8 (p<0.001), 12.0 
(p<0.05), 16.9 (p<0.05), 10.3 (p<0.05), 19.6 (p<0.01), 19.5 (p<0.01), 11.0 (p<0.05), 
12.4 (p<0.05) and 10.6 (p<0.05) respectively. The marine extracts which were found 
to have antihyperglycaemic effect in sucrose loaded rat model were of Ceriops tagal, 
Sinularia erecta and Sinularia firma. The average antihyperglycaemic activity were 
noted in this model i.e. 12.4%, 12.7% and 13.0% respectively; whereas, the similar 
extracts showed 25.8%, 16.1% and 18.8% antihyperglycaemic effect in STZ-induced 
diabetic rats. This is being the first report for any antihyperglycaemic property in the 
said plant/marine extracts. 
Search for lead based antidiabetic molecules/natxiral substances was one of 
the objectives of our studies. Three major in-vitro antidiabetic targets were 
standardised i.e. a-glucosidase, aldose reductase and protein tyrosine phosphatase-IB. 
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a-Glucosidase, a major target for antidiabetic drug discovery, is located on the brush 
border membrane of small intestine. If any agent found to inhibit this enzyme, there is 
possibility that agent may delay glucose absorption across small intestine and 
consequently prevent the postprandial hyperglycaemia. The next target which directly 
deals with secondary diabetic complications like cataract, neuropathy, nephropathy 
etc. is Aldose reductase. The enhanced expression and activity of this enzyme was 
found in diabetic situation. It converts more and more glucose to sorbitol, which give 
rise to multifaceted problems that later on give rise to macro and microvascular 
complication of diabetes mellitus. Any inhibitor of aldose reductase would be 
developed as drug for the treatment of diabetic complications for which no drug is 
available yet in the market. Protein tyrosine phosphatase-IB, an enzyme of high 
importance, play important role in carrying out insulin signaling cascade together wdth 
protein tyrosine kinase. In normal circumstances there is a synchronization in between 
these two enzymes i.e. protein tyrosine kinase and protein tyrosine phosphatase. In the 
case of insulin resistance the activity of protein tyrosine phosphatase-IB was found to 
be increased because of the high expression of PTP gene. Therefore, for the treatment 
of insulin resistance and non-insulin dependent diabetes mellitus one has to inhibit the 
activity of protein tyrosine phosphatase-IB. An inhibitor of protein tyrosine 
phosphatase can be used effectively to reverse insulin resistance and consequently 
insulin sensitivity for liver and muscles can be increased. Some library compounds 
i.e. L-000-17-10, L-000-17>ll, L-000-17-16 and L-000-17-17 were found to inhibit 
both a-glucosidase and aldose reductase to the tune of 90 to 100% at 250 i^M. 
Compound L-001-8-26, L-001-8-27, L-001-8-28, L-001-8-36, L-001-8-37, L-001-8-
62 and L-001-8-63 were found to inhibit protein tyrosine phosphatase-IB to the tune 
of 93 to 100% at 100 \iM. Their percent inhibitions were also compared with their 
standard inhibitors like Acarbose which inhibits a-glucosidase upto 68.4% at 250 |iM, 
Quercitrin, a known inhibitor of aldose reductase was found to inhibit this enzyme by 
69.6% at 250 ^M m the present study and the next known mammalian inhibitor i.e. 
peroxovanadate could inhibit protein tyrosine phosphatase-IB to the tune of 80.5% at 
100 ^ iM concentration. 
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The two standardized antidiabetic preparations i.e. CDR-134 and CT-1 proved 
their antihyperglycaemic property in STZ-induced diabetic rats. CDR-134 and CTl 
showed 25.4% (p<0.01) and 21.4% (p<0.01) lowering of blood glucose in diabetic 
rats. Both preparations showed dose dependency in STZ-induced diabetic rats and 
their ED50 values were calculated to be around 243 and 94.6 mg/kg, respectively. It 
seemed that CDR-134 and CT-1 exert their glucose lowering effect by inhibiting a-
glucosidase present in the brush border membrane of small intestine, with IC50 of 42 
and 40 |ig/ml respectively. The nature of inhibition was found to be non-competitive 
in each case. 
Two rat models have been standardised by manipulating the diet and injecting 
diabetogenic agent Streptozotocin (STZ), respectively for studying the 
pathophysiology of insulin resistance, hyperinsulinemia and type 2 diabetes mellitus. 
Fructose-enriched diet fed rat and neonatal-STZ rat model were used as animal 
models for non-insulin dependent diabetes mellitus (type 2 diabetic condition i.e. 
impaired glucose tolerance and insulin resistance). These animal models of type 2 
diabetes were used for the evaluation of antihyperglycaemic and insulin resistant 
reversal activity of standardized preparations i.e. CDR-134 and CT-1.These animal 
models were used to evaluate the short and long term effects of CDR-134 and CT-1 
on primary and secondary biochemical changes during diabetes and insulin resistance. 
Biomolecules and regulatory enzymes of carbohydrate metabolism were chosen for 
the study. These include blood glucose, oral glucose tolerance test (OGTT), serum 
insulin, pyruvate kinase, phosphofiiictokinase, glycogen phosphorylase, glucose-6-
phosphatase, phosphoenolpyruvate carboxykinase, lactate dehydrogenase and protein 
tyrosine phosphatase. These animals showed slightly elevated fasting blood glucose, 
impaired glucose tolerance and the state of insulin resistance and hyperinsulinemia. 
These preparations (CDR-134 and CT-1) have shown promising results in these 
models as indicated by correction in impaired fasting blood glucose profile, impaired 
glucose tolerance and normalization of the elevated serum insulin level, as well as 
activating the rate limiting/regulatory enzymes of carbohydrate metabolism 
responsible for insulin resistance and type 2 diabetes. 
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After 10 weeks feeding of Fructose enriched diet to Sprague Dawley, 
significant amount of deterioration occur in oral glucose tolerance curve. In the case 
of neonatal rats oral glucose tolerance curve was significantly altered after 8 weeks 
post STZ injection. On week 13*, 15^ 18^ ,^ 20^ ^ and 22"*^  impairedness in oral 
glucose tolerance became more prominent. Serum insulin level was also found to be 
significantly higher in fructose fed and neonatal-STZ rats. During five weeks 
treatment with CDR-134 in neonatal rats and fructose fed rats, oral glucose tolerance 
found to become normal. CDR-134 helped in normalizing the oral glucose tolerance 
in these two rat models for non-insulin dependent diabetes mellitus. Three weeks 
feeding of CT-1 to these models also improved impaired glucose tolerance by 
correcting impaired glucose tolerance (IGT). 
These preparations were found to alter the activities of regulatory enzymes of 
carbohydrate metabolism in these two animal models for type 2 diabetes and insulin 
resistance. CDR-134 and CT-1 were found to decrease the activities of glucose-6-
phosphatase and Phosphoenolpyruvate carboxykinase and consequently reducing 
hepatic glucose production by the process of gluconeogenesis in tissues like liver and 
muscles. These agents also assisted in glucose uptake and its utilization by increasing 
the activities of pyruvate kinase, phosphofiiictokinase and lactate dehydrogenase. 
Pyruvate kinase plays an important role in the utilization of glucose and thereby 
helping glucose uptake. Its activity was found to be decreased in the liver and muscle 
of both ammal models, however, treating v^th CDR-134/CT-1 helped in bringing the 
activity back to normal levels. The activity of other key enzyme of glucose 
metabolism i.e. phosphofiiictokinase was found to be diminished in the liver and 
muscles of finctose fed and STZ- neonatal rats. Both CDR-134 and CT-1 helped in 
the enhancement of PFK activity. However, both have no effect on kidney PFK. 
These preparations helped in the restoration of lactate dehydrogenase activity of liver 
only. The beneficial effect of these antihyperglycaemic and insulin resistant reversal 
agents might be due to the elevation in insulin sensitivity to glucose as observed by 
sufficient reduction in the activity of protein tyrosine phosphatase, one of the key 
enzymes of insulin signaling cascade involved in insulin resistance, reduction in its 
activity would definitely help in insulin action. These preparations have the potency 
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to normalize the impaired glucose tolerance and altered enzyme activities involved in 
glucose catabolism and anabolism; possibly they are doing so by declining the 
activities of glucose-6-phosphatase and PEPCK and therefore helping in the decrease 
of hepatic glucose production, one of main reason of hyperglycaemia. It is evident 
that these agents improve insulin resistance by decreasing hyperinsulinemia and by 
declining the activity of PTPase (protein tyrosine phosphatase), glucose intolerance 
and normalizes many of the altered biochemical parameters of liver, kidney and 
muscles associated with non-insulin dependent diabetes mellitus and insulin 
resistance. 
Insulin resistance was measured using HOMA index (homeostasis model 
assessment). It is a mathematical model utilizing ratio of fasting glucose (mM): 
fasting insulin (}iU/ml) that has been used to indicate the degree to which they 
combine to give hyperglycaemia with low, normal or raised basal plasma insulin 
concentrations. As mentioned both standardized preparations i.e. CDR-134 and CT-1 
were found to correct hyperinsulinemia by decreasing fasting serum insulin in 
fructose fed and neonatal-STZ rat models, respectively. CDR-134 and CT-1 prevented 
the rise in serum insulin levels following glucose load during insulin kinetic studies in 
STZ-induced diabetic rats. Insulin resistance was foimd to be established as calculated 
by HOMA index formula using fasting glucose and fasting serum insulin. Fructose 
fed and neonatal-STZ rats exhibited insulin resistance index 5.0-6.0 which returned 
back to normal levels after the treatment v^th either CDR-134 or CT-1. It is again 
proved that CDR-134 and CT-1 possess the property of reversing insulin resistance 
and enhancing insulin action by increasing insulin sensitivity towards glucose. This is 
being the first report about the existence of insulin resistant reversal property in 
natural products like CDR-134 and CT-1. 
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